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1.1 NEURAL TUBE CLOSURE 
1.1.1 Principles of neurulation 
The closure of the neural tube in the human embryo initiates after three weeks of 
conception and is completed within 28 days, before many women are aware that 
they are pregnant. Most data and knowledge concerning the process of neural 
tube formation and closure are acquired from animal models 1;2, while only few 
human data have been reported 3.  
The induction of ectoderm by the notochord leads to the formation of the neural 
plate 1. Subsequently the neural plate transforms into the neural tube that begins 
with elevation of the edges relatively to the midline, resulting in formation of a neural 
groove 4. This neural groove formation is initiated by reshaping of the medial neural 
plate cells from columnar to wedge shape forming the medial hinge point (MHP) 2. 
As elevation proceeds the neural groove deepens and the dorsal parts of the neural 
walls transform into neural folds. During formation of hinge points in the neural folds, 
i.e. lateral hinge points (LHP), the neural folds converge towards the midline 2. 
Subsequent closure of the neural tube occurs through apposition of the neural folds 
followed by adhesion and fusion of the neuroepithelial cells 1;2. 
The processes of elevation 
and closure of the neural 
walls are driven by a 
multitude of factors, which 
are categorised in intrinsic 
and extrinsic factors 2. 
Examples of intrinsic factors 
are the mediolateral 
narrowing and longitudinal 
extension of the neural 
plate by intercalation of 
neural plate cells 5, and by 
an increase in the number of neuroepithelial cells through spatial distinct cell 
proliferation patterns 6. Apical narrowing of the neuroepithelial cells by constriction of 
actin microfilaments that are situated circumferentially at the apical side of the cell is 
another example 7-9. The latter results in the above described reshaping of neural 
plate cells from columnar to wedge shape leading to elevation and convergence 
movements, and possibly to the formation of hinge points and generating furrowing 
(Figure 1) 2. Extrinsic factors include expansion of the underlying tissue and of the 
surface ectoderm. 
The exact closure mechanism of the neural tube differs for the various regions of 
closure and can be divided in three types 10. In the first type only the MHP is present 
resulting in a neural tube with a slit-shaped lumen. In the second type, besides the 
LHP
notochord
actin filaments
ectoderm
MHP
neural wall
neural fold
Figure 1.  
Schematic representation illustrating bending of the neural plate. MHP: 
medial hinge point, LHP: lateral hinge point.  
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MHP, paired LHP are formed leading to a diamond-shape lumen. In the last type, the 
entire neuroepithelium is bending and hinge points are not discernible, resulting in a 
circular lumen.  
 
1.1.2 Neural tube closure initiation sites 
The closure of the neural tube initiates at several sites, which was firstly observed in 
the mouse, where at least four different closure initiation sites were found 11. Multiple 
initiation sites were subsequently observed in many other species, e.g. chicken 12, 
rabbit 13 and pig 14. After closure of the first initial closure site two openings in the 
neural tube remain that are referred to as neuropores, i.e. the anterior neuropore 
(ANP) at the cranial side of the initial closure site and the posterior neuropore (PNP) 
at its caudal side.  
Also in man several closure initiation sites were found 15. The first closure occurs at the 
cervical region (site A) (Figure 2) and progresses both cranially and caudally along 
the neural groove. The second closure site is located between the future 
mesencephalon and rhombencephalon (site B). As a result, a small slit-like opening 
between closure site A and B occurs, that is present for a few hours only. Closure B 
progresses bidirectionally as well, towards the rostral end of the neural groove and 
towards closure site A. Closure of the neural tube is also initiated at the rostral tip of 
the anterior neuropore (site C) and proceeds caudally over the future 
prosencephalon, until it meets the closure started at site B. 
Initial closure is a peculiar mechanism: the neural walls appose from the beginning 
onwards and subsequently open to form a lumen 16. Probably due to this closure 
mechanism, neural tube defects barely exist at initial closure sites but are mostly 
present in the region between these sites. 
 
1.1.3 Neural tube closure defects 
The various forms of neural tube defects in man can be explained by the initial 
closure site model described above and can roughly be divided in three types 15;17. 
Failure of closure that involves the brain and the spinal cord is referred to as total 
dysraphism (craniorachischisis totalis) and is not compatible with postnatal life. 
Neural tube closure defects in the cranial region are referred to as anencephaly. 
Children that survive the delivery die shortly after birth. Closure defects more 
caudally in the neural tube, at the cervical, thoracal and lumbosacral region, are 
referred to as spina bifida aperta. Two forms of spina bifida aperta can be defined, 
i.e. meningocele, which is a sacullar herniation of meninges through a bony defect 
of the spine, and meningomyelocele, which is characterised by herniation of the 
spinal cord, nerves or both through a bony defect in the spine. Meningoceles are 
mostly covered by skin while meningomyeloceles are usually open defects 17. In 
contrast to anencephaly, most neonates born with meningo(myelo)cele survive, 
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usually with the help of medical and surgical treatment. Possible disabilities are 
deformation or dysfunction of the limbs, spine, bladder, bowel and sexual organs. 
Additionally, learning disabilities, hydrocephalus and paralysis occur.  
Neural tube closure defects are part of neural tube defects. Other examples of 
neural tube defects are encephalocele, which is a defect in the calvaria through 
which the brain and meninges 
herniate, and spina bifida occulta, 
which is a bony defect of the spine, 
usually covered by normal skin.  
 
1.1.4 Neural tube closure in the 
chick embryo 
In this thesis special attention is paid 
to the cranial neurulation in the 
chick. The use of the chick embryo 
as animal model has several 
advantages. Examples of these are 
the possibility to time the 
development of the embryo, the 
easy accessibility of the embryos 
through its development outside the 
mother and the possibility to 
manipulate the embryos after 
pealing off the egg shell and shell 
membranes with good survival. 
Because of that, investigations in the 
chick embryo have led to a detailed 
description of neural tube closure, 
which is summarised below 18. 
After induction of the neural plate in the chick embryo, the location of the first 
closure is at the future mesencephalic region (site A) (Figure 2) creating a neuropore 
at the anterior side of the neural tube (ANP). The second closure site is located in 
between the somites, and is referred to as the intersomitic closure (site B). This second 
closure site creates a rhombencephalic neuropore (RNP) at the cranial site, in 
between site A and B, and a posterior neuropore (PNP) at the caudal site of closure 
B. From these sites onwards further closure proceeds, which is illustrated in Figure 2. 
Closure A progresses craniallly until the cranial site of the neural tube is completely 
closed and extends caudally until it meets closure B. The intersomitic closure site B 
extends bidirectionally i.e. cranially towards closure A and caudally towards the end 
of the neural groove. The closure of the neural tube starts when the embryo is at a 
Figure 2. Illustration of the multiple closure sites of the neural 
tube in human and chick embryo. Represented are the 
initial closure sites (A, B and C) and neuropores. 
ANP=anterior neuropore, RNP=rhombencephalic neuropore, 
PNP= posterior neuropore 
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developmental stage of 0-1 somites and is completed when the embryo is 24 
somites. The ANP has a triangular shape, is present from 1-somite stage onwards, 
increases in size till the 4-somite stage and closes from that stage onwards till the 9-
somite stage 12;16. The RNP has a rhomboid shape, and is present for a few hours only, 
when the embryo is between 6 and 7 somites. It is suggested that the somites and 
axial curvature may play a role in closure of the RNP 12. The PNP has a pear-like         
shape, and is present from 8 somites until the neural tube is completely closed at 24 
somites 12. The way of neural tube closure depends on the developmental stage of 
the embryo. The cranial closure proceeds in a zipper-like manner, while the closure 
progressing caudally initiate with button-like contacts before complete fusion takes 
place. Consecutively, the PNP closes at a zipper-like manner 12. 
As previously mentioned special attention is paid to the cranial neural tube and ANP 
closure in particular. The role of actin-containing microfilaments in ANP closure has 
been mentioned before and is based on several studies. Microfilaments have been 
detected by transmission electronic microscopy in neuroepithelial cells 8 and 
specifically at the apical side of this cells by staining of mesencephalic closure 
sections with actin-coupled rhodamine 9. Administration of cytochalasin-D, an 
inhibitor of microfilament polymerization, resulted in widening of the neural folds in  
rat 19 and in chick embryos 9. Other studies demonstrated that various actin-related 
gene knock-out mouse models result in cranial neural tube closure defects 20. Thus, it 
is apparent that actin is a major driving force in cranial neural tube closure. 
 
1.2. PREVALENCE OF NTD AND RISK FACTORS FOR NTD 
Neural tube defects are relatively common and vary per country with a prevalence 
of 1 per 2500 in Finland, 1 per 300 in Mexico till 1 per 80 births in South Wales. In the 
Netherlands the prevalence varied between 1.4 and 2.0 per 1000 births between 
1988-1998 21. The prevalence of NTD is mostly determined by the number of NTD 
observed in live-born infants. The increase in prenatal screening has raised the 
number of elective abortions of infants with NTD, which can result in an 
underestimation of the prevalence because these numbers are often not well 
registered and subsequently excluded from the prevalence calculation 22.  
The causes of NTD are multifactorial, in which genetic predisposition as well as 
environmental factors play a joint role. Evidence for genetic predisposition as 
determinant for NTD are a preponderance of NTD in females, prevalence differs with 
racial and ethnic background 23;24, increased rates in monozygotic twins 25;26, 
increased prevalence in siblings 27 and a two-fold increased risk in individuals 
homozygous mutant for the 677 C>T polymorphism in the methylenetetrahydrofolate 
reductase gene 28;29. NTD that are due to a genetic predisposition only, like 
chromosomal abnormalities and single-gene mutations account for fewer than 10 
percent of the NTD cases 30. Environmental factors that are risk factors of NTD are the 
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use of antiepileptic drugs like valproic acid 31 and maternal conditions like diabetes 
32, hyperthermia 33,34 obesity 35 and profession 36;37. 
Higher rates of NTD have also been observed in groups with lower socio-economic 
status, which indicate that nutritional factors are involved in the etiology of NTD 38. 
In 1976 Smithells et al. 39 investigated the nutritional status of women carrying a child 
with NTD and observed that red cell folate levels were decreased. In a following 
study 40 they observed a 86% lower recurrence frequencies in a study population of 
women supplemented with folic acid compared to women not supplemented with 
folic acid from the same centre. The randomised MRC trial 41 observed that the risk 
for recurrent NTD was 72% lower in women supplemented with 4 mg folic acid daily 
than the non-supplemented folic acid group. Ceizel et al. 42 reported a lower risk for 
first occurrence of NTD when women took a multivitamin containing 800 µg folic 
acid, daily. An intervention study carried out in a low and a high NTD incidence area 
in China revealed a significant reduced risk for NTD when women took 400 µg folic 
acid daily 43. These findings lead to the general scientific consensus that 
periconceptional folic acid supplementation prevents NTD and to the advise for 
women planning a pregnancy to take 400 µg folic acid, daily. Because most 
pregnancies are unplanned in the united states all grain products are fortified with 
0.4 mg folic acid per gram product, in the USA since 1998. Since this folic acid 
fortification 20% reduction in NTD has been observed in the USA 44.  
 
1.3  FOLATE 
Folate is a vitamin for humans and is obtained from the diet. Dietary folates mainly 
exist as polyglutamates 45. Because the uptake and transport of folate in the body 
occurs as monoglutamates, the dietary polyglutamated folates have to be 
deconjugated to monoglutamates, before absorption. The enzyme responsible for 
this deconjugation is folylpoly-γ-glutamate carboxypeptidase (FGCP) 2, which is 
anchored to the intestinal apical brush border 46. This enzyme is encoded by the 
glutamate carboxypeptidase II (GCPII) gene.  After the deconjugation process the 
folate monoglutamates are absorbed in the proximal small intestine by the intestinal 
folate carrier. 
Once folate has entered the blood stream, it is mainly present as 5-methylTHF 
monoglutamate, which primarily enters the cell by the folate receptor alpha (FR-α) 
which is a membrane receptor with a high affinity for the monoglutamate                 
5-methylTHF 47. Other folate receptors are the folate receptor-beta, folate receptor-
gamma and the reduced folate carrier (RFC) but all possess a lower affinity for         
5-methylfolate than FR-α. To retain the folate in the cell the enzym folylpolyglutamate 
synthase adds glutamyl groups to the glutamyl group of folate as polyglutamates are 
poorly transported over the cell membrane. 
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Upon entering in the cell 5-methylTHF functions as a methyldonor for the 
remethylation of homocysteine to methionine with subsequent formation of THF 
(Figure 3). Methionine is the precursor for the synthesis of S-adenosylmethionine 
(AdoMet), the major cellular methyl donor for DNA, RNA, proteins and phospholipid 
methylation. In situations of folate deficiency methionine formation is reduced 
resulting in decreased AdoMet levels, consecutive leading to hypomethylation of 
several compounds.  
The THF formed after demethylation of 5-methylTHF is used as a substrate in several 
reactions (Figure 3). THF can be converted to 10-formylTHF. This reversible reaction is 
catalyzed by the tri-functional enzyme methylenetetrahydrofolate dehydrogenase 
(MTHFD), i.e. formyltetrahydrofolate synthase (FS). The other two enzymatic properties 
of MTHFD are methenyltetrahydrofolate cyclohydrolase that reversibly converts 10-
formylTHF to 5,10-methenylTHF, and methylenetetrahydrofolate dehydrogenase that 
reversibly converts 5,10-methenylTHF to 5,10-methyleneTHF 48. The folate metabolism 
donates one carbon units in the synthesis of the purines adenine and guanine, which 
Figure 3.  
Simplified folate/homocysteine metabolism 
THF=tetrahydrofolate; DHF=dihydrofolate; MS=methionine synthase; MAT=methionine adenosyltransferase; SAHH=S-
adenosylhomocysteine hydrolase; BHMT= betaine-homocysteine methyltransferase; CBS=cystathionine β-synthase; 
C=γ-cystathionase; MTHFR=methylenetetrahydrofolate reductase; SHMT=serine hydroxymethyltransferase; 
MTHFD=methylenetetrahydrofolate dehydrogenase; TS=thymidilate synthase; DHFR=dihydrofolate reductase; 
AdoMet=S-adenosylmethionine; AdoHcy=S-adenosylhomocysteine; B6=vitamin B6 (PLP); B12=vitamin B12 
(cobalamin); B2=vitamin B2 (riboflavin) 
Homocysteine
Methionine
THF
Methy lated product
Methy l acceptor
5-methy lTHF5,10-methy leneTHF
SHMT
10-formy lTHF
5,10-metheny lTHF
DHF
dUMP
dTMP
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MSB12
Betaine
SAHH
Cystathionine
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MTHFR
MTHFD
TS
B6
C B6
B6
B2
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MTHF
D MTHFD
Blood
Cell
BHMT
AICAR
FGARGAR
AdoMet
AdoHcy
Adenosine
MAT
DHFR
Dimethy lglycine
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are building blocks for DNA. Another DNA building block is thymidine, which synthesis 
is catalyzed by the enzyme thymidilate synthase (TS). In this reaction, 5,10-
methyleneTHF donates a methylene group to dUMP to form dTMP and dihydrofolate 
(DHF). In situations of folate deficiency, insufficient conversion of dUMP to dTMP can 
result in reduced thymidine levels, which can cause uracil misincorporation into DNA 
strands during replication 49. Uracil misincorporation leads to an increase in double-
strand breaks and can induce point mutations during uracil excision repair 50-52. The 
dihydrofolate (DHF) resulting from the synthesis of thymidine is reduced back to THF 
by the enzyme dihydrofolate reductase (DHFR).  
 
Table 1. Overview of genetic variation in the folate/homocysteine pathway and associations with 
homocysteine and NTD 
Gene Genetic variant 
(amino acid 
change) 
Allele frequency 
% 
Homocysteine* NTD* Referenties 
MTHFR A226V (677 C>T) 30-40 + + 28;58 
MTHFR Q433A (1298 A>C) 30-40 +/- +/- 58;59 
RFC R27H (80 G>A) 46-53 -/1 +/- 60-62 
cSHMT L474F  (1420 C>T) 32 +/1 - 63 
mSHMT 1721 deletion 4 bp 3 - - 63 
MTHFD R653Q (1958 G>A) 56 ? +/- 64;65 
MTRR I22M (66 A>G) 51-56 +/- +/- 66;67 68-70 
MS D919G (2756A>G) 15-20 - - 68;71 
CBS 844 insertion 68 bp 5-12 - - 72;73 
BHMT Q239R (716 G>A) 32 - ? 74 
*+ association, +/- possible association, - no association, ? not examined, 1 based on one study  
 
The enzyme  serine hydroxymethyltransferase (SHMT) catalyses the reversible 
conversion of serine and THF to glycine and 5,10-methyleneTHF and is present in two 
isoforms i.e. a cytosolic and a mitochondrial form (Figure 3). Both enzymes require 
pyridoxal phosphate, which is an active form of vitamin B6 53. The 5,10-methyleneTHF 
can be further reduced to 5-methylTHF. This last reaction is catalysed by the enzyme 
methylenetetrahydrofolate reductase (MTHFR). This enzyme has been shown to be of 
great importance for the regulation of available folate for the remethylation of 
homocysteine 54. The 677 C>T polymorphism in the MTHFR gene results in a reduced 
activity of the enzyme leading to a decreased availability of 5-methylTHF required for 
the remethylation of homocysteine (Table 1) 28;54;55. The homozygous mutant form of 
this polymorphism is associated with an increased risk for NTD 28;29;56. In addition, most 
studies reported increased plasma homocysteine levels in individuals homozygous 
mutant for this polymorphism, which in line with a reduced cellular remethylation of 
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homocysteine 28;55. This may lead to a decreased methionine synthesis, reducing the 
methylation of DNA, RNA and proteins. Recently, the MTHFR 677 TT genotype was 
reported to be associated with decreased global DNA-methylation 57. Interestingly, 
the increase in homocysteine levels was not so pronounced in individuals 
homozygous for this polymorphism possessing a high folate status, indicating a 
preventive effect of a high folate intake for the effects of this polymorphism. 
Therefore, it is expected that  
 
women with both, the homozygous mutant form of this polymorphism and with a low 
folate status may have an additional increase in risk for getting a child with NTD. A 
second polymorphism was observed in the MTHFR gene, the 1298 C>T polymorphism, 
which also reduces the MTHFR enzyme activity 59. However, conflicting findings have 
been reported concerning the association of this polymorphism with NTD and 
homocysteine levels 59;75-77. 
Other genetic variants observed in the enzymes involved in the folate metabolism 
are described below and summarised in Table 1. In the RFC a R27H substitution was 
found and associated with increased NTD risk in patients and mothers 60 while Shaw 
et al. 61 could not confirm this association in patients with NTD, but observed a 
possible increased risk in mothers that did not take folic acid containing supplements 
periconceptionally. So far, one study examined homocysteine levels in combination 
with this polymorphism but observed no association 78. The R653Q polymorphism in 
the MTHFD gene was found to be associated with 1.52 times increased risk for in 
mothers of children with NTD 65  while no such association was observed in patients 
with NTD 64. In the gene encoding  SHMT two genetic variations were found. The 
L474F polymorphism in the cytosolic form of SHMT was not associated with NTD, but 
increased homocysteine levels were observed in individuals with the wild type 
genotype 63. In the mitochondrial form of SHMT a TCTT deletion at base pair 1721-
1724 was observed in the heterozygous form only, which was not associated with 
NTD or increased homocysteine levels 63.  So far, the MTHFR 677 C>T polymorphism is 
the only genetic variation in the folate-dependent homocysteine metabolism clearly 
associated with NTD risk, but can only explain a small part of the elevated 
homocysteine observed in mothers of NTD children, indicating the presence of other 
genetic variations 79.  
 
1.4 HOMOCYSTEINE 
The above described pathways in which folate is involved illustrate the complexity of 
unravelling the preventive effect of folate supplementation on the occurrence of 
NTD. The observation of increased plasma homocysteine levels in mothers of children 
with NTD and the identification of the MTHFR 677 C>T genotype as risk factor for NTD 
brought the main focus of research concerning the preventive effect of folate on 
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NTD at the homocysteine/methionine pathway (Figure 3). Homocysteine is 
remethylated to methionine by the donation of a methyl-group from 5-methylTHF or 
betaine, the so-called remethylation. Methionine is subsequently metabolised to 
AdoMet that donates its methyl-group to methyltransferases leading to the formation 
of AdoHcy. The latter conversion is referred to as the transmethylation reaction. 
Besides remethylation, homocysteine is metabolized to cysteine in the 
transsulfuration pathway. These three pathways i.e. the remethylation, 
transmethylation and transsulfuration pathway are described in more detail below. 
 
1.4.1  Remethylation 
The remethylation of homocysteine occurs by two different enzymes and methyl-
group donors. The betaine-dependent remethylation by the enzyme betaine-
homocysteine methyltransferase (BHMT) involves the donation of a methyl-group 
from betaine to homocysteine leading to the formation of dimethyl-glycine and 
methionine, which occurs in the liver only. On the other hand, the folate-dependent 
remethylation by the enzyme methionine synthase (MS) is a house-hold pathway that 
takes place in all cells, except in red blood cells, and involves the donation of a 
methyl-group from 5-methylTHF to homocysteine leading to the formation of 
intestine Intestinal cell
blood cellstomach
Cbl
TCCbl
TC
Cbl
TCCbl
HC
HC
HC
Cbl
Cbl
Cbl(III)MS-Met
MetTHF THF
HcyMet
Cbl(I)MS
AdoMet AdoHcy
Cbl(II)MS Cbl(III)MS-Met
l l
l l
TC
Cbl
Cbl
MMA
IF IF
IFCbl
IF
MTRR
mitochondrion
L-methylmalonyl CoA succinyl CoAmutase
Cbl
Figure 4.  
Vitamin B12 (cobalamin) pathway 
Cbl=cobalamin (vitamin B12); IF=intrinsic factor; HC=haptocorrin; TC=transcobalamin; MTRR=methionine synthase 
reductase; mutase=L-methylmalonyl CoA mutase; MMA=methylmalonic acid; Hcy=homocysteine; 
Met=methionine; AdoMet=S-adenosylmethionine; AdoHcy=S-adenosylhomocysteine; 
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methionine and THF. The enzyme MS requires vitamin B12 as a cofactor. Upon 
binding of vitamin B12 (cobalamin (cbl)) to MS the cbl(I)MS complex is formed to 
which the methyl-group of 5-meTHF can bind (methylcbl(III)MS) (Figure 4). After 
donation of this methyl-group to homocysteine, cbl(I)MS is formed back and 
available for another methyl donation by MeTHF. The cbl(I)MS complex is sensitive to 
oxidation into the inactive cbl(II)MS. The cbl(II)MS complex can be reactivated to the 
functional enzyme methylclb(III)MS by the enzyme methionine synthase reductase 
(MTRR)  and the donation of a methyl-group from AdoMet. A polymorphism in the 
gene encoding MTRR i.e. the I22M transition (Table 1), was reported to be associated 
with NTD only when vitamin B12 levels were low 66. Other polymorphisms have been 
described for the above mentioned enzymes (Table 1). In the MS gene a D919G 
polymorphism was found which was not associated with NTD or elevated 
homocysteine levels 71. The polymorphisms found in BHMT, i.e. the G199S and the 
Q239R did not effect homocysteine levels and have not been screened in a NTD 
study population, so far 80.  
 
1.4.1.1 Vitamin B12 uptake, transport and metabolism 
Like folate vitamin B12 is an essential vitamin for humans and need to be obtained 
by the diet. Vitamin B12 is only available for uptake from animal products and 
vegetarians are therefore at risk to develop vitamin B12 deficiency. Upon entering 
the stomach vitamin B12 is released from food by peptidases, subsequently bound to 
haptocorrin (HC), and transferred to the duodenum (Figure 4). In the duodenum 
vitamin B12 is released from HC and bound to intrinsic factor (IF), which derived from 
the parietal cells in stomach. The IF-vitamin B12 complex is absorbed in the ileal 
mucosal cell by receptor-mediated endocytosis bound by cubulin, the IF-B12 
receptor. Within the enterocyte vitamin B12 is bound to transcobalamin (TC) and 
released into the circulation 81. TC facilitates transport of vitamin B12 in blood to 
various tissues. Only 20 percent of the total vitamin B12 in plasma is bound to TC, the 
remaining 80 percent is bound to HC. The role of HC in blood is unclear, but is has 
been suggested that it functions as binder for vitamin B12 analogues to transport 
these to the liver for excretion 82.  
Holo-TC is the proportion of TC that contains vitamin B12, as opposed to apo-TC to 
which no vitamin B12 is bound. The same nomenclature applies for HC. Since TC 
transports the vitamin B12 to the cell, low plasma holo-TC concentrations may be the 
earliest indicator of a negative vitamin B12 balance 83 and may be a better indicator 
of vitamin B12 status than plasma total vitamin B12 concentrations (holo-TC + holo-
HC). Recently, it was reported that an increase in vitamin B12 intake results in a first 
and great increase in holo-TC concentrations and a later and smaller rise in          
holo-HC 84; 85  
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Holo-TC binds to receptors present on the cells surface and is internalised by 
receptor-mediated endocytosis 86. In the cell vitamin B12 is converted to two 
metabolic active forms i.e. methylcobalamin required as a cofactor for methionine 
synthase, which is present in the cytosol and 5’-deoxyadenosylcobalamin necessary 
for the function of methylmalonyl CoA mutase present in the mitochondria (Figure 4). 
The latter converts L-methylmalonyl CoA to succinyl CoA. Vitamin B12 deficiency will 
result in elevated L-methylmalonyl CoA concentrations, and a subsequent rise in 
methylmalonic acid (MMA) 87 and in elevated homocysteine concentrations. 
Because homocysteine concentrations are determined by many different 
factors,cplasma MMA levels are reported to be the best indicator of the cellular 
vitamin B12 status 84;85.  
 
1.4.2 Transmethylation 
Methionine adenosyltransferase (MAT) catalyses the biosynthesis of                        
S-adenosylmethionine (AdoMet) from methionine and ATP (Figure 3). MAT is present 
in two isoforms: the non-liver-specific form encoded by the MAT2a gene, which is 
present in nearly all tissues and the liver-specific form encoded by the MAT1a gene 
that is expressed in liver, only. AdoMet is the ultimate source of methyl-groups for 
methylation reactions. The transfer of a methyl-group from AdoMet to a methyl-
acceptor results in the formation of S-adenosylhomocysteine (AdoHcy). AdoHcy is 
hydrolysed to adenosine and homocysteine by the enzyme AdoHcy hydrolase. The 
equilibrium of this reversible reaction however favours AdoHcy, which is an allosteric 
inhibitor of methylation. Therefore, homocysteine and adenosine need to be 
metabolised quickly, in order to maintain low AdoHcy levels. 
  
1.4.3 Transsulfuration 
In the transmethylation and remethylation pathway homocysteine is retained. In the 
transsulfuration pathway homocysteine is irreversibly degraded to cysteine by two 
pyridoxal-phosphate (active form of vitamin B6)-dependent enzymes, i.e. 
cystathionine β-synthase (CBS) which catalyzes the condensation of serine and 
homocysteine to cystathionine, and γ-cystathionase which catalyzes the hydrolysis of 
cystathionine to cysteine and α-ketobutyrate (Figure 3).  
Vitamin B6 is present in different forms; pyridoxine, pyridoxal, and pyridoxamine, and 
their phosphate esters. The metabolic active coenzyme form of vitamin B6 in the 
homocysteine metabolism is pyridoxal 5’-phosphate (PLP). After absorbtion in the 
upper small intestine, the different forms of vitamin B6 are transported to the liver, 
where the major part is transformed to pyridoxal 5’-phosphate (PLP) 88;89. 
Several genetic variations in the CBS gene are described. The 833 T>C transition 
results in a decreased enzyme activity and causes severe elevations in homocysteine 
concentration. The frequency of most CBS variations is low and associations with NTD 
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are scarcely examined. One genetic variation that has been studied in relation to 
NTD is the 68 bp insertion/I278T but has not been associated with NTD risk             
(Table 1) 72;73.    
 
1.5 ANIMAL MODELS 
1.5.1. NTD mutant  models 
To examine the mechanism behind the preventive effect of folate on occurrence of 
NTD, animal models with NTD are studied in which folate supplementation may 
decrease the frequency of NTD. Of the approximately 100 NTD mouse mutant 
models described so far, only three mouse mutant NTD models are known for their 
preventive effect of folic acid on NTD. In Splotch mice, which exhibit both 
exencephaly and spina bifida, NTD was prevented in 35% of the homozygous 
embryos after maternal supplementation with folic acid 90. The outcome of the 
deoxyuridine suppression test led the authors to suggest that the NTD were partly due 
to an inborn error in the provision of folate intermediates for the production of 
pyrimidines during DNA biosynthesis. Cart1 mice have a null-mutation in the cart1 
gene encoding a transcription factor and develop cranial NTD. The incidence of 
NTD was prevented by folic acid supplementation by approximately 60% 91. In 
Crooked tail (Cd) mice that exhibit exencephaly, a dose and gender dependent 
reduction in prevalence of NTD up to 55% occurred when the dam was 
supplemented with folic acid 92.  The preventive mechanism in the last two mouse 
models is still to be unraveled. 
 
1.5.2. Knockout models 
An important method to examine the role of a protein in the etiology of NTD, is the 
complete or tissue specific knock-out of the encoding gene in an animal model. This 
technique has been used for the complete knock-out of the gene encoding folate-
binding protein (Folbp1). Nullizygous folbp1 mice had severe abnormalities among 
which NTD and died in utero 93. This phenotype could be prevented by 
supplementation of the dams with folinic acid. Inactivation of another folate binding 
protein (Folbp2) that binds folate poorly, resulted in normally developed mice.   
Several genes encoding enzymes involved in the folate-homocysteine metabolism 
have been inactivated in mouse models. Knock-out of the gene encoding the 
enzyme MTHFR in mice leads to increased homocysteine levels and hypomethylation 
but did not result in NTD 94. Antisense modulation of MTHFR expression however 
resulted in a dose-dependent increases in frequencies of embryos with NTD 95. 
Disruption of the methionine synthase (MS) gene in mice resulted in slightly elevated 
homocysteine levels in heterozygous knock-out mice. Homozygous knock-out mice 
died in utero and were reabsorbed before embryonic day 9, NTD could thus not be 
assessed. Supplementation with folate, choline, betaine, methionine or inositol failed 
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to rescue the nullizygous embryos 96. Homozygous mutant mice completely lacking 
the CBS gene had 40 times higher homocysteine levels than wild type mice. They 
had severe growth retardation and most of them died within five weeks after birth 97. 
Heterozygous CBS knock-out mice had about twice the normal homocysteine levels. 
Knock-out of the CBS gene did not lead to NTD in homozygous as well as 
heterozygous knock-out mice.  
 
1.6 OBJECTIVES AND OUTLINE OF THIS THESIS 
1.6.1 Objectives 
Elucidate whether a low or disturbed vitamin B12 metabolism in addition to folate 
plays a role in the etiology of NTD and whether a possible association could be 
explained by genetic variations in genes encoding proteins of the vitamin B12 
metabolism. 
Identifying genetic risk factors for NTD that are related to the folate-dependent 
homocysteine pathway, in addition to the MTHFR 677 C>T polymorphism. Examine 
whether these genetic variations are associated with increased homocysteine levels 
and increased risk for NTD. This knowledge would make it possible to identify women 
genetically predisposed for getting a child with NTD. 
To get more insight into the mechanism behind the preventive effect of folic acid on 
NTD, by manipulation of the folate-dependent homocysteine metabolism in a chick 
embryo model.  
 
1.6.2. Outline 
Part 1 includes the examination of vitamin B12 status in mothers of NTD children by 
using several parameters for vitamin B12 status. Known and new genetic variations in 
genes encoding vitamin B12-related proteins are studied and the association of 
these variations with NTD, vitamin B12 determinants and homocysteine 
concentrations are analyzed (chapters 3-5). The association of other metabolites 
and genetic variations involved in the folate/homocysteine metabolism with NTD risk 
and homocysteine are examined (chapters 2, 6 and 7). 
Part II  contains the studies that manipulated the homocysteine metabolism in the 
chick embryo. The influence of elevated homocysteine levels on the process of 
neural tube closure in chick embryos is examined. The effect of methylation inhibitors 
on cranial neural tube closure and on AdoMet and AdoHcy levels is studied 
(chapters 8 and 9).  
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ABSTRACT 
In the diet the natural form of folate exists predominantly in the form of 
polyglutamates. Before absorption, these polyglutamates must be deconjugated to 
monoglutamates by the enzyme folylpoly-γ-glutamate carboxypeptidase (FGCP) 
located in the jejunum. Recently, a H475Y polymorphism in the glutamate 
carboxypeptidase II (GCPII) gene, encoding the FGCP enzyme, was reported to be 
associated with decreased plasma folate and increased plasma homocysteine 
(tHcy) levels. Low folate and elevated tHcy levels are risk factors for neural tube 
defects (NTD). Therefore, we examined whether this polymorphism is associated with 
NTD risk and plasma folate, erythrocyte folate and plasma tHcy levels in 96 NTD 
patients, 113 mothers, 97 fathers and 101 controls. This variation was associated with 
increased plasma folate (P<0.04) and tended to be associated with decreased 
plasma tHcy (P<0.09). It was not associated with erythrocyte folate or the risk for NTD. 
The H475Y polymorphism in the GCPII gene may increase the deconjugation activity 
of the FGCP enzyme, resulting in an increased absorption of folate in the body, as 
reflected by the increased plasma folate and decreased plasma homocysteine 
concentrations.  
 
 
INTRODUCTION 
Folate is an essential vitamin for humans and is obtained from the diet. Dietary folates 
exist mainly as polyglutamates 45. Because the uptake and transport of folate in the 
body occurs as monoglutamates, the dietary polyglutamated folates have to be 
hydrolyzed to monoglutamates, before absorption. The enzyme responsible for this 
deconjugation is folylpoly-γ-glutamate carboxypeptidase (FGCP)2, which is 
anchored to the intestinal apical brush border 46. After the deconjugation process, 
the folate monoglutamates are absorbed in the proximal small intestine by the 
intestinal folate carrier. 
A low folate status has been associated with increased risk for neural tube defects 
(NTD) 98. Several studies established that periconceptional folic acid supplemen-
tation reduces NTD risk by 60% 41;42;99. The exact mechanism of this preventive effect 
of folic acid on NTD is unknown. In addition to its involvement in the synthesis of 
purines and thymidine, folate is also required for the remethylation of homocysteine 
to methionine. Several papers reported elevated plasma homocysteine levels in 
mothers children with NTD 100-102 which can be reduced by folic acid intake 101;103;104. 
Part of the preventive effect of folate is explained by the methylenetetrahydrofolate 
reductase (MTHFR) 677 C>T polymorphism; women with this polymorphism in the 
homozygous form have low plasma folate and elevated plasma homocysteine levels 
and have about a twofold higher risk of having a child with NTD 28;58. This 
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demonstrates that genetic defects in enzymes involved in the folate-homocysteine 
pathway can affect the risk for NTD.  
Recently, a H475Y polymorphism (1561 C>T) in the glutamate carboxypeptidase II 
(GCPII) gene, encoding the above-described FGCP enzyme, was reported to 
decrease the enzyme’s activity and was associated with decreased plasma folate 
levels and increased plasma total homocysteine tHcy levels 105. Thus, this variant may 
be associated with increased NTD risk. It is worth mentioning that the supplemented 
form of folate, folic acid, is a synthetic monoglutamate and does not require FGCP 
before absorption.  
The aim of our study was to investigate whether the H475Y polymorphism in the GCPII 
gene is associated with NTD risk and whether it influences plasma and red cell folate 
levels and plasma tHcy in patients with NTD, their parents and in a control 
population.     
 
 
METHODS 
Study population 
Samples of patients with spina bifida and their parents were collected from two 
study populations. All individuals were Dutch Caucasians. One group was recruited 
in collaboration with the Dutch society for patients with central nervous system 
defects (BOSK). The second study population consisted of patients and their parents 
recruited by participation of the department of Child Neurology of the University 
Medical Center Nijmegen. The control groups consisted of healthy employees of our 
University Medical Center with no history of NTD. The protocol was approved by the 
local ethics committee and written informed consent was obtained. The final study 
population consisted of 96 patients (mean age 16 ± 11 years), 113 mothers (mean 
age 43 ± 11 years), 97 fathers (mean age 45 ± 10 years) and 101 controls (mean age 
35 ± 8 years). The percentage supplement users in our study population is unknown. 
However, samples of  the study population were collected in the early 1990s when 
supplement use was uncommon in the Netherlands. 
 
Method 
Erythrocyte and plasma folate and plasma vitamin B-12 levels were determined by 
using the Dualcount Solid Phase Boil Radioassay (Diagnostic Products Corporation, 
Los Angeles, California, USA). Homocysteine concentrations were determined in 
EDTA plasma by HPLC with fluorescence detection 106.  
The H475Y polymorphism was determined by restriction fragment length 
polymorphism-polymerase chain reaction on genomic DNA as described by Devlin 
et al. 105 and the prevalence of the MTHFR 677C>T mutation was investigated as 
described by Frosst et al 54.   
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Statistics 
Odd ratios (OR) and 95% confidence interval (CI) for patients, mothers and fathers 
compared with controls were calculated by logistic regression analyses. Plasma and 
erythrocyte folate and plasma homocysteine concentrations showed a non-normal 
distribution. Therefore, natural logarithmically transformed values were used for all 
calculations and mean values were expressed as geometric means. Comparison of 
mean biochemical concentrations between the genotypes was performed with 
general linear model analysis and adjusted for age, gender and the MTHFR 677 C>T 
polymorphism. All analyses were performed with the SPSS 10.0 software package 
and statistical significance was accepted at P<0.05. 
 
 
RESULTS 
The GCPII H475Y polymorphism was analyzed on genomic DNA of patients, their 
parents and controls. The prevalence of this polymorphism and other characteristics 
of patients, their parents and controls are summarized in Table 1.   
 
Table 1. Characteristics and distribution of the H475Y polymorphism in the GCPII gene in NTD patients, 
their parents and controls  
Controls  
  
Patients 
 
Mothers  
 
Fathers  
 Female (n=28) Male (n=73) 
Age (y)1 16.4 ± 11.3 (95) 42.9 ± 10.9 (113)7 44.9 ± 10.2 (97)8 35.6 ± 8.3 34.1 ± 8.8 
Gender (% female)2 55 (56%) 113 (100%) 97 (100%) 73 (100%) 28 (100%) 
11.7 (10.5-12.9) (80) 12.7 (11.6-13.8) (110) 12.2 (11.2-13.3) (90) 14.7 (13.4-16.1) 13.5 (11.4-16.1) 
476 (442-512) (77) 542 (504-582) (107) 574 (539-610) (88) 560 (517-607) 585 (528-648) 
Plasma folate (nmol/L)3 
RBC folate (nmol/L)3 
Plasma tHcy (µmol/L)3 11.8 (11.0-12.5) (88) 12.5 (11.7-13.2) (112) 14.2 (13.4-15.1) (94) 12.3 (11.7-12.9) 16.2 (13.6-19.2) 
Plasma vitamin B-123 282 (252-315) (81) 209 (190-231) (110) 233 (218-249) (90) 223 (204-245) 210 (185-237) 
HH 85 (88.5%) 103 (91%) 86 (89%) 89 (88%) 
HY 11 (11.5%) 10 (9%) 11 (11%) 10 (10%) 
GCPII H475Y2, 6 
 
 YY 0 0 0 2 (2%) 
 HY/YY versus HH4 1.0 (0.4-2.3) 0.7 (0.3-1.8) 0.9 (0.4-2.3) 15 
1 Values are mean ± sd (n), 2 Values are n (percentage), 3 Values are geometric mean (95% confidence interval) (n) 
P-values are age-adjusted, 4 Values are odds ratio (95% confidence interval), 5  Reference category, 6  χ2 = 0.42, 
P=0.52, 7 Different from female controls P<0.05, 8 Different from male controls P<0.05 
 
The distribution of the H475Y polymorphism in the total study population was in Hardy-
Weinberg equilibrium (χ2 =0.42, P=0.52). The allele frequency of the Y allele was 6.9% 
in the control population and 5.7%, 4.4% and 5.7 % in patients, mothers and fathers, 
respectively. Since the homozygous YY genotype was present in two controls only, HY 
and YY genotypes were combined for both, the calculation of OR (Table 1) and the 
examination of possible associations with metabolic compounds. The metabolite 
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concentrations in the two individuals with the YY genotype were 13 and 21.0 nmol/L 
for plasma folate, 490 and 790 nmol/L for erythrocyte folate and 14.7  and 19.8 
µmol/L for plasma tHcy, respectively. The high plasma homocysteine levels of the 
second subject may have been due to low vitamin B-12 levels (130 pmol/L).  
Because the genotype distribution did 
not differ among patients, mothers, 
fathers and controls, we combined 
parents of NTD patients and controls to 
increase statistical power for the 
examination of possible associations of 
this polymorphism with plasma folate, 
erythrocyte folate and plasma tHcy 
levels. Because homocysteine 
concentrations are age dependent and 
appropriate controls for the much 
younger NTD patients were not available, 
NTD patients were excluded from this 
analysis. Plasma folate levels of the GCP II 
genotypes  are depicted in Figure 1. 
Analyses for a possible association 
between the GCPII polymorphism and 
plasma folate levels were performed in 
297 individuals. Individuals with the HY/YY 
genotypes had greater plasma folate concentrations than their HH peers (P=0.043). 
Erythrocyte folate levels in 294 subjects did not differ between HH (mean 555 nmol/L, 
95% CI 533-578) and HY/YY (mean 582 nmol/L, 95% CI 518-654) genotypes (P=0.45). 
The possible association of the GCPII H475Y polymorphism with plasma homocysteine 
levels was examined in 296 individuals; plasma homocysteine levels tended to be 
lower (P=0.087) in individuals with the HY/YY (mean 12.3 µmol/L, 95% CI 11.1-13.5)  
genotype compared with HH (mean 13.4 µmol/L, 95% CI 13.0-13.9)  subjects. 
Analyses of plasma and erythrocyte folate and plasma tHcy levels for mothers, 
fathers and controls separately did not reveal any significant differences. 
 
 
DISCUSSION 
We observed an association of the H475Y polymorphism in the GCPII gene with 
increased plasma folate levels and decreased plasma tHcy concentrations. 
Erythrocyte folate levels were not associated with this polymorphism and we did not 
observe an association of the H475Y variation with NTD risk in our study population.  
12
14
16
18
HY/YY (n=32) HH (n= 265)
GCPII H475Y
Pl
a
sm
a
 fo
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te
 (n
m
ol
/L
) 
P=0.04
Figure 1 
Plasma folate levels in the study participants analyzed 
by the H475Y polymorphism in the GCPII gene. Plasma 
folate levels are significantly increase for the HY/YY 
genotypes (P=0.04). Values are geometric means 
shown as diamonds with 95% confidence interval (CI). 
Geometric mean levels were adjusted for age, 
gender, plasma vitamin B-12 and the MTHFR 677 C>T 
polymorphism. Statistically significance was accepted 
at P<0.05. 
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Despite of our relatively large study group, the low prevalence of the H475Y 
polymorphism could have preclude the finding of a risk factor for NTD; therefore 
larger study populations are necessary to investigate this association further. 
Folate is required for the remethylation of homocysteine, and the increased plasma 
folate levels observed in individuals with the 475HY/YY genotype in the GCPII gene 
are therefore in line with the decreased plasma tHcy concentrations in our 
population. This finding indicates that the H475Y polymorphism in the GCPII gene 
may increase activity of the FGCP enzyme, resulting in a greater availability of 
monoglutamates from the small intestine, which subsequently leads to increased 
plasma folate and decreased plasma tHcy concentrations.    
A recent study by our group in a different population of controls and patients with 
cardiovascular disease supports this observation because increased plasma and 
erythrocyte folate levels were observed in individuals with the GCPII 475HY/YY 
genotype 107. In a study published very recently, no association of this variant with 
plasma folate and tHcy levels was observed in 644 women and 680 men as a group. 
When subjects were divided by gender, however, a significant association of the 
475HY/YY genotype with elevated plasma folate levels in men was observed 108. 
Brancaccio et al. 109 analyzed 146 NTD patients and 289 controls for the H475Y 
polymorphism and reported a decreased risk for NTD with an OR of 0.34 (0.12-0.86) 
for this polymorphism. Although we could not confirm this reduced risk for NTD in our 
smaller study population of 96 patients, the reduced risk for NTD is in line with our 
finding of increased plasma folate and decreased tHcy levels. Our data do not 
agree with those of Devlin et al. 105, who were the first group to describe this 
polymorphism. Their findings for serum folate as well as plasma tHcy concentrations 
were the opposite of ours. However, their results were based on only six individuals 
who were heterozygous for this polymorphism. Homozygosity for this polymorphism 
was not observed. In contrast, the present study examined 31 individuals with the HY 
genotype and two persons homozygous for this genotype.  
In summary, the H475Y polymorphism in the GCPII gene is associated with increased 
plasma folate levels and decreased plasma tHcy levels. An association with NTD risk 
was not observed.  To elucidate whether this polymorphism in the GCPII gene 
influences the function of the FGCP enzyme, other types of studies are required, e.g., 
intervention studies in which the influence of controlled dietary folate on folate levels 
is analyzed in individuals with different genotypes for the GCPII polymorphism. 
Furthermore, the activity of the FGCP enzyme seems to depend on the content of 
other compounds in the food consumed, which should therefore be controlled       
too 110. 
Our results and the previously reported results of Lievers et al. point instead toward 
increased conjugation activity of the FGCP enzyme, resulting in increased folate 
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absorption in the body and therefore increased plasma folate, rather than toward 
decreased GCP II activity and decreased plasma folate levels.  
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ABSTRACT 
Periconceptional folic acid supplementation reduces the risk of neural tube defects 
(NTD). Homocysteine levels are elevated in mothers of NTD children, which may be 
due to decreased cellular vitamin B12 levels, as vitamin B12 is a cofactor for the 
methylation of homocysteine. Transcobalamin II (TC II) transports vitamin B12 to the 
tissues. To examine whether altered plasma transcobalamin levels are a risk factor for 
NTD we determined the apo and holo form of TC II and haptocorrin (TCI + TCIII), 
vitamin B12 and homocysteine concentrations in plasma of 46 mothers with NTD 
children, and 73 female controls. 
Holo-tc II levels and holo-tc II percentages (holo-tc II/total tc II) in the first quartile of 
the control distribution were related to a three-fold (OR=2.9, 95% CI=0.9-9.2) 
respectively five-fold (OR=5.0, 95% CI= 1.3-19.3)  increased risk, respectively, for 
having a child with NTD, when compared with the last quartile. Homocysteine levels 
were significantly higher among individuals with low holo-tc II, low total vitamin B12 
concentrations and low holo-tc II percentages. 
These low holo-tc II percentages are probably caused by reduced affinity of TC II for 
vitamin B12 which may be explained by genetic variation in the TC II gene. Vitamin 
B12 supplementation might therfore be warranted, in addition to folate, in the 
prevention of NTD. 
 
 
INTRODUCTION 
Neural tube defects (NTD) arise due to failure of closure of the neural tube, and are 
one of the most common congenital malformations. Periconceptional intake of folic 
acid reduces the occurrence and recurrence risk of neural tube defects (NTD)41;42.  
The mechanism of this protective effect is still unknown. Steegers et al 101 were the first 
to show that elevated homocysteine concentrations are present in mothers of NTD 
children. Later, we identified the first genetic risk factor for NTD, i.e. the C677T 
mutation in the methylenetetrahydrofolate reductase (MTHFR) gene, which causes 
elevated homocysteine concentrations 28. This C677T mutation in the MTHFR gene 
can, however, only partly explain the protective effect of folate  and of the high 
homocysteine levels present among mothers of NTD children. Therefore, other 
functional variants in genes involved in homocysteine metabolism may be       
present 102.  
Vitamin B12 (cobalamin) is a cofactor in the folate-dependent homocysteine 
metabolism. Methionine synthase requires vitamin B12 to transfer the methylgroup of 
5-methyltetrahydrofolate to homocysteine. The products formed are methionine and 
tetrahydrofolate. Intracellular vitamin B12 deficiency may therefore result in 
increased plasma homocysteine concentrations. Low vitamin B12 concentrations in 
the cell could be the result of a low vitamin B12 intake, but could also be due to a 
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disturbance in the absorption, transport or cellular uptake of this vitamin. Upon 
entering the stomach, vitamin B12 is bound to haptocorrin (HC) and transferred to 
the duodenum, where intrinsic factor (IF), arriving from the stomach, binds vitamin 
B12 111. The IF-vitamin B12 complex is absorbed via the IF-B12 receptor, and vitamin 
B12 is subsequently bound to transcobalamin II (TC II) and released into the 
circulation 81. TC II facilitates the transport of vitamin B12 in blood to various tissues. 
Only 20 % of the vitamin B12 in plasma is bound to TC II, the remaining 80 % being 
bound to HC, also referred to as TC I and TC III. So far the role of HC in plasma is 
unclear, it may function as a storage for vitamin B12 112. Holo-tc II is the proportion of 
TC II that contains vitamin B12, and apo-tc II is the proportion of TC II which does not 
contain vitamin B12. A similar nomenclature holds for holo- and apo-hc. The total 
amount of vitamin B12 in plasma is the sum of holo-tc II and holo-hc. Since TC II 
transports the vitamin B12 to the cell, low plasma holo-tc II concentrations may be 
the earliest indicator of a negative vitamin B12 balance 83 and may be a better 
indicator of vitamin B12 status than plasma vitamin B12 concentrations (holo-tc II + 
holo-hc). 
Kirke et al. found an association between decreased maternal plasma vitamin B12 
and an increased risk for getting a child with NTD 113. In addition, Steen et al. 114 and 
Steegers et al. 115 observed decreased vitamin B12 levels in amniotic fluid of mothers 
with NTD children. These findings point to a possible role for vitamin B12 in the 
aetiology of NTD. Magnus et al. 116 showed that  apo-tc I and apo-tc II in midtrimester 
amniotic fluid of mothers who had previously had a child with NTD were significantly 
elevated when compared to control levels. Furthermore, Gardiki-Kouidou and    
Seller 117 found significantly elevated apo-tc II and apo-hc (apo-tc I and -III) levels 
and significantly decreased vitamin B12 levels in amniotic fluids of mothers carrying a 
child with NTD, or who had had a child with NTD. They concluded that this might 
indicate a genetic defect in the transport of vitamin B12 resulting in a disturbed  
vitamin B12 metabolism. 
 In the present study, we examined a possible association between the apo- and 
holo- forms of TC II and HC levels in plasma and the risk for having a child with NTD, 
and whether changes in these concentrations had an affect on homocysteine 
metabolism. We therefore determined the apo- and holo- forms of TC II and HC, total 
vitamin B12 (holo-tc II + holo-hc) and homocysteine concentrations in plasma of 
mothers with NTD children and in female controls. In addition, we analysed whether 
known polymorphisms in the TC II gene i.e. the Pro259Arg and the Gln234Arg 
mutations 118, were associated with a disturbed TC II function. 
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SUBJECTS AND METHODS 
Study population 
Mothers of patients with non-syndromic NTD were recruited by participation from the 
Pediatric department of the University Hospital Nijmegen and were all Dutch 
Caucasians. The controls were healthy female volunteers with no history of NTD in 
their family and were also Dutch Caucasians. The study population consisted of 46 
mothers with NTD children (mean age 38 ± 4 years) and 73 controls (mean age 35 ± 8 
years). The protocol was approved by the local ethics committee and written 
informed consent was obtained. 
 
Methods 
Holo-tc II and holo-hc levels were determined in EDTA plasma according to the 
method described by Benhayoun et al 119. Plasma vitamin B12 (holo-tc II + holo-hc) 
was determined using the Dualcount Solid Phase Boil Radioassay (Diagnostic 
Products Corporation, Los Angeles, Calif, USA). After determination of plasma vitamin 
B12 concentration, TC II was removed with Heparin-Conjugated-Sepharose and the 
remaining holo-hc was also determined by the Dualcount Solid Phase Biol 
Radioassay. Holo-tc II levels were calculated as the difference between holo-hc 
levels and plasma vitamin B12 levels.  
Plasma apo-tc II and apo-hc levels were determined according to the method 
described by Nielsen et al. 120. Briefly, serum samples were incubated with excess 
amounts of 57Co-labelled cyanocobalamin. Subsequently, each sample was loaded 
on a Sephacryl column (HRS300 Hiload 16/60, Pharmacia), with an automatic 
fraction collector and 170 fractions were collected. Radioactivity was counted in 
each fraction by a gamma scintillation spectrometer. By integration of the resulting 
elution peaks, the levels of apo-tc II and apo-hc were calculated by using the 
specific radioactivity of Co-Cbl. The lower detection limit was 1 pmol/L and the run-
to-run precision of apo-tc II after 20 runs was 9.6% (mean 216 pmol/L) and 10.7% for 
apo-hc (mean 529 pmol/L). 
Homocysteine concentrations were determined in EDTA plasma by HPLC with 
fluorescence detection 106. Erythrocyte vitamin B12 and plasma folate levels were 
determined by using the Dualcount Solid Phase Boil Radioassay (Diagnostic 
Products). 
The prevalence of the TC II Pro259Arg and the TCII Gln234Arg polymorphism was 
determined by PCR on genomic DNA, using restriction enzyme digestion with Scr FI 
for the Pro259Arg, and MSPI for the Gln234Arg variant, followed by agarose gel 
electrophoresis. No DNA was available of four mothers with NTD children. 
The MTHFR C677T mutation was determined as described by Frosst et al54 
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Statistical analyses 
P-values for differences in characteristics between mothers of NTD children and 
controls were calculated with linear regression analysis and were adjusted for age. 
Odds ratios (OR) with  95 % confidence intervals (CI) for having a child with NTD were 
calculated by logistic regression analysis, and were also adjusted for age. Test for 
linear trends in the observed distribution of these ORs were performed by logistic 
regression analysis. 
Homocysteine levels showed a non-normal distribution, and logarithmically 
transformed homocysteine concentrations were used in all calculations. Mean 
homocysteine values were expressed as geometric means. P-values for differences in 
homocysteine levels between TC percentiles were calculated with linear regression 
and were corrected for age, plasma folate, the MTHFR C677T genotype and plasma 
HC concentrations where necessary. For correlations Pearson’s correlation 
coefficient was used. All calculations were performed by using the SPSS-software 
package 9.0, statistical significance was accepted at P < 0.05. 
 
 
RESULTS 
An overview of the median (range) age and of important biochemical variables of 
mothers with NTD children and controls are summarized in Table 1. Age was 
significantly higher in mothers of NTD children compared with controls; therefore, all 
other p-values were adjusted for age. Other parameters were not significantly 
different between 
  
Table 1. Characteristics of mothers of children with NTD, and controls  
 Mothers 
(n=46) 
Controls 
(n=73) 
p-value 
Age (years) 38.0 (29-48) 34.0 (20-55) 0.03* 
Holo-tc II  (pmol/L) 41.0 (1-372) 50.0 (0.5-186) 0.27 
Apo-tc II (pmol/L) 607.5 (294-908) 557.0 (344-946) 0.24 
holo-hc (pmol/L) 161.0 (37-628) 168.0 (52-434) 0.58 
Apo-hc (pmol/L) 56.5 (26-190) 49.0 (19 -332) 0.71 
Plasma vitamin B12 (pmol/L) 220.0 (70-1000) 220.0 (89-600) 0.40 
Erytrocyte vitamin B12 (pmol/L) 35.0 (20-180) 39.0 (20-150) 0.76 
Homocysteine ( µmol/L) ) 12.4 (6.3-27.1) 12.2 (7.3-19.8) 0.16 
All values are expressed as median (range). P-values are adjusted for age. * significant different (p<0.05)  
mothers of NTD children and controls. To examine whether altered transcobalamin 
concentrations increased the risk for having a child with NTD we calculated the odds 
ratios (OR) for the different quartiles of transcobalamines on the basis of the control 
distribution. We calculated the OR for each quartile by using the first (0-25th 
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percentile) or the last (75-100th percentile) quartile as the reference category. Figure 
1 shows the ORs for NTD, with 95% CIs, for holo-tc II, apo-tc II, the percentage holo-tc 
II (holo-tc II / total tc II), which is an indication for the proportion vitamin B12 bound to 
TC II, and plasma vitamin B12 (holo-tc II + holo-hc).  A holo-tc II level in the first 
quartile of the distribution was associated with a nearly three-fold increased risk for 
having a child with NTD (OR=2.9, 95% CI=0.9-9.2). A holo-tc II percentage in the first 
quartile was associated with a significant five-fold increase in risk for having a child 
with NTD (OR=5.0, 95% CI= 1.3-19.3). The OR for having a child with NTD associated 
with apo-tc II levels in the last quartile was 2.8 (95% CI=0.9-8.6). To examine a possible 
trend in ORs for NTD, a linear trend test was performed on the consecutive 10th 
percentiles of the different transcobalamin concentrations. The ORs calculated for 
holo-tc II concentrations and holo-tc II percentages gave a significant p-value for 
trend (p=0.04 and p=0.03), indicating that a decrease of holo-tc II or holo-tcII 
percentage is related to an increase in risk for having a child with NTD. 
To investigate the relationship between the different TC and HC levels and 
homocysteine concentrations we combined the mothers of NTD children and the 
controls to increase statistical power. We calculated geometric mean homocysteine 
concentrations in each quartile of the different TC concentrations (Figure 2). All p-
values were adjusted for age, plasma folate, the MTHFR C677T genotype and, when 
necessary, for HC. For holo-tc II, mean homocysteine levels differed significantly 
between the first and third (p=0.025), the first and last (p=0.003) and the second and 
last quartiles (p=0.005). For the holo-tc II percentage mean homocysteine levels were 
0
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Figure 1.  
Odds ratios (OR) for having a child with NTD, for the different quartiles of plasma holo-tc II, apo-tc II, holo-tc II/total
tc II, total tc II and plasma vitamin B12, compared to their respective reference quartiles. ORs are shown as
diamonds, and 95% CIs as thin vertical lines. Quartile I, 0-25th percentile; II, 25-50th percentile; III, 50-75th percentile;
IV, 75-100th percentile. 
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significantly different between the first and third (p=0.0001), first and last (p=0.016), 
second and third (p=0.001) and the second and last quartiles (p=0.036). For vitamin 
B12, mean homocysteine levels were  
Figure 2.  
Relationship between quartiles of holo-tc II (A), apo-tc 
II(B), holo-tc II/total tc II(C), total tc II(D), total vitamin 
B12(E) and mean homocysteine (hcy) concentration in 
mothers of NTD children and controls together. A. Mean 
hcy levels differ significantly between the first and third 
(p=0.025), the first and last (p=0.003) and between the 
second and last quartile (p=0.005) of holo-tc II. B. There 
are no significant differences in mean hcy between 
quartiles of apo-tc II. C. For holo-tc II/total tc II mean 
hcy levels are significantly different between the first 
and third (p=0.0001), first and last (p=0.016), second 
and third (p=0.001) and between the second and last 
quartile of (p=0.03). D. There are no significant 
differences in mean hcy between quartiles of total tc II. 
E.  Mean hcy levels are significantly different between 
the first and third (p=0.004) and between the first and 
last (p=0.013) quartile of total vitamin B12.Quartiles are 
based on the controls distribution. (All p-values are corrected for age, plasma folate, HC levels and the MTHFR C677T 
mutation. P-values for plasma vitamin B12 are not corrected for HC levels.) 
 
significantly different between the first and third (p=0.004) and the first and last 
(p=0.013) quartiles of total vitamin B12. Another functional effect of low holo-tc II 
concentrations, in addition to the high homocysteine concentration, is the vitamin 
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B12 concentration in the cell. Therefore we calculated the mean erythrocyte vitamin 
B12 concentration per quartile of holo-tc II (Figure 3). The mean erythrocyte vitamin 
B12 concentration was significantly different when comparing the first with the third 
quartile (p=0.03) and the first with the last quartile (p=0.006). 
To investigate if the low amount of vitamin B12 bound to TC II, the low holo-tc II 
percentage, (holo-tc II/total tc II) is caused by a deficiency of vitamin B12 or by 
disturbed binding of vitamin B12 to TC II, we calculated mean plasma vitamin B12 
concentrations with 95% CIs per quartile 
of holo-tc II (Figure 4). We also plotted 
the vitamin B12 concentrations against 
the holo-tc II concentrations below vs. 
above the 50th percentile of the control 
distribution (Figure 5). Holo-tc II 
concentrations above the 50th 
percentile showed a positive correlation 
(r=0.838, p=0.00001) with plasma vitamin 
B12, whereas holo-tc II concentrations 
below the 50th percentile showed no 
correlation (r=-0.063, p=0.60) between 
holo-tc II and vitamin B12. 
The frequency of the Pro259Arg 
polymorphism did not vary significantly 
between mothers of NTD children (14%) 
and controls (21%) (Table 2). The 
Gln234Arg polymorphism was not 
observed in the study population. For mean holo-tc II and homocysteine 
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Figure 3. 
Mean erythrocyte vitamin B12 concentrations with
95% CI per quartile of holo-tc II 
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Figure 4. 
Mean plasma vitamin B12 concentrations with 95% 
CI per quartile of holo-tc II 
Figure 5.  
Relationship between plasma vitamin B12 and plasma 
holo-tc II concentrations, the straight line (—) 
indicates the relation for holo-tc II concentrations 
below the 50th percentile of holo-tc II and the dashed 
line (----) indicates the relationship above the 50th 
percentile. Individual values above the 50th 
percentile are represented by grey triangles and 
individual values below the 50th percentile are 
represented by black triangles. The holo-tc II level of 
the 50th percentile was 50.0 pmol/L based on the 
control distribution. 
Plasma vitamin B12 (pmol/L)
7006005004003002001000
H
ol
o-
tra
ns
co
b
a
la
m
in
 II
 (p
m
ol
/L
)
250
150
50
-50
r = 0.838 
r = 0.063 
  
 41 
V
itam
in B12 and N
TD
V
itam
in B12 and N
TD
concentrations per genotype, we combined the mothers with the controls. Holo-tc II 
levels differed significantly between the three Pro259Arg genotypes with, 
respectively, mean holo-tc II concentrations of 34.8 (± 24.9) pmol/L for the 259-Arg 
homozygotes, 48.8 (± 33.2) pmol/L for the heterozygotes and 61.8 (± 35.6) pmol/L for 
the 259-Pro homozygotes. Homocysteine levels did not  
 
Table 2. Genotype distribution of the TC II Pro259Arg polymorphism in mothers of NTD children and in 
controls 
 Arg-259 homozygous Pro259Arg heterozygous Pro-259 homozygous 
Mothers of NTD children (n=42) 6 (14%) 25 (60%) 11 (26%) 
Controls (n=73) 15 (21%) 36 (49%) 22 (30%) 
 
 differ significantly between the genotypes; mean homocysteine concentrations 
were 13.5 (±3.3) µmol/L for the 259-Arg homozygotes, 12.9 (±3.6) µmol/L for the 
heterozygotes and 12.0 (±2.9) µmol/L for the homozygotes 259-Pro. 
 
 
DISCUSSION 
We found that loss of affinity of TC II for vitamin B12 is relatively common and is 
related to an increased risk for NTD. Low holo-tc II levels were associated with a 
three-fold higher risk (OR=2.9, 95% CI=0.9-9.2) and reduced holo-tc II percentages, 
which indicate the proportion of vitamin B12 bound to the total amount of the TC II 
protein, increased the risk five-fold (OR=5.0, 95% CI= 1.3-19.3). The significant linear 
trend analyses confirmed the relation between holo-tc II and holo-tc II percentage 
and the risk for having a child with NTD.  
There may be three causes for a low holo-tc II percentage. Firstly, total TC II 
concentrations may be increased, for example, due to increased expression of the 
TC II gene; secondly, vitamin B12 levels may be deficient, leading to low plasma 
vitamin B12 and low holo-tc II concentrations; and thirdly, the binding of vitamin B12 
to TC II can be disturbed, which will result in low holo-tc II levels in the presence of 
normal vitamin B12 levels. The data presented in Table 1 and Figure 2 demonstrate 
no differences between the mothers of NTD children and the controls in the total TC II 
concentrations, indicating that the observed low holo-tc II percentage are not due 
to increased transcription and translation of TC II. Figure 4 shows that low holo-tc II 
levels are not due to low plasma vitamin B12, but rather are the result of reduced 
binding of vitamin B12 to TC II. The latter is made clearer in Figure 5, which 
demonstrates a lack of correlation between holo-tc II and vitamin B12 
concentrations when the holo-tc II concentration is below the 50th percentile. 
Obviously, TC II in these individuals has lost its normal affinity for vitamin B12. The 
disturbed binding of vitamin B12 to TC II could be caused by genetic variation in the 
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TC II gene, resulting in an altered binding site of vitamin B12 or a different folding of 
the TC II protein that reduces the binding of vitamin B12 to TCII, which would both 
result in lower holo-tc II concentrations. Although the Pro259Arg polymorphism 
significantly decreases holo-tc II concentrations, the frequencies of this mutation 
could not explain the higher risk for NTD by low holo-tc II concentrations and low 
holo-tc II percentages. Moreover, no significant differences in homocysteine levels 
were observed between the different genotypes of this polymorphism. Therefore it is 
unlikely that the Pro259Arg polymorphism in the TC II gene strongly influences the risk 
for NTD.  
Magnus et al. 116 found elevated mean apo-tc II levels in the amniotic fluid of 
mothers with a previous NTD pregnancy when compared to controls. They 
concluded that this could be due to a defect in the gene or in its regulation of the 
expression or due to differences in intake of vitamin B12. Gardiki-Kouidou and      
Seller 117 also found significantly elevated median apo-tc II levels and reduced 
vitamin B12 levels in amniotic fluid. They also concluded that this could be due to a 
genetic defect in the production or transport of transcobalamins. We did not find a 
significant difference in apo-tc II concentration between mothers of NTD children 
and controls. A possible explanation for this may be that we used plasma from non-
pregnant women in stead of amniotic fluid. However, our results are in agreement 
with the elevated apo-tc II levels reported by Magnus et al. 116 and Gardiki-Kouidou 
and Seller 117, because a reduced binding of vitamin B12 to TC II results in lower holo-
tc II levels and, as a consequence, in higher apo-tc II levels.  
Vitamin B12 is required in the remethylation of homocysteine to methionine. 
Therefore, low vitamin B12 levels in the cell could lead to increased plasma 
homocysteine concentration. The functional effect of low holo-tc II concentrations 
and low holo-tc II percentages is demonstrated by significantly higher homocysteine 
levels in these groups. Another functional effect of low holo-tc II levels resulting in 
reduced delivery of vitamin B12 to the cell, is shown by the clear relation between 
holo-tc II and vitamin B12 concentrations in the cell, in this case the erythrocyte 
(Figure 3).  
Low plasma holo-tc II concentrations and low holo-tc II percentages are relative 
common and increase the risk of NTD. Both findings are best explained by a 
disturbed binding of vitamin B12 to holo-tc II. Therefore, our future research will focus 
on mutations in the TC II gene that may explain the observed low holo-tc II 
concentrations, low holo-tc II percentages, increased homocysteine and decreased 
erythrocyte vitamin B12 concentrations. Supplementation of vitamin B12 will raise 
holo-tc II levels and holo-tc II percentages, and thereby lower homocysteine levels 
and increase cellular vitamin B12, which could result in a decreased risk for NTD. In 
addition to folic acid supplementation, vitamin B12 supplementation should be 
considered in the prevention of NTD in women planning a pregnancy.  
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ABSTRACT 
Homocysteine levels are elevated in mothers of neural tube defect (NTD) children, 
which may be due to a disturbed folate or vitamin B12 metabolism. Vitamin B12 is 
transported to the tissues by transcobalamin (TC). We previously showed that a low 
holo-TC/total-TC ratio is a risk factor for NTD, possibly due to an impaired binding of 
vitamin B12 to TC.  The coding region of the TC gene of 12 individuals was analysed 
for genetic variations responsible for a disturbed vitamin B12 binding. The influence of 
the genetic variations observed on total-TC, holo-TC, holo-TC/total-TC, erythrocyte 
vitamin B12, plasma homocysteine concentrations and risk for NTD was explored in 
42 mothers of a child with NTD and in 73 female controls. Direct sequencing analyses 
revealed five single nucleotide polymorphisms (SNPs). Three SNPs affected total-TC 
concentrations, whereas two SNPs seem to affect the binding of vitamin B12. None 
of the genotypes defined by the SNPs had a significant effect on homocysteine 
levels, or was associated with an increased NTD risk. Among the five SNPs observed 
only P259R could partly explain the reduced proportion of vitamin B12 bound to TC, 
which has been associated with an increased risk for having a child with NTD. Some 
of the variants studied affected total-TC and holo-TC/total-TC ratio but a larger study 
population is required to elucidate whether these SNPs influence delivery of vitamin 
B12 to the tissue, influence homocysteine levels and whether they are associated 
with an increased NTD risk. 
 
 
INTRODUCTION 
In man, the neural tube closes during the fourth week of gestation and failure of 
closure results in a neural tube defect (NTD), among which anencephaly and spina 
bifida are the most common. Periconceptional folic acid supplementation reduces 
the risk of NTD with 50-70 percent 41;42. So far, the mechanism behind this preventive 
effect of folic acid supplementation on the occurrence and recurrence of NTD is 
poorly understood. Besides its involvement in the synthesis of purines and thymidine, 
folate is also used in the remethylation of homocysteine to methionine. A part of the 
protective effect of folic acid can be explained by the metabolic effects of the 
677C>T variation in the methylenetetrahydrofolate reductase (MTHFR) gene. This 
common variant is the first identified genetic risk factor for NTD, which in homozygous 
state is associated with increased homocysteine levels 28. Several studies found that 
homocysteine levels were elevated in mothers of children with NTD 100-102.  
Homocysteine is remethylated to methionine by methionine synthase (MS) which 
catalyses the transfer of the methyl group of 5-methyltetrahydrofolate (5-methyl-THF), 
via vitamin B12, to homocysteine. Several investigators examined a possible 
association between vitamin B12 concentrations in blood or amniotic fluid and the 
risk for NTD but with ambiguous outcome 101;113-115;121. 
  
 47 
 Transcobalam
in SN
PS, hom
ocysteine and N
TD
 risk
Transcobalam
in SN
PS, hom
ocysteine and N
TD
 risk
In plasma, about 20% of the vitamin B12 is bound to transcobalamin (TC), and ~80 
percent is bound to haptocorrin (HC). Holo-TC is the proportion of TC that contains 
vitamin B12, as opposed to apo-TC to which no vitamin B12 is bound. TC transports 
the vitamin B12 to the cell whereas the role of HC is unclear, so far. A reduced 
cellular vitamin B12 availability may be detected earlier by determination of plasma 
holo-TC levels than by total plasma vitamin B12 levels, which is the sum of holo-TC 
and holo-HC.  
In our recent study, we found low plasma holo-TC levels to be associated with an 
increased risk for having a child with NTD (OR: 2.9 95%CI: 0.9-9.2) whereas, no such 
association was observed with total plasma vitamin B12 levels 122. Moreover, we 
found that a low percentage of vitamin B12 bound to TC (holo-TC/total-TC) is 
associated with an increased risk for NTD (OR: 5.0 95%CI: 1.3-19.3). Because total 
plasma vitamin B12 levels were not decreased in individuals with low holo-TC levels, 
our results suggested a disturbed binding of vitamin B12 to TC. We hypothesised that 
genetic variations in the TC gene may explain an impaired TC function.  
In the present study we sequenced the entire coding region of the TC gene in eight 
individuals with a low and in four individuals with a high proportion vitamin B12 bound 
to TC and examined the exonic sequences for genetic variations. The influence of 
the genetic variations observed on total-TC, holo-TC, holo-TC/total-TC ratio, 
erythrocyte B12, plasma homocysteine levels and risk for NTD was assessed in 42 
mothers of NTD children and 73 female controls.  
 
 
MATERIALS AND METHODS 
Study population 
The study population has been described before 122 and consisted of 46 mothers of 
patients with non-syndromic NTD (mean age 38 ± 4 years), mainly spina bifida, 
recruited by participation of the department of Pediatrics of the University Medical 
Center Nijmegen and of 73 controls (mean age 35 ± 8 years). The controls were 
healthy female employees of our University Medical Center with no family history of 
NTD. All participants were Dutch Caucasians. DNA was available of 42 mothers with 
a NTD child and of all 73 controls. The protocol was approved by the local ethics 
committee and written informed consent was obtained from all participants. 
 
Laboratory methods 
Plasma determination 
Holo-TC and holo-HC levels were determined in EDTA plasma according to the 
method described by Benhayoun et al 119. Plasma vitamin B12 (holo-TC + holo-HC) 
was determined using the Dualcount Solid Phase Boil Radioassay (Diagnostic 
Products Corporation, Los Angeles, CA, USA). TC was removed with Heparin-
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Conjugated-Sepharose and the remaining holo-HC was also determined by the 
Dualcount Solid Phase Boil Radioassay. Holo-TC levels were calculated as the 
difference between holo-HC levels and plasma vitamin B12 levels. Plasma apo-TC 
and apo-hc levels were determined according to the method described by Nielsen 
et al.120. Homocysteine concentrations were determined in EDTA plasma by HPLC 
with fluorescence detection 106. Erythrocyte vitamin B12 and plasma folate levels 
were determined by using the Dualcount Solid Phase Boil Radioassay (Diagnostic 
Products). 
 
Sequencing analyses 
We selected eight individuals (six mothers of NTD children and two female controls) 
with low holo-TC levels and a low holo-TC/total-TC ratio. In addition, four subjects 
(one mother of a NTD child and three female controls) with high holo-TC levels and a 
high holo-TC/total-TC ratio were selected for DNA analysis of their TC gene. The TC 
gene consists of nine exons 123, which were sequenced using primers that were 
located in the flanking introns (Table 1). PCRs were carried out in a total volume  
 
Table 1. Primers used for the molecular genetic analysis of the TC gene 
 Forward primer (5’→3’) Reverse primer (5’→3’) 
Exon 1 GGA AGC TGC GTC TCT CGG GAT GTG TTA AAT GCT GAG GTC 
Exon 2 GGT GTG TGC TGG GTG GAG AGT ACC CAA GTT TCC CAT CTC 
Exon 3 TGG GGT GGG TGC TGT AAG TGG ATG GTG GGA AAG ACG 
Exon 4 GGG CTG AGG CAA TGA AGG TTC GGA GGA GCC CCA AG 
Exon 5 CTC AAG CCC CTG CCT GTC AGA GAG AGA GGA AGT CAG CCG 
Exon 6 TCA GGG GTG GAG TGG TCA G ATT TTG GCT GCT GTG TCC C 
Exon 7 GGG AAG ACA AGA AGA CAA ATA ATC TGT TCC CCG TCT CTT CTG TG 
Exon 8 TTT TGC TGC TGT GGG TGA G GCT GGG GTG AGT TGA TGA AG 
Exon 9 CTG GAA GAT GAG GTT GCG G AGG GAC ATC AGG AGG GAG G 
All primers are based on intronic  sequences (Genbank Acc. No: AC005006) 
 
of 50 µl, containing 50 ng of the sense and antisense primer (Table 1), 200µM each 
dNTP, 10 mM Tris-HCl buffer (pH 8.3), 1.0 mM MgCl2 and 0.5 units Taq polymerase (all 
from Life Technologies, The Netherlands) in a Perkin Elmer 9600 thermocycler (PE 
Biosystems, The Netherlands). PCR conditions were: initial denaturation at 92ºC for 2 
min, followed by 35 cycles: of 30 s at 92º C, 30 s at 47-58º C, and 30 s at 72º C, and a 
final step at 72º C for 7 min. Subsequently, all PCR products were sequenced on both 
strands using the ABI Prism BigDye Terminator cycle sequencing kit according to the 
manufacturer’s recommendations (PE Biosystems, The Netherlands) on an ABI Prism 
377 automated DNA sequencer. 
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SNP analyses 
The prevalences of the variants detected by DNA sequencing analysis were 
analysed by PCR-RFLP and subsequent separation on agarose gels (Table 2). For the  
 
Table 2. Sequence variations in the TC gene  
 Nucleotide change Amino acid change RFLPa 
Exon 2 67 A>G Ile23Val + RsaI 
Exon 3 280 G>A Gly94Ser + AlwNI 
Exon 5 701 A>G Gln234Arg + MspI 
Exon 6 776 C>G Pro259Arg - ScrFI 
Exon 7  1043 C>T Ser348Phe - EspI * 
Exon 8 1196 G>A Arg399Gln  - BsmAI 
a Restriction Fragment Length Polymorphism. * Artificially created restriction site 
 
screening of S348F in exon 7, an artificial EspI restriction side was created by using the 
mutagenic sense primer 5’CCGTACAGACAGTCCGTC 3’ that, in combination with 
the wild type allele, resulted in the  EspI recognition site. The prevalences of the 
previously described P259R and Gln234Arg variants were also determined by ScrFI 
and MspI  restriction enzyme analysis, respectively (Table 2). The MTHFR 677 C>T 
polymorphism was determined as described by Frosst et al 54. 
Prediction of the putative secondary structure changes in the TC protein by each of 
the SNPs was performed using the Chou-Fasman 124 and GOR II (Garnier, Osgu-
thorpe, Robson) 125 algorithms included in the OMIGA version 2.0 software package. 
 
Statistical analyses 
Odds ratios (OR) with 95% confidence interval (CI) were calculated using logistic 
regression analyses. Homocysteine levels showed a non-normal distribution; we 
therefore used logarithmically-transformed homocysteine concentrations in all 
calculations, and homocysteine concentrations were expressed as geometric 
means.  
 Differences in mean metabolic variables between the various genotypes were 
assessed by linear regression analyses. All P-values were only adjusted for age, 
except those concerning homocysteine concentrations which were adjusted for 
age, plasma folate and the MTHFR 677 C>T polymorphism. Tests for trend were 
calculated using linear regression analyses.  All tests were performed two-tailed, and 
statistical significance was accepted at P<0.05.  All analyses were performed using 
SPSS software package version 10.0. 
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RESULTS 
Direct sequencing analyses of the coding region of the TC gene in 12 selected 
individuals revealed 5 sequence variants; each of these, including the previously 
described Gln234Arg variant was subsequently analysed in the entire study 
population of 42 NTD mothers and 73 healthy controls (Table 2). The Gln234Arg 
variant 118  was not detected in our study groups. Table 3 summarises the genotype 
distributions in mothers of NTD children and in controls. On the basis of these 
frequencies we calculated ORs with 95 % confidence interval (CI) as estimates of the 
relative risk for NTD. No particular genotype was associated with an increased NTD 
risk. 
 
Table 3. Distribution of the SNPs in the TC gene in mothers of NTD children and controls  
 Genotype Mothers 
(n=42) 
Controls 
(n=73) 
Odds ratios 95% CI 
II 34 (81%) 53 (74%) 1A - 
IV 7 (17%) 17 (24%) 0.6 0.2-1.7 
Ile23Val* 
 
VV 1 (2%) 2 (3%) 0.8 0.1-8.9 
GG 40 (95%) 73 (100%) - - Gly94Ser 
 GS 2 (5%) 0 - - 
 SS 0 0 - - 
PP 11 (26%) 22 (30%) 1A - 
PR 25 (60%) 36 (49%) 1.4 0.6-3.4 
Pro259Arg  
RR 6 (14%) 15 (21% 0.8 0.2-2.6 
SS 30 (71%) 50 (68%) 1A - 
SF 12 (29%) 21(29%) 1.0 0.4-2.2 
Ser348Phe  
 
FF 0 2 (3%) - - 
RR 36 (86%%) 69 (94%) 1A - Arg399Gln  
 RQ 6 (14%) 4 (6%) 2.9 0.8-10.8 
 QQ 0 0 - - 
 * Number of controls =72. A Reference category 
 
 
The 67 A>G transition is located in exon 2 and results in an isoleucine by valine 
replacement at codon 23 (I23V). The allele frequency of the 23V allele in controls 
and in mothers of NTD children was 15% and 11%, respectively (total study population 
13%). The secondary structure of the TC protein did not change due to this amino 
acid change, as assessed by both Chou-Fasman and GOR II secondary structure 
prediction programs. 
The 280 G>A transition is located in exon 3 and mandates a glycine by a serine 
substitution at codon 94 (G94S). The secondary structure of the mutated polypeptide 
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was identical to its wild type counterpart. This variant was only observed in the 
heterozygous state and in two mothers of NTD children, resulting in an allele 
frequency of  2% (total study population 0.9%).  
The third variant detected is a 1043 C>T transition in exon 7, that results in the 
replacement of serine by phenylalanine at codon 348 (S348F). Again, no change in 
secondary structure was predicted using the above-mentioned algorithms. The allele 
frequency of the 348F allele was 17% in controls and 14% in mothers of NTD children 
(total study population 16%). The distribution of the genotypes in controls and in 
mothers of NTD children was similar; however, the homozygous 348FF genotype was 
not observed among NTD mothers.  
In exon 8, we observed an 1196 G>A transition, that mandates an amino acid 
change from arginine to glutamine at codon 399 (R399Q). Also, this variant is not 
expected to change the secondary structure of the TC protein. The R399Q variant 
was present only in the heterozygous state with an allele frequency of 3% in controls 
and 7% in cases (total study population 4%). The prevalence of the 399RQ genotype 
was higher in mothers of NTD children although this did not lead to a significantly 
increased NTD risk (OR: 2.9 (0.8-10.8)) (Table 3).  
We also encountered the previously described P259R variant, which has an allele 
frequency of 45% in controls and 44% in mothers of NTD children (total study 
population 45%). In our study population none of the genotypes defined by this 
polymorphism was associated with an increased NTD risk. According to the Chou-
Fasman algorithm the P259R substitution will change the secondary structure of the 
protein: a tendency to form helix structures occurred by the substitution of proline at 
codon 259 by arginine. A change in secondary structure was also predicted by using 
the GOR II method, which revealed a tendency to form turn structures.  
To establish whether the SNPs influence TC function, we investigated its effects on the 
total-TC, holo-TC, holo-TC/total-TC ratio, erythrocyte B12 and plasma homocysteine 
concentrations. Mean concentrations of these parameters were calculated for each 
of the genotypes defined by the SNPs and are depicted in Figure 1. The most 
pronounced effect was observed on total-TC concentrations (Figure1A). The 
heterozygous 23IV genotype was associated with significantly lower total-TC 
concentrations compared with the 23II wild type. Those individuals with the 
homozygous 259RR and heterozygous 259PR genotypes also had lower total-TC 
concentrations compared with 259PP homozygotes, with the lowest concentration 
observed in the 259RR peers. Also the R399Q genotypes influenced the total-TC 
concentration: the 399RQ heterozygotes showed a higher total-TC compared with 
the 399RR homozygotes. An effect on holo-TC concentrations was only observed for 
the P259R variant; homozygous 259RR individuals had a significantly lower holo-TC 
concentration compared with those with the 259PP genotype (Figure1B).  
The proportion vitamin B12 bound to TC, calculated by the holo-TC/total-TC ratio, 
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Figure 1.  
Associations of SNPs in the
transcobalamin (TC) gene
with mean total-TC (A),
holo-TC (B), holo-TC/total-
TC ratio (C) and geometric
mean homocysteine (D)
concentrations. Mean
levels are shown as
diamonds, 95% CI as thin
vertical lines. The values of
the CI’s exceeding the
graph are indicated in the
figure. P-values are only
shown when significant
differences were observed
(P<0.05). All P-values were
adjusted for age and P-
values for homocysteine
were also adjusted for
plasma folate and the
MTHFR 677C>T
polymorphism.  
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 was significantly higher in heterozygous 23IV individuals compared with their wild 
type 23II peers. The homozygous 259RR genotype was associated with a significantly 
lower proportion vitamin B12 bound to TC compared with the wild type. The S348F 
showed a significant trend (P=0.03) in increasing proportion vitamin B12 bound to TC 
with the presence of this SNP (Figure1C).   
We subsequently studied the association between TC genotypes and plasma 
homocysteine concentrations. None of the TC genotypes was associated 
significantly with elevated plasma homocysteine concentrations, although an 
apparent trend was observed for the P259R variant (Figure 1D). In addition, vitamin 
B12 levels in erythrocytes were not influenced by the TC genotypes (data not shown). 
Finally, we calculated mean apo-TC levels for each P259R genotype, to elucidate 
whether the decrease in total-TC concentration related to the P259R variant was 
merely due to a decrease in holo-TC or also due to a decrease in apo-TC. Individuals 
homozygous for the arginine residue showed lower apo-TC concentrations 
compared with individuals with the heterozygous 259PR (P=0.05) and wild type 259PP 
genotypes (P=0.002). In addition, individuals with the heterozygous form of this 
variant tended to have lower apo-TC concentrations than the wild type individuals 
(P=0.07). The association between the P259R genotypes and decreased proportion 
bound vitamin B12 to TC could not be explained by low vitamin B12 levels in blood 
because holo-HC levels, which represent 80% of vitamin B12 in plasma, were similar in 
the three genotype groups (data not shown). 
 
 
DISCUSSION 
DNA sequencing analyses of the coding region of the TC gene revealed five 
variants: I23V, G94S, P259R, S348F and the R399Q. Some of the genotypes defined by 
these variants influenced total-TC protein content in plasma, holo-TC concentrations 
and the proportion vitamin B12 bound to TC: however, no effect on homocysteine 
and NTD risk could be detected. 
The previously published P259R variant 118;122 was associated with a distinct reduction 
in total-TC protein and apo-TC. Moreover, it was also associated with a pronounced 
decreased holo-TC concentration and holo-TC/total-TC ratio. A possible explanation 
for the latter could be a low total vitamin B12 status. However, holo-HC and total 
vitamin B12 concentrations were not different between the three P259R genotypes. 
Therefore, the low holo-TC/total-TC ratio may be explained by a reduced binding of 
vitamin B12 to TC. In spite of this observation, this variant cannot explain the elevated 
risk for NTD associated with a low proportion vitamin B12 bound to TC as reported by 
us previously 122, as the prevalence of this variant was even lower in mothers of NTD 
children compared with controls. No significant effect of the P259R polymorphism 
was found on erythrocyte vitamin B12 and plasma homocysteine concentrations, 
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although a tendency towards higher homocysteine levels in homozygous 259RR 
individuals compared with 259PP subjects was found (P=0.07). Larger studies are 
required to elucidate whether this P259R variant affects plasma homocysteine, 
intracellular vitamin B12 concentrations and NTD risk.  
The effect of the P259R variant on TC levels may be explained by differences in 
charge of the protein resulting from the substitution of a proline by an arginine, i.e, a 
neutral by a positively charged one 118. According to Chou-Fasman secondary 
structure predictions, a tendency to form helix structures was predicted as previously 
described by Li et al 118. Although the helix structure was not confirmed using the 
GOR II algorithm 118, we found that the latter method predicted a tendency to form 
turn structures. Both predictions point towards a change in secondary structure. The 
P259R is not located in one of the six hydrophobic regions, postulated to form the 
hydrophobic pocket for vitamin B12 binding 126. Nevertheless, due to the intra-
molecular folding, the P259R substitute may result in a disturbed binding of vitamin 
B12 to TC.  
Our results partly corroborate those of Namour et al. 127, who also found an 
association of the P259R variant with decreased apo-TC concentrations in 159 
healthy Caucasians. They observed significantly lower homocysteine levels in 259RR 
homozygotes compared with the heterozygous 259PR individuals. In contrast, our 
results point towards elevated homocysteine levels in 259RR homozygotes. In both 
studies the number of individuals included, may not have been sufficient to 
elucidate whether this SNP is associated with increased homocysteine 
concentrations. 
Heterozygosity for the I23V variant was associated with lower total-TC 
concentrations, however, it lead to a higher proportion vitamin B12 bound to TC. The 
I23V variant was previously described by Li et al. 123. In that study, the coding region 
of the TC gene was aligned to the coding regions of intrinsic factor (IF) and one of 
the two haptocorrins, termed ’TCI’ in that study. The authors reported that this variant 
was located in a conserved region of the TC protein; however, both IF and ‘TCI’ 
encode a valine instead of an isoleucine at codon 23, which may indicate that the 
substitution of isoleucine by valine may even improve vitamin B12 binding. In 
addition, the I23V SNP was not located in one of the 6 hyrdophobic regions 
postulated to be involved in vitamin B12 binding.  
The R399Q variant is associated with increased total-TC concentrations but does not 
seem to affect vitamin B12 binding and erythrocyte vitamin B12 or plasma 
homocysteine concentrations. In addition, the R399Q is not situated in one of the six 
hydrophobic regions thought to be involved in vitamin B12 binding. More individuals 
have to be examined to elucidate whether this SNP affects metabolic variables and 
whether it is associated with an increased risk for NTD.  
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The allele frequencies of some of the SNPs studied are very low. This applies to the 
G94S, for which only two individuals are heterozygous. The homozygous 23VV 
genotype was found in only three individuals and the homozygous 348FF was 
observed in two individuals. The S348F showed a trend towards a higher proportion 
B12 bound to TC. A consequence of the low prevalences is that this study on 
potential effects of these SNPs on metabolic variables and on the risk for NTD is 
lacking power. Examination of these SNPs in larger studies may reveal a potential 
effect on TC function. 
 In summary, none of the SNPs found in the TC gene was associated with a 
significantly increased risk for NTD. The P259R variant, that is expected to change the 
secondary structure of TC, can only partly explain the reduced proportion vitamin 
B12 bound to TC, which is associated with an elevated NTD risk. Some of the SNPs 
seem to affect TC concentrations or function; however, the relatively small number 
of individuals in our study precludes a conclusion whether these SNPs affect vitamin 
B12 and plasma homocysteine levels. Therefore, larger studies on these aspects are 
warranted. In addition, expression of the TC SNPs in an appropriate expression system 
may provide more information about their possible effects on TC function. 
Furthermore, in specific situations, some of these TC variants may critically effect 
homocysteine remethylation and risk for disease for example in individuals with a low 
B12 status.  
The SNPs observed in the coding region of the TC gene can only partly explain the 
reduced binding of vitamin B12 to TC, related to a five-fold increased risk for NTD 122. 
Possibly, non-coding regions of the TC gene contain variations that influence splicing, 
affecting TC function. Further research should focus on the non-coding region of the 
TC gene, using proteomics and RNA technology, to find an explanation for the 
disturbed binding of vitamin B12 to TC in mothers of NTD children. 
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ABSTRACT 
Periconceptional folic acid supplementation reduces the risk for neural tube defects 
(NTD). 5-Methyltetrahydrofolate serves as a substrate for the remethylation of 
homocysteine to methionine, which is catalysed by the vitamin B12-dependent 
enzyme methionine synthase. In addition to a low folate status, a reduced vitamin 
B12 status may be a risk factor for NTD. We previously reported an association 
between low holo-transcobalamin (holo-TC) levels and having a child with NTD, 
pointing to a disturbed vitamin B12 delivery to the cell in mothers of NTD children.  
To elucidate the cellular vitamin B12 status, we determined plasma methylmalonic 
acid (MMA) levels, which are an indicator of cellular vitamin B12 status, in a study 
population consisting of mothers of NTD children and female controls.  
Elevated MMA levels above the 70th, 80th and 90th percentile were associated with a 
2.2 to 7.0 times increased risk for having a child with NTD. In addition, significant, 
albeit weaker, associations were observed between low levels of holo-TC and total 
vitamin B12 and NTD risk. All ORs were adjusted for folate status.  
These findings demonstrate a reduced cellular vitamin B12 status in women who 
gave birth to a child with NTD and may point towards a disturbed vitamin B12 
metabolism in mothers as a risk factor for NTD.  
 
 
INTRODUCTION 
Periconceptional folic acid supplementation reduces the occurrence and 
recurrence of neural tube defects (NTD), and low maternal folate levels are 
associated with increased risk of NTD 101;102;113. A low folate status can result in 
increased homocysteine levels. We and others reported elevated plasma total 
homocysteine (tHcy) levels in mothers of children with NTD 100;102. The methylene-
tetrahydrofolate reductase (MTHFR) 677 C>T polymorphism, which, in homozygous 
mutant form, is associated with increased tHcy levels and increased risk for NTD, can 
only partly explain elevated tHcy levels in mothers with a NTD child 102. The 
remethylation of homocysteine is catalysed by the ubiquitous enzyme methionine 
synthase (MS), which requires vitamin B12 as cofactor and 5-methyltetrahydrofolate 
as co-substrate. Thus both low folate and vitamin B12 status will disturb the 
homocysteine metabolism and may therefore increase the risk for NTD. 
Decreased vitamin B12 levels in amniotic fluid of women carrying a child with NTD 
have been reported 114;117;128-130. Data on plasma vitamin B12 concentrations and 
NTD are sparse and non-conclusive. Kirke et al. 113 observed decreased vitamin B12 
levels in women carrying a NTD child whereas Mills et al. 121 did not observe such 
association in another study population of women carrying a NTD child. Some studies 
reported decreased plasma vitamin B12 levels in non-pregnant mothers of NTD 
children 102;131;132. Other studies did not find such an association 101;133.  
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Vitamin B12 is taken up by the cells as a complex with transcobalamin (TC) (holo-TC), 
which binds approximately 20% of the total vitamin B12 in plasma. Holo-TC, is 
therefore considered to be a more accurate estimate of vitamin B12 status than 
plasma total vitamin B12. We 122 recently reported an association between low TC 
parameters and NTD. No such association with NTD was observed with plasma 
vitamin B12 levels. 
The aim of the present study is to elucidate whether impaired vitamin B12 status, 
monitored by plasma methylmalonic acid (MMA) concentration, is related to NTD 
risk. Decreased cellular vitamin B12 levels result in a reduced activity of the vitamin 
B12-dependent enzyme methylmalonyl-CoA mutase leading to increased MMA 
levels. This explains why the MMA level is a useful indicator of cellular vitamin B12 
status 134. We assessed plasma MMA, total homocysteine (tHcy), holo-TC and total 
vitamin B12 levels in our study population, consisting of mothers of children with NTD 
and female controls. 
 
 
METHODS 
Study population 
The study population, which has been described before 59;122 was recruited by 
participation of the department of Neuropaediatrics of the University Medical Center 
Nijmegen and included 46 mothers of patients with non-syndromic NTD, mainly spina 
bifida. The controls were 72 healthy female employees of our University Medical 
Center with no family history of NTD. All participants were Dutch Caucasians. The 
protocol was approved by the local ethics committee and written informed consent 
was obtained from all participants.  
 
Laboratory methods 
MMA levels were determined in plasma by a modification of the method of Husek et 
al. 135. The method includes protein precipitation with isopropanol, derivatization of 
MMA in the aqueous medium with isopropylchloroformate, and liquid-liquid 
extraction of the isopropylesters into toluene. d3-MMA was used as internal standard. 
The esters were analyzed by gas chromatography-mass spectrometry and 
separation was achieved on a DB-5 capillary column from J&W Scientific (10 m 
length, 0.18 mm inner diameter), and detected in the single ion monitoring mode at 
m/z 142.7 (MMA) and m/z 145.7 (d3MMA). The coefficient of variation of the assay 
was < 5 %.  
Holo-TC levels were determined in EDTA plasma according to the method described 
by Benhayoun et al 119. Plasma vitamin B12 levels were determined using the 
Dualcount Solid Phase Boil Radioassay (Diagnostic Products Corporation, Los 
Angeles, CA, USA). Plasma apo-TC levels were determined according to the method 
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described by Nielsen et al.120. Plasma tHcy concentrations were measured in EDTA 
plasma by HPLC with fluorescence detection 106. Erythrocyte vitamin B12 levels and 
plasma folate levels were assessed by using the Dualcount Solid Phase Boil 
Radioassay (Diagnostic Products). 
 
Statistic analyses 
All variables that showed a skew distribution were natural log transformed and mean 
levels were expressed as geometric mean. Comparisons of mean metabolite levels 
were performed with GLM analyses and adjusted for age. Odds ratios as estimates of 
the relative risk were calculated with logistic regression. Adjustments were made for 
age. Percentile values were derived by using female controls. Odds ratios were 
obtained by comparing subjects above the 70th, 80th and 90th percentile (MMA and 
tHcy) with subjects below these percentiles and subjects below the 10th, 20th and 30th 
percentile (holo-TC, TC-saturation, total vitamin B12, erythrocyte vitamin B12 and 
folate) with subjects above these percentiles. Linear trend test were performed on 
the increasing deciles, which derived from the control distribution. Correlations were 
assessed as Pearson correlation coefficients. All analyses were carried out by SSPS 
software version 10.0. Statistical tests were performed two-tailed, and statistical 
significance was accepted at P-value < 0.05.  
 
 
RESULTS 
The geometric mean plasma MMA levels were significantly increased (P=0.006) in 
mothers of NTD children (mean 0.20 µmol/L (CI 0.17-0.25)) compared with female 
controls (mean 0.15 µmol/L (CI 0.14-0.16)). 
Geometric mean plasma holo-TC levels were 
significantly decreased (P=0.045) in mothers 
of NTD children (mean 27.0 pmol/L (CI 18.0-
40.5)) compared with female controls (mean 
39.5 pmol/L (CI 31.3-49.8)). Because the age 
was significantly higher in female controls 
compared to mothers of NTD children, all P-
values were adjusted for age. Geometric 
mean plasma tHcy, plasma total vitamin B12, 
erythrocyte vitamin B12, TC-saturation and 
plasma folate did not differ between mothers 
of NTD children and controls. Odds ratios 
(ORs), as estimates of the relative risk, for 
having a child with NTD were calculated for values above the 70th, 80th and 90th 
percentile of plasma MMA and tHcy levels and for values below the 10th, 20th and 
Figure 1.  
Odds ratios (OR) for having a child with NTD for 
MMA levels above the 60th, 70th 80th and 90th 
percentile. ORs are shown as diamonds, 95% CI 
as thin vertical lines. Odd ratios are adjusted for 
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30th percentile of plasma total vitamin B12, erythrocyte vitamin B12, holo-TC, TC-
saturation and folate (Table 1). In individuals with plasma MMA levels above the 70th  
 
Table 1. Odds ratios and 95% confidence interval for having a child with NTD according to high plasma 
MMA and tHcy levels and low plasma total vitamin B12, holo-TC, TC-saturation and folate levels 
Blood indices  Odds ratios (95 %CI)  P-values for trend 
  >70th percentile >80th percentile >90th percentile   
Plasma MMA  2.4 (1.1-5.2) 3.5 (1.6-8.0) 7.1 (2.35-21.2)  0.01 
Plasma tHcy  0.98 (0.4-2.2) 1.5 (0.62-3.6) 2.9 (1.0-8.2)  0.7 
  <30th percentile <20th percentile <10th percentile   
Plasma total B12  1.7 (0.77-3.7) 1.7 (0.77-3.8) 3.5 (1.2-10.6)  0.4 
Plasma Holo-TC  2.2 (1.0-4.9) 2.1 (0.85-4.9) 2.5 (0.84-7.2)  0.04 
TC-saturation  2.3 (1.0-5.0) 2.5 (1.0-5.8) 3.1 (1.1-9.2)  0.04 
Erythrocyte B12  1.3 (0.59-3.0) 1.1 (0.42-2.8) 2.0 (0.69-5.5)  0.3 
Plasma folate  1.2 (0.55-2.5) 1.4 (0.64-3.2) 1.9 (0.76-4.8)  0.3 
All ORs are adjusted for age. Percentile distribution was derived by using female controls. Test for linear trend was 
performed through deciles. 
 
percentile, the OR for having a child with NTD was 2.4 (1.1-5.2), which increased up 
to 7.1 (2.4-21.2) for plasma MMA levels above the 90th percentile (Figure 1). 
Moderately (ORs from 2.2 to 3.5) but significantly increased risk of NTD was observed 
at tHcy levels above the 90th percentile, total vitamin B12 and holo TC below the 
10th and 30th 
percentile, respectively, 
and TC-saturation below 
the 30th, 20th and 10th 
percentile (Table 1) 
(Figure 1). Adjustment of 
the ORs for folate 
concentration did not 
change the results. To 
examine a possible 
trend in the relationship 
between metabolite 
levels and risk for NTD, 
we performed a linear 
trend test on the 
increasing deciles (Table 
1). There was a 
significant trend in risk for NTD for plasma MMA levels (P-value=0.01), holo-TC levels 
(P=0.04) and TC-saturation (P=0.04).  
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Figure 2. 
 Odds ratios (OR) for having a child with NTD for plasma MMA and 
homocysteine levels above the 90th percentile and for plasma total vitamin 
B12, holo-TC, TC-saturation, folate and erythrocyte vitamin B12 
concentrations below the 10th percentile. ORs are shown as diamonds, and 
95% CI as thin vertical lines. Odd ratios are adjusted for age. Percentiles are 
obtained from the metabolite distribution in controls.
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Table 2 shows the correlation between MMA levels and vitamin B12 related 
parameters, plasma folate and plasma tHcy levels  for mothers of  NTD  children  and  
 
Table 2. Correlation coefficients between plasma MMA levels and metabolite levels of mothers of NTD 
children and controls 
 Mothers (n=46) Female controls (n=72) Total study population (n=118) 
Plasma tHcy 0.26 (0.09) 0.19 (0.1) 0.25 (0.007*) 
Plasma total B12 -0.46 (0.001*) -0.22 (0.07) -0.38 (< 0.001*) 
Plasma Holo-TC -0.46 (0.001*) -0.006 (1.0) -0.32 (<0.001*) 
TC-saturation -0.31 (0.04*) -0.17 (0.2) -0.27 (0.003*) 
Erythrocyte B12 -0.41 (0.005*) -0.18 (0.1) -0.30 (0.001*) 
Plasma folate 0.28 (0.06) -0.24 (0.05*) 0.031 (0,7) 
Values are Pearson correlation coefficients (P-values) 
 
controls, separately, and for the total group. In NTD mothers, significant negative 
correlation’s (Pearson r of 0.3-0.4) were observed for plasma MMA levels with plasma 
and erythrocyte vitamin B12, plasma holo-TC and TC-saturation. A significant positive 
correlation with plasma tHcy levels was observed for the total study population, only. 
The correlation coefficients for the controls were not significant for the vitamin B12 
estimates.  
 
 
DISCUSSION 
The presence of increased MMA and decreased holo-TC levels in mothers of NTD 
children with normal folate levels points towards a role of a low vitamin B12 status in 
the aetiology of NTD. Moreover, individuals with MMA levels above the 70th 
percentile showed a 2.4 times higher risk for having a child with NTD, which increased 
up to 7 times for MMA levels above the 90th percentile. This indicates that a low 
cellular vitamin B12 status, as estimated by MMA concentration, was more frequent 
in mothers of NTD children than in female controls. Furthermore, low total vitamin B12 
levels, holo-TC levels and TC-saturation ratios were more frequently observed in 
mothers of NTD children compared to female controls, which all point to a low 
vitamin B12 status as risk factor for NTD. In addition, a significant linear trend was 
observed for plasma MMA, holo-TC and TC-saturation. The increased ORs observed 
for vitamin B12 estimates are not related to folate status because adjustment of the 
ORs for folate concentration did not change the results. 
Possible cofounders of this study could have been renal function, diet or age-
difference between mothers of NTD children and the controls. However all women 
included in this study were healthy and adjustments were made for age difference 
observed.  
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Although low maternal plasma vitamin B12 levels were associated with increased risk 
of NTD, associations with high MMA levels were stronger. Thus, increased MMA in 
mothers of NTD children suggests a disturbed vitamin B12 transport or cellular 
metabolism, although a low dietary vitamin B12 intake cannot be excluded. 
Impaired disposition of vitamin B12 can result from variations in genes encoding 
receptors, transport proteins or enzymes involved in the vitamin B12 pathway, 
leading to dysfunctional proteins.  
Increased MMA levels in mothers carrying a NTD child were found by Adams et       
al. 136, but they did not observed increased MMA in non-pregnant mothers of NTD 
children when compared with non-pregnant controls. Mills et al. 100 measured MMA 
levels, and vitamin B12 levels in plasma of women carrying a NTD child. In their first 
study 113, they found decreased vitamin B12 levels as compared to a control group. 
Later, they reported no differences in MMA levels in such mothers as compared to 
vitamin B12-matched controls 100. One study published data on plasma MMA levels in 
NTD patients but observed no differences in MMA levels when compared to   
controls 137. Different study populations as well as different technologies used for 
MMA measurement may contribute to the discrepant results.  
Most studies that examined the relation between vitamin B12 status and NTD only 
measured plasma total vitamin B12 levels. In such studies, no association between 
total vitamin B12 levels and NTD was demonstrated 121;133;138. Only 20% of the total 
vitamin B12 is bound to TC. Because holo-TC represents the biologically active B12 
fraction and is responsible for the transport of the vitamin into the cell, holo-TC levels 
may be a more accurate estimate of vitamin B12 status than total vitamin B12 levels.  
The present study shows that a low vitamin B12 status, estimated by MMA levels 
above the 90th percentile of the controls distribution, is associated with a seven times 
increased risk for NTD. The question raised is whether vitamin B12 in addition to folic 
acid should be supplemented to women planning a pregnancy. A meta-analysis 
revealed that addition of vitamin B12 to folic acid supplements reduces blood tHcy 
concentrations by an additional seven percent 103. Recently, Quinlivan et al. 139 
observed that vitamin B12 became the main determinant of homocysteine in a 
study population supplemented with folic acid. The importance of vitamin B12 and 
folate as main determinants of homocysteine is further underlined by Obeid et al. 140 
who used plasma MMA, holo-TC and total vitamin B12 levels as estimates for vitamin 
B12 status in Syrian stenosis patients and controls. They found that these indicators of 
vitamin B12 status influenced plasma tHcy levels.  
To elucidate whether supplementation with vitamin B12 confers a risk reduction 
beyond that obtained with folic acid, a randomised placebo controlled trial is 
required, comparing folic acid versus folic acid plus vitamin B12 supplementation in 
women planning a pregnancy.  
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In summary, the present study shows that vitamin B12 status is reduced in mothers of 
children with NTD. Our results suggest that supplementation of vitamin B12 in addition 
to folic acid, may have greater benefits for the reduction in NTD, than folic acid 
alone.  
We hypothesise that low vitamin B12 status may be of greater importance in the 
development of NTD than hitherto recognised.  
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INTRODUCTION 
Neural tube defects (NTD) originate from an incomplete closure of the neural tube 
and are one of the most common and severe congenital malformations. The 
aetiology of NTD is multifactorial, indicating a combination of environmental and 
genetic factors. One of the most important environmental factors is the maternal 
vitamin status. Periconceptional folic acid supplementation can prevent about 60 % 
of the NTD cases 41;42. The exact preventive mechanism of folate on the occurrence 
and recurrence of NTD is unknown. Folate in the form of 5-methyltetrahydrofolate (5-
meTHF) is required for the remethylation of homocysteine to methionine by the 
enzyme methionine synthase (MS). Therefore, a deficiency in folate may result in 
elevated plasma homocysteine concentrations. Although mothers of NTD children 
are not deficient in folate, their folate levels are in the lower range of the control 
levels and their plasma homocysteine concentrations are elevated 100-102. The 677C>T 
mutation in the methylenetetrahydrofolate reductase (MTHFR) gene is the first 
genetic risk factor for NTD and is partly responsible for these changes in 
homocysteine concentrations 28. Another vitamin involved in the methylation of 
homocysteine is vitamin B12, which functions as a cofactor of methionine synthase 
(MS). Some studies showed an association between decreased plasma vitamin B12 
levels or decreased plasma holo-transcobalamin (holo-tc) levels and NTD 113;122. Via 
the transulfuration pathway homocysteine can be irreversibly degraded to cysteine 
by two pyridoxal-phosphate (active form of vitamin B6)-dependent enzymes, i.e. 
cystathionine β-synthase (CBS) which catalyzes the condensation of serine and 
homocysteine to cystathionine, and γ-cystathionase which catalyzes the hydrolysis of 
cystathionine to cysteine and α-ketobutyrate. Another pyridoxal-phosphate-binding 
enzyme is serine hydroxymethyltransferase (SHMT) which catalyses the reversible 
reaction of tetrahydrofolate and serine to 5,10-metylene tertrahydrofolate (5,10-
MeTHF) and glycine, therefore it plays a key role in the folate metabolism 53. 
 Vitamin B6 is present in different forms; pyridoxine, pyridoxal, and pyridoxamine, and 
their phosphate esters. The metabolic active coenzyme form of vitamin B6 is 
pyridoxal 5’-phosphate (PLP). After absorbtion in the upper small intestine, the 
different form of vitamin B6 are transported to the liver, where they are transformed 
to pyridoxal 5’-phosphate (PLP) 88;89. 
 So far the relationship between PLP levels and NTD hardly has been studied. 
Conflicting results are published concerning the association between fasting 
homocysteine and PLP levels 141-146. However, post methionine load homocysteine 
levels are attenuated after pyridoxin supplementation 143;145;147. Steegers et al. 
showed that besides elevated fasting homocysteine levels also elevated post-load 
homocysteine levels were associated with risk for NTD-affected pregnancies 101. 
In this study we examined whether decreased PLP levels in mothers who had given 
birth to a NTD child  were associated with an increased risk of NTD. 
  
 67 
V
itam
in B6 and N
TD
 risk
V
itam
in B6 and N
TD
 risk
METHODS 
Study design 
Mothers of patients with non-syndromic NTD were recruited by participation of the 
Paediatric department of the University Medical Centre Nijmegen and were all 
Dutch Caucasians. The controls, who also were Dutch Caucasians, were healthy 
female volunteers with no history of NTD in their family. The study population 
consisted of 47 mothers of NTD children and 74 female controls. The protocol was 
approved by the local ethics committee and written informed consent was 
obtained of all participants. 
 
Table 1. Characteristics of mothers with a NTD child and controls   
 Mothers 
(n=47) 
Controls 
(n=74) 
P-value 
Age (years) 38.6 (37.1-40.1) 35.5 (33.6-37.4) 0.02* 
PLP (nmol/L) 39.8 (36.5-43.4) 43.4 (40.2-46.8) 0.14 
Homocysteine (µmol/L)  12.8 (11.8-14.0) 12.2 (11.6-12.8) 0.36 
All values are expressed geometric mean (95% confidence interval). P-values are adjusted for age. * Significant 
different (p<0.05).  
 
 
Laboratory methods 
PLP levels were determined in whole blood by the high-performance liquid 
chromatography (HPLC) technique as described by Schrijver et al, with modifications 
described by Steegers-Theunissen et al. 148;149. Briefly, 1 ml of a 1.2 M perchloric acid 
(HClO4) solution was added to 1 ml of heparinized blood. After centrifugation at 1000 
x g for 10 minutes supernatant was collected, and 0.05 ml of a 4.4 M potassium 
hydroxide (KOH) solution was subsequently added to 0.5 ml supernatant, centrifuged 
(1000 x g for 10 minutes) and the supernatant was collected. Next, 0.2 ml of the 
supernatant was injected on the HPLC. The fluorescence was determined with a 
Shimadzu RF-5000 fluorospectrophotometer (Shimadzu Corporation, Tokyo, Japan) 
by using 367 nm for excitation and 478 nm for emission. The minimal detectable 
concentration is 2 nmol/l at a fluorescence response of signal-to-noise ratio of at 
least three. The precision of the technique in terms of the intra-assay and inter-assay 
coefficient of variation from a whole blood control sample stored in separate tubes 
at -20° C until use was 1.6% (20 replicate determinations, mean concentration 52 
nmol/l) and 5.5% (15 determinations on several days, mean concentration 53 nmol/l), 
respectively.  
Homocysteine concentrations were determined in EDTA plasma by HPLC with 
fluorescence detection 106, the intra-assay and inter-assay coefficient of variation 
was 8.6% and 3.2%. Plasma folate levels were determined by using the Dualcount 
Solid Phase Boil Radioassay (Diagnostic Products). Holo-tc levels were measured in 
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EDTA plasma according to the method described by Benhayoun et al 119. The 
prevalence of the MTHFR 677C>T mutation was investigated as described by Frosst et 
al 54.   
 
Statistical analyses 
Linear regression analysis was performed to calculate differences in mean 
characteristic, logistic regression analysis was applied to calculate odds ratios (OR) 
with 95 % confidence intervals (CI), both 
estimates were adjusted for age. PLP and 
homocysteine concentrations showed a 
non-normal distribution; therefore 
logarithmically transformed PLP and 
homocysteine concentrations were used in 
all calculations and PLP and homocysteine 
values were expressed as geometric 
means. Differences in mean plasma 
homocysteine levels were assessed using 
logistic regression analyses and P-values 
were adjusted for age, plasma folic acid, 
plasma holo-tc concentrations and the 
MTHFR 677C>T polymorphism. P-value for 
trend in homocysteine concentrations was 
calculated with linear regression analyses 
and was adjusted for age, plasma folic 
acid, plasma holo-tc concentrations and 
the MTHFR 677C>T polymorphism. All 
calculations were performed by using the 
SPSS-software package 9.0, statistical significance was accepted at P < 0.05, all test 
were analyzed two-tailed. 
 
 
RESULTS 
An overview of the mean age, plasma homocysteine and whole blood PLP levelses 
of mothers with a NTD child and controls are summarised in Table 1. Age was 
significantly different between mothers of NTD children and controls; therefore, all 
calculated P-values were adjusted for age. 
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Figure 1.  
Odds ratios (ORs) for having a child with NTD based
on the different quintiles of plasma PLP when
compared to the reference quintile (V). ORs are
given by thick horizontal bars (-) and 95%
confidence intervals (CI) are indicated by thin
vertical lines. Quintile I=0-20th percentile; II=20-40th
percentile; III=40-60th percentile; IV=60-80th
percentile and; V=80-100th percentile. 
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We calculated the risk of NTD for different levels of PLP; PLP levels were divided in 
quintiles based on the distribution of PLP levels in controls. ORs between mothers of 
NTD children and controls were calculated using the highest PLP quintile as a 
reference category. PLP 
concentrations in the lowest 4 
quintiles showed elevated ORs 
compared to the reference 
quintile, although not 
significant (Figure1).  We 
examined whether an 
association was present 
between PLP levels and 
plasma homocysteine 
concentrations by calculating 
geometric mean 
homocysteine levels for each 
of the PLP quintiles (Figure 2). 
To increase statistical power 
we combined the mothers of 
NTD children and the controls. No significantly different mean homocysteine 
concentrations were found between the quintiles of PLP, nor a trend (P=0.56) was 
observed.  
 
 
DISCUSSION 
Mothers of children with NTD have PLP concentrations in the lower 4 quintiles of PLP 
more often than controls, although no significant differences were found. This study 
shows no clear association between PLP and homocysteine levels, any association 
present disappeared after adjustment for other factors influencing homocysteine, 
like age, folate, holo-tc and the MTHFR 677 C>T mutation. The study population is 
relative small, only 47 mothers and 74 controls were included. A higher number of 
mothers and controls is required to elucidate a possible relationship between 
decreased PLP levels and NTD.   
Steegers et al. 101 also examined the relationship between PLP levels and NTD in 41 
mothers of children with NTD. They found no association between PLP levels and NTD, 
fasting homocysteine or post-load homocysteine. Nevertheless, they found an 
association of NTD with fasting homocysteine and post-load homocysteine 
concentration. Nine mothers with a NTD child had elevated post-load homocysteine 
concentrations potentially related to an impaired transulfuration or a low PLP status. 
10
11
12
13
14
15
I             II             III            IV            V
Pl
a
sm
a
 h
o
m
o
cy
st
ei
ne
 (
µm
o
l/
L)
 
Vitamin B6 quintiles
Figure 2.  
Relationship between quintiles of PLP and geometric mean 
homocysteine concentration with 95% CI in mothers of a NTD child 
and controls together. Geometric mean homocysteine 
concentration is given by bars and 95% CI’s are indicated by thin 
vertical lines. No significant differences were observed.  
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However, CBS activity, measured in cultured fibroblasts, of these 9 individuals was 
within the reference range.  
Several other studies investigated the relation between PLP levels and homocysteine 
concentration. Some studies found no association between PLP levels and 
homocysteine. Moreover, pyridoxin supplementation of individuals with 
hyperhomocysteinaemia or with low PLP levels, had no effect on fasting plasma 
homocysteine concentrations 144-146. In contrast with that, Selhub et al. 141 found an 
association between PLP and fasting homocysteine and McKinley et al. 142 showed 
that pyridoxine supplementation to elderly who were folate and riboflavin repleted 
decreases fasting homocysteine concentrations. Ubbink et al 143 showed that, 
patients deficient in PLP had higher fasting homocysteine and post-methionine load 
homocysteine levels, but only the post-load homocysteine levels decreased after 
supplementation with pyridoxine. Furthermore, Brattstrom and Dudman 145;147 found a 
reduction in post-load homocysteine concentration after pyridoxine 
supplementation. In addition, Martinez et al. showed that vitamin B6 deficient-rat 
had elevated plasma homocysteine concentrations and reduced activity of CBS 
and SHMT in the liver 150. This indicates that the cause of the association between PLP 
and elevated plasma homocysteine levels may not only be related to an impaired 
transulfuration pathway but also an impaired funtion of SHMT. 
Unfortunately, in the present study we did not have post-methionine load 
homocysteine levels and can therefore not exclude a possible association between 
NTD or PLP and post-load homocysteine levels. Nevertheless, this study gives an 
indication that mothers of NTD children have PLP levels in the lowest quintiles more 
often than controls. Further studies with higher numbers of mothers with NTD children 
and controls are required to elucidate whether low vitamin B6 (PLP) levels are 
related to an increased risk for NTD.  
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ABSTRACT 
Most studies showed that mothers of children with NTD have elevated  homocysteine 
levels pointing to a disturbed homocysteine metabolism as a risk factor for NTD. 
Folate lowers homocysteine levels by remethylation of homocysteine to methionine. 
Homocysteine can be irreversibly converted to cystathionine by the vitamin B6-
dependent enzyme CBS. Recently, our group showed that a 31bp VNTR in the CBS 
gene was associated with decreased CBS activity and increased tHcy levels after 
methionine loading in a CVD population. 
The aim of our study was to investigate whether this VNTR influences tHcy levels and 
risk for NTD. In addition, we assessed the role of vitamin B6 as an effect modifier in this 
possible interaction. We examined possible gene-gene interaction with the MTHFR 
677 C>T polymorphism.  We screened genomic DNA of 88 NBD patients, 100 mothers, 
88 fathers and 505 controls for this CBS 31bp VNTR.  
In this study population five different alleles with 16,17, 18, 19 and 21 times the 31bp 
repeat were observed that constituted 10 different genotypes. The most common 
18/18 VNTR genotype was associated with higher tHcy levels compared with the 
17/18 and 18/19 VNTR genotypes. Vitamin B6 levels did not influence this association. 
In addition, no association with risk for NTD was found. Combination of the CBS VNTR 
with the MTHFR 677C>T polymorphism revealed an additional increase in 
homocysteine levels in 18-18 individuals compared with 17-18 peers within subjects 
homozygous mutant for the MTHFR 677 C>T polymorphism.  
Conclusions: The present study indicates that the number of 31bp repeat elements in 
the CBS gene influences tHcy levelsThis VNTR seems not to be associated with an 
increased risk for NTD.  
 
 
INTRODUCTION 
Neural tube closure occurs during the third and fourth week of pregnancy and its 
incomplete closure results in neural tube defect (NTD) of which anencephaly and 
spina bifida are the most common. Its is established that periconceptional 
supplementation of folic acid reduces the occurrence and recurrence risk of NTD 
with approximately 60 % 41;42. So far, the molecular mechanism behind this preventive 
effect is only partly understood. It is known that folic acid plays an important role in 
the homocysteine metabolism, in which 5-methylenetetrahydrofolate (THF), formed 
upon reduction of 5,10-methyl-THF by the enzyme metylenetetrahydrofolate 
reductase (MTHFR), donates its methyl group via the vitamin B12-dependent enzyme 
methionine synthase (MS) to homocysteine to form methionine. Therefore, a low 
folate status, which is associated with an increased NTD risk 98, may reduce the 
remethylation of homocysteine to methionine resulting in elevated homocysteine 
(tHcy) levels. Elevated tHcy levels in mothers of NTD children have subsequently been 
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reported 100-102. Another major pathway of homocysteine metabolism is the 
transsulfuration pathway in which homocysteine is irreversibly condensed with serine 
to cystathionine by the vitamin B6-dependent enzyme cystathionine beta-synthase 
(CBS). CBS is only expressed in liver and kidney, although Quere et al. 151 reported 
that CBS is also expressed during early embryogenesis. Thus, CBS may play a role in 
the developing embryo.   
Genetic variations in genes encoding enzymes of the homocysteine metabolism or 
depletion of cofactors of these enzymes can result in elevated plasma tHcy levels. A 
well-studied example is the MTHFR 677C>T polymorphism which results in reduced 
activity of MTHFR with concomitant elevated tHcy levels. Moreover, this 
polymorphism was identified as the first genetic risk factor for NTD 28;58. More genetic 
variations in enzymes involved in the homocysteine metabolism are known, but none 
of these genetic variations have been identified as a distinct risk factor for NTD, so 
far. 
Recently, we 152 and others 153 showed that a 31bp VNTR in the CBS gene increases 
plasma tHcy levels in particular after methionine loading. We revealed that this VNTR 
reduces CBS activity, probably because it spans across the exon-intron border 
leading to alternative splicing and putatively to an abnormal CBS protein. Besides 
elevated fasting tHcy levels, elevated post-load tHcy levels have been described as 
a risk factor for having a child with NTD 101. Therefore, in this study we tried to 
elucidate whether this 31bp VNTR in the CBS gene is a risk factor for NTD and whether 
it influences plasma tHcy levels in NTD patients and their parents.  
 
 
METHODS 
Study population 
Patients with spina bifida and their parents were derived from two study populations; 
all individuals were Dutch Caucasians. One group was recruited in collaboration with 
the Dutch society for patients with central nervous system defects (BOSK). The 
second study population included patients with spina bifida and their parents 
recruited by participation of the Neuropaediatric department of the University 
Medical Center Nijmegen. Two control groups with no history of NTD were included. 
The first were healthy employees of our University Medical Center. The second 
control group was recruited in 1993 from a general practice in The Hague 154. Part of 
this control group (241 individuals) had been used in our previous study 152. The 
protocol was approved by the local ethics committees and written informed 
consent was obtained from all participants. The final study population consisted of 88 
NTD cases, mainly spina bifida patients (mean age 16.1 years), 100 mothers (mean 
age 42.4 years), 88 fathers (mean age 44.7 years) and 505 controls (mean age 47.9 
years). Vitamin B6 levels were available of 37 mothers, 31 fathers and 94 controls. 
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Methods 
Fasting tHcy concentrations were determined in EDTA plasma by HPLC with 
fluorescence detection 106. The 31bp VNTR was determined by PCR on genomic DNA 
and numbered as described previously by Lievers et al. 152, i.e. the first repeat started 
in exon 13 152. Vitamin B6 (pyridoxal-phosphate (PLP)) levels were determined in 
whole blood by a high-performance liquid chromatography (HPLC) technique as 
described by Schrijver et al. 148, with some modifications 149. Plasma folate and 
vitamin B12 levels were determined by using the Dualcount Solid Phase Boil 
Radioassay (Diagnostic Products Corporation, Los Angeles, California, USA). 
The MTHFR 677C>T variant was investigated as described by Frosst et al 54.   
 
Statistical analyses 
Odds ratios (ORs) and 95% confidence interval (CI) as estimates of relative risk for 
NTD associated with different genotypes were calculated by logistic regression 
analyses. Variables that showed a non-normal distribution were natural 
logarithmically transformed and mean values were expressed as geometric means. 
Differences in tHcy levels across all genotypes were calculated with general linear 
model analysis (GLM) and were adjusted for age, gender, plasma folate, plasma 
vitamin B12 levels and the MTHFR 677 C>T mutation. In addition, an interaction factor 
for plasma folate with the MTHFR 677C>T mutation was included in the GLM analyses. 
P-values for comparison of individual genotypes were calculated with GLM analyses 
followed by Bonferroni test for multiple comparisons and adjusted for the above-
described parameters. All analyses were performed two-tailed and with SPSS 
software package version 10.0. P-values were accepted as significantly different at 
P<0.05. 
 
 
RESULTS 
In this study population the 31bp VNTR displayed five different alleles consisting of 16, 
17, 18, 19 and 21 repeat elements. In the total study population the 18 allele was the 
most frequent with an allele frequency of 77 %; alleles with 16,17, 19 and 21 repeats 
had allele frequencies of 0.1 %, 10 %, 11 % and 2 %, respectively. The genotype 
distribution observed in patients, mothers, fathers and controls is summarised in Table 
1. Overall, 10 different genotypes were observed. The association between these 
VNTR genotypes and the risk for NTD was analysed by calculating odds ratios (OR) for 
NTD for patients and their mothers compared to the controls. The VNTR genotypes 
were not associated with an increased risk for NTD in this study population. As 
demonstrated by the odds ratios (95% CI’s) for the  three most  prevalent  genotypes, 
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which were 0.97 (0.51-1.9) for the 17-18 and 1.10 (0.60-2.0) for the 18-19 genotype 
when compared to the most common 18-18 variation calculated for mothers of NTD 
 
 Table 1. CBS 31 bp VNTR distribution in NTD patients, their parents and controls 
Genotype 31 bp VNTR Controls (n=505) 
n (%) 
Mothers (n=100) 
n (%) 
Fathers (n=88) 
n (%) 
Patients (n=88) 
n (%) 
16-17 1 (0.2) 0 0 0 
17-17 8 (1.6) 1 (1.0) 1 (1.1) 1 (1.1) 
17-18 72 (14.3) 13 (13.0) 13 (14.8) 14 (15.9) 
17-19 9 (1.8) 3 (3.0) 3 (3.4) 2 (2.3) 
17-21 2 (0.4) 1 (1.0) 1 (1.1) 0 
18-18 307 (60.8) 57 (57.0) 51 (58.0) 52 (59.1) 
18-19 78 (15.4) 16 (16.0) 18 (20.5) 16 (18.2) 
18-21 15 (3.0) 7 (7.0) 1 (1.1) 3 (3.4) 
19-19 7 (1.4) 2 (2.0) 0 0 
19-21 6 (1.2) 0 0 0 
 
children compared with controls. Odds ratios for being a patients were 1.15 (0.60-2.2) 
and 1.21 (0.66-2.2) for 17-18 and 18-19, respectively, compared with the 18-18 
genotype. In addition, odds ratios were calculated per allele, but also this analysis 
did not result in any significant association with NTD risk.  
Because no association was observed between the risk for NTD and the VNTR, we 
performed analyses for a possible association between the VNTR genotypes and 
fasting plasma tHcy levels in mothers, fathers and controls together to increase 
statistical power. NTD patients however, were not included in these analyses 
because these children have a much younger age, which strongly influences tHcy 
levels. From the remaining group of 693 individuals, only one individual had a 16 
allele (tHcy = 15.6 µmol/L) and was excluded from further analyses. A complete 
profile of metabolic variables and the MTHFR 677C>T polymorphism was available for 
678 of the 692 individuals. The geometric mean plasma tHcy levels for these 678 
individuals, subdivided per VNTR genotype are represented in Figure 1. THcy levels 
across all genotypes tended to be different (P-value= 0.07), Separate analysis of tHcy 
levels of the three most prevalent VNTR genotypes revealed that mean plasma tHcy 
levels in individuals possessing the 18-18 genotype  were significantly higher 
compared with 17-18 genotypes (P= 0.020) and significantly higher compared with 
the 18-19 variations (P=0.049).  
Mean tHcy levels for the MTHFR 677C>T genotypes are shown in Figure 1. Individuals 
with the TT genotype had greater plasma tHcy levels than CT (P<0.001 ) and CC 
(P<0.001) peers (Figure 3). 
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Figure 1. 
Geometric mean tHcy levels for the various CBS 31bp VNTR genotypes (A), the MTHFR 677C>T polymorphism (B) and
the for the three most frequent CBS 31bp VNTR genotypes, stratified by MTHFR 677 C>T genotypes (C). Means are
shown as diamonds, 95% CI as thin vertical lines. A. Overall P-value =0.07. Analyses of the three most frequently
observed VNTR genotypes showed that mean tHcy levels are significantly increased for the 18-18 VNTR genotype
compared with the 17-18 (P=0.020) and the 18-19 (P=0.049) genotypes. B. Mean tHcy levels are significantly
increased for the TT genotype compared with the CT (P<0.001) and the CC (P<0.001) genotype. C. Mean
homocysteine levels are significantly increased for the 18-18 VNTR /TT genotype compared with the 17-18 VNTR/TT
genotype (P=0.004). Overall P-value <0.0001.  Mean tHcy levels and P-values are all adjusted for age, gender,
plasma folate and plasma vitamin B12 and the MTHFR 677 C>T polymorphism in figure A. Statistically significance was
accepted at P<0.05. 
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The combination of the 31bp VNTR and the MTHFR 677 C>T polymorphism may result 
in an additional change of plasma tHcy, therefore, we calculated mean plasma 
tHcy levels for individuals with the various combined 31bp VNTR and 677C>T 
genotypes (Figure 1). Only the 17-18, 18-18 and 18-19 VNTR genotypes were included 
in this analysis as the frequency of the remaining VNTR genotypes was too low. 
Individuals with the combined 18-18 and 677TT genotype had a significant 4.2 µmol/L 
higher plasma tHcy levels compared with combined 17-18 and 677TT genotype (P-
value = 0.004) peers. Comparison within 18-18 subjects revealed that individuals with 
the 677TT genotype had an increase in tHcy concentration of 4.3 µmol/L compared 
with 677CC subjects (P <0.0001). The 677TT individuals within 18-19 subjects had a not 
significant 2.6 µmol/L higher tHcy levels than 677CC peers . Comparison within 17-18 
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subjects revealed similar tHcy levels for individuals with the 677TT and 677CC 
genotypes.  
 A possible role of vitamin B6 levels as effect modifier on the association of the 31bp 
VNTR with plasma tHcy levels was assessed by stratification of geometric mean tHcy 
levels for low (< median) and high (> median) vitamin B6 levels for each VNTR 
genotype (data not shown). This subdivision did not result in differences in mean 
plasma tHcy levels between the various VNTR genotypes. 
 
 
DISCUSSION 
We observed an association of the 31bp VNTR in the CBS gene with increased 
plasma tHcy levels for the most common 18-18 VNTR genotype when compared with 
the 17-18 and the 18-19 variation. Vitamin B6 levels did not  affect this association. 
Individuals with the combined 18-18 VNTR and the 677 TT genotype had significantly 
higher plasma tHcy concentrations compared with individuals with the combined 
17-18 VNTR and the 677 TT genotype. No association was observed between the 
VNTR and risk for NTD.  
Our previous study 152 showed that the CBS 31bp VNTR, consisting of heterogeneous 
repeat units is associated with CBS activity which may be explained by possible 
alternative splicing at the exon 13-intron 13 splice junction site. Any alternative 
splicing will result in frame shifts and premature stop codons. This might explain the 
difference in mean homocysteine levels between individuals with the 18-18 and 17-
18 genotype. 
Gene-gene interactions were observed; individuals with 18-18/677TT have a distinct 
increase in tHcy concentration of 4.3 µmol/L and 4.2 µmol/L compared with 18-
18/677CC and 17-18/677TT peers, respectively. These observations indicate that the 
combination of genetic variations, which both influence enzyme activities of the 
homocysteine metabolism may result in an additional increase in tHcy 
concentration. Another interesting observation is that within individuals with the 17-18 
genotype, the 677 TT genotype does not seem to influence tHcy levels. This indicates 
that the relatively high CBS activity in 17-18 genotype subjects may compensate for 
the reduced activity of the MTHFR 677TT genotype. Gene-gene interaction between 
the MTHFR and the CBS gene were previously reported by De Stefano et al.155, who 
observed that the raising effect of the MTHFR 677TT genotype on tHcy levels was 
abolished by the presence of the CBS 68bp insertion. 
The prevalence of the various genotypes of the 31 bp VNTR in the present study are 
in line with the results of our previous published study 152 and with the results of Yang 
et al 153.  Although, both studies found no association of the 31 bp VNTR with fasting 
tHcy levels, Yang et al reported a significantly higher increase in tHcy levels after a 
methionine load in individuals with the 18-18 VNTR compared with 17-18 and 18-19 
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peers. In addition, our previous study 152 observed increased post-load tHcy levels for 
18-18 individuals as compared to 17-18 individuals. Another observation in our 
previous study i.e. the positive association between increased number of repeat units 
and post-load tHcy levels could not be confirmed on fasting tHcy levels in the 
present study. The larger and different study population used in the present study 
could have contributed to the current finding. 
The reported association of elevated post-load tHcy with the VNTR could not be 
examined in this study population as data on post-load tHcy levels were not 
available. A possible association between the VNTR and risk for NTD was not 
observed in this study group. So far, none of the genetic variations described in the 
CBS gene have shown to be a distinct risk factor for NTD 72 73.  An additional 
argument against an important role of CBS in the aetiology of NTD is the absence of 
NTDs in CBS knock out mice, in homozygous as well as in heterozygous state 156.  
NTD is a multifactorial disorder, in which a combination of genetic and 
environmental factors results into incomplete closure of the neural tube. Therefore, a 
combination of relatively “mild” genetic variations in genes involved in neural tube 
closure, including variations in the CBS gene, may play a role in the etiology of NTD. 
Such studies will requirevery large groups of cases and controls to elucidate the 
contribution of this genetic variations to NTD risk. 
 
 
ACKNOWLEDGEMENTS  
We gratefully acknowledge the excellent support of D. van Oppenraaij-Emmerzaal. 
This study was supported by grant no. 00-108  from the Prinses Beatrix Fonds, The 
Netherlands and by grant no. D97.021 and D99.023 of The Netherlands Heart 
Foundation. 
 
 
 
  
  
  
 
 
 
 
PART II CHICK EMBRYO 
 
  
  
  
C
hap
ter 8
C
hap
ter 8
 
 
 
 
 
 
 
 
 
 
 
 
 
 
HOMOCYSTEINE INTERFERENCE IN NEURULATION; A 
CHICK EMBRYO MODEL 
 
 
 
Lydia A. Afman, Henk J. Blom, Nathalie M.J. van der Put, Henny W.M. van 
Straaten 
 
 
 
Birth Defects Research (Part A). 2003; 67:421-428 
 
  82 
C
ha
pt
er
 8
C
ha
pt
er
 8
ABSTRACT 
Periconceptional folic acid supplementation reduces the occurrence and 
recurrence risk of neural tube defects (NTD). Mothers of children with NTD have 
elevated plasma homocysteine levels. Administering homocysteine to chick embryos 
is reported to cause 27% NTD. Therefore, elevated plasma homocysteine levels per se 
or a disturbed homocysteine metabolism may be teratogenic to the embryo and 
may interfere with neural tube closure. Our aim was to obtain a chick embryo model 
to explore the interference of homocysteine in neural tube closure.  
Homocysteine or saline was administered to chick embryos in ovo at 3 hr, 30 hr and 
60 hr of incubation and harvested at 74 hr. Homocysteine was then applied to chick 
embryos in vitro at a defined time window of four to six somites and followed for 6 hr.  
Homocysteine administration to chick embryos in ovo resulted in several 
malformations but not in an increased number of NTDs. Homocysteine administration 
to chick embryos in vitro resulted in a transient, dose-dependent widening of the 
anterior neuropore and closure delay of the rhombencephalic neuropore. After 16 hr 
of incubation the neural tube was closed.  
The in vitro chick embryo model appears a good model to explore the interference 
of a disturbed homocysteine metabolism in neurulation. 
 
 
INTRODUCTION 
Neural tube defects (NTD) are among the most common birth defects, which often 
result in infant mortality or serious disability. Anencephaly and spina bifida aperta are 
the two major types of NTD and arise due to failure of closure of the neural tube. 
Both genetic and environmental factors are involved in the development of NTD. 
One factor that showed a clear preventive effect on NTD is periconceptional folic 
acid supplementation. A 70 % reduction in recurrence risk for NTD in women 
supplemented with folic acid was shown in the MRC trial 41. A study of Czeizel and 
Dudas (’92) showed a complete reduction of first occurrence NTD in women 
supplemented with folic acid. Three mouse mutant NTD models are known for a 
preventive effect of folic acid on NTD 90-92. The underlying preventive mechanism of 
folic acid in human is unknown so far, but a part can be explained by the presence 
of the 677 C>T polymorphism in the methylene tetrahydrofolate (MTHFR) gene, which 
is shown to be a risk factor for NTD (Van der Put et al., ’95, ‘97a). The enzyme MTHFR 
catalyzes the formation of 5-methyltetrahydrofolate (5-MeTHF) out of 5,10-methyl-
THF. Subsequently, 5-MeTHF is a substrate in the remethylation of homocysteine to 
methionine. Decreased 5-MeTHF levels will therefore result in elevated homocysteine 
levels (Fig. 1). In addition, several studies have shown that plasma homocysteine 
levels were elevated in mothers of children with NTD 100-102 and that these elevated 
homocysteine levels were reduced after folic acid supplementation 101;103;104;157, 
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leading to the hypothesis that the elevated plasma homocysteine levels per se may 
be teratogenic for the embryo. Rosenquist et al. (96’) tested this hypothesis by 
administering homocysteine to chick embryos before and during the stages of neural 
tube closure; 27% of these embryos developed NTD. The authors suggested that this 
teratogenic effect might be due to a growth factor-like effect influencing the 
expression of genes involved in neural tube closure. In a later experiment the authors 
suggested that homocysteine was inhibiting the activity of the N-methyl-D-aspartate 
receptor 158;159. 
The closure of the neural tube involves many processes that are far from understood. 
Elevation and convergence of the neural folds is generated by intrinsic factors like 
apical constriction of actin microfilaments in the neuroepithelial cells, spatially 
distinct cell proliferation patterns, intercalation of neural plate cells, reshaping of 
neural plate cells from columnar to ‘wedge’ shape leading to the formation of the 
hinge points, as well as by extrinsic factors, which include expansion of the 
mesoderm and medial expansion of the ectoderm. The closure of the neural folds 
includes apposition, adhesion and cell fusion 1;2. Disturbance of any of these proces-
ses may result in NTD; the complexity and vulnerability of neurulation is further 
illustrated by the presence of many NTD mouse mutants, which nowadays regard 
genetic variations of over 60 genes 160. 
It is unclear how homocysteine or a disturbed homocysteine metabolism interferes 
with the process and timing of neural tube closure. Besides the hypothesis of the 
teratogenicy of homocysteine levels per se, another more indirect effect of elevated 
homocysteine levels 
on NTD is suggested; 
homocysteine is 
formed of S-
adenosylhomocys-
teine (AdoHcy) (Fig. 
1), but the 
equilibrium of this 
reaction favors 
AdoHcy formation. Thus, elevated homocysteine levels may lead to increased 
AdoHcy levels which will inhibit most transmethylation reactions by S-
adenosylmethionine (AdoMet). Elevated homocysteine levels may therefore disturb 
methylation of many targets, like genes and proteins that are involved in neural tube 
closure 161;162. In case of folate deficiency, reduced 5-MeTHF levels result in a reduced 
remethylation of homocysteine to methionine and consequently, into a reduced 
methylation.  
We developed a chick embryo model enabling us to unravel how elevated 
homocysteine levels may affect the process of neural tube closure. We first repeated 
Homocysteine
Methionine AdoMet
AdoHcy
SAHH
MS
5-methyl-THF B12
THF
Methylated product
Methyl acceptor
Figure 1. 
Homocysteine metabolism. AdoMet: S-adenosylmethionine, AdoHcy, S-
adenosylhomocysteine; SAHH, S-adenosylhomocysteine hydrolase; MS,
Methionine synthase; THF, Tetrahydrofolate. 
  84 
C
ha
pt
er
 8
C
ha
pt
er
 8
the study of Rosenquist et al. (96’) by administering homocysteine to chick embryos 
in ovo. We could not, however, confirm their results. We therefore used chick 
embryos in vitro and within a narrow time window to examine more specifically the 
interference of homocysteine in the neurulation process. We selected the 
developmental process of closure of the anterior neuropore (ANP) and of the 
rhombencephalic neuropore (RNP) at the stages beginning at four to six somites, 
since the morphogenesis of these processes have been reported in detail (Van 
Straaten et al., 96’, 97’). 
 
 
METHODS 
White Leghorn chicken eggs were obtained from a commercial breeding farm and 
stored at 12 °C. At the start of the experiment, eggs were incubated  at 38°C and 
55% humidity (Polyhatch; Brinsea Products, Sandford, United Kingdom).  
 
Homocysteine application to embryos in ovo 
The experiments of Rosenquist et al. ('96) were repeated as described by the authors. 
Briefly, at the start of the experiment the egg was placed vertically with the air 
chamber up and a hole of 2 mm was made in the outer shell membrane, through 
which 50 µL 0.1 M L-homocysteine thiolactone (Sigma) in saline (Locke’s solution: 154 
mM NaCl, 6 mM KCl, 2 mM CaCl2, 10 mM D-glucose) or 50 µL saline was applied on 
the inner shell membrane at Stages 2, 7 and 10 of Hamburger and Hamilton 18. 
Empirically, Stages 2, 7 and 10 appeared to correspond with incubation times of 3, 30 
and 60 hr, while Rosenquist et al. ('96) found 3, 24 and 48 hr for these stages.  
The hole was subsequently sealed with tape and incubation was continued. The 
embryos were harvested 74 hr after initiation of incubation, and their developmental 
stage was determined by counting the number of somite pairs. Embryos were 
screened morphologically for NTDs, other malformations and degeneration. Several 
eggs were taken into the experiment without any treatment, to control for an effect 
of hole drilling. Differences in frequency of NTD between homocysteine and saline 
treatment in the in ovo experiment were calculated with Chi-square analysis. 
Difference in mean number of somites were calculated with Student’s t-test. 
 
Homocysteine application to cultured embryos 
Embryos were cultured in vitro on a substrate of agar (1% agar (Difco, Detroit, MI) in 
saline with egg white 1:1) in a Petri dish at 38°C. Eggs were carefully broken in a bowl 
filled with saline of 38°C and the egg white was removed from the vitelline 
membrane. Only embryos with four to six somite pairs were dissected and 
subsequently placed on the substratum with the vitelline membrane up. Embryos 
were incubated for 30 min to adapt before one of the following solutions (in saline) 
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were applied: 80 µL of 30 mM L-homocysteine thiolactone, 10 or 30 mM L-
homocysteine, 10 or 30 mM L-cysteine, 10 or 30 mM leucine or saline. L-homocysteine 
solution was freshly prepared from L-homocysteine thiolactone (Sigma) by alkaline 
hydrolysis (5 min, 37°C, 5 N NaOH) and subsequent neutralisation. L-homocysteine is 
unstable since it oxidizes into its disulfide homocystine. Therefore, L-homocysteine 
thiolactone, which is more stable, was also used in these experiments. The average 
number of somites of the embryos at the start of the experiments was not significantly 
different between the various treatments. Embryos were initially analyzed together to 
increase statis-
tical power. 
Digital images 
were made 
immediately be-
fore administra-
tion of a solution 
as well as every 
hour after the 
administration up 
to 6 hr using a 
stereo micro-
scope (Leica MZ 
FLIII) equipped 
with a video camera (JVC KY-F 55B). The developmental stages at 0 an 6 hr were 
determined by counting the number of somites. 
The anterior neuropore (ANP) begins as a narrow slit at the stage of zero somites, 
broadens subsequently till the stage of four somites, then narrows and finally closes at 
the stage of ten somites (Van Straaten et al., ’96, ’97). The reduction in width of the 
ANP was selected as a parameter of ANP closure. The width of the ANP was 
measured on each digital image (Fig. 2)   
The rhombocepalic neuropore (RNP) is a transient opening between the closing 
mesencephalic neural tube and the intersomitic closure. It arises at the stage of 6 
somites and is closed at the stage of 8 somites 12. The closure duration of the RNP 
from the start of the experiment was determined for each embryo by screening the 
digital images (Fig. 2).  
Difference in mean number of somites between the start of the experiment and after 
six hr as well as differences in width of the ANP and differences in time of RNP closure 
were determined with one way analysis of variances (ANOVA) followed by 
Bonferonni corrected t-test for multiple comparisons.  Two-tailed analyses were 
carried out and P<0.05 was considered statistically significant.  
saline, 0 hrs saline, 4 hrs
30 mM L-homocysteine, 0 hrs 30 mM L-homocysteine, 4 hrs 
Figure 2.  
Image of living chick embryos in culture incubated with saline or 30 mM L-
homocysteine, before and after 4 hr of incubation. The ANP (line) narrows in controls, 
but widens after administration of homocysteine. The width of the ANP was measured 
as indicated by the white line. The RNP (arrow) closes in controls, but closure is delayed 
after homocysteine administration. Bar=200µm 
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Total homocysteine concentrations in the embryos after 6 hr of incubation with 10 or 
30 mM L-homocysteine were measured. Nine embryos were pooled in 1 ml 10 mM 
phosphate buffer of pH 7 and sonicated. From this solution 100 µl was used to 
determine the protein content. 163. The remaining solution was freeze dried overnight, 
dissolved in 100 µl water and subsequently total homocysteine was determined by 
HPLC with fluorescence detection 106. The detection limit of the homocysteine was 
0.25 µmol/l and the detection limit for the homocysteine concentration per mg 
protein was calculated to be 0.09 nmol/mg protein. 
 
 
RESULTS 
Homocysteine application to embryos in ovo 
Evaluation of the outcome of the in ovo experiments is summarized in Table 1. 
Homocysteine  treatment  did  not  increase  the  frequency  of  NTD  in  the  embryos  
 
Table 1. Effects of homocysteine on development and NTD prevalence of chick embryos in ovo 
 Normal NTD Degenerateda Other 
malformationsb 
Somitesc 
Control (n=24) 20 (83) 1 (4) 0 3 (13) 29 
Saline ( n=40) 25 (62) 1 (3) 6 (15) 8 (20) 30 
0.1 M L-homocysteine thiolactone 
(n=148) 
47 (32) 4  (3) 54 (36) 43 (29) 31 
Values are n (%). a Only undefined tissue was present. b Blisters, somite deformation, caudal degeneration, blood 
spots, disturbances in vein development. c Mean, counted in normally developed embryos only. 
 
(P=0.94). No differences in mean number of somites of the normally developed 
embryos between the various treatments were found (P= 0.15), but homocysteine 
treatment did result in more malformations and degenerated embryos than 
treatment with saline. 
 
Homocysteine application to cultured embryos 
Administration of 30 mM L-homocysteine or 30 mM L-homocysteine thiolactone 
resulted in a widening of the ANP during 3-4 hr as illustrated in Figure 2, followed by a 
narrowing, whereas saline administration resulted in a constant decrease in width of 
the ANP, being 160 µm after the incubation period of 6 hr (Fig. 3A). A dose-effect 
relation was found: administration of the 10 mM homocysteine solution resulted in a 
transient ANP widening as well, but less pronounced. Administration of 100 mM 
homocysteine resulted in complete disintegration of the embryos. Therefore, this 
concentration was not further used in the experiments. Treatment with 10 mM 
cysteine resulted in a decrease in width comparable to saline and treatment with 30 
mM cysteine resulted in the same decrease in width, however, after an initial small 
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widening of the ANP (Fig. 3B). Administration of 10 mM as well as 30 mM leucine also 
resulted in a decrease in width comparable to saline (Fig. 3C). 
Subdivision of the embryos by their number of somites at the start of the experiments 
showed that the increase in width 
was most profound in embryos 
with four somites as compared to 
embryos with five and six somites 
(Fig. 4).  
The effects of homocysteine 
administration on RNP closure 
were comparable to the effects 
on ANP closure, i.e. a dose-
dependent trend in closure delay 
of the RNP was observed 
(P=0.03), although the differences 
between the solutions were 
borderline significant (ANOVA 
P=0.07) (Fig. 5). Cysteine 
administration showed similar, but 
insignificant results. Treatment 
with leucine had no effect on 
RNP closure.  
As expected, subdivision of the 
embryos by number of somites at 
the start of the experiment 
revealed that the time for 
complete RNP closure was 
somite-dependent, indicating a 
longer RNP closure duration in 
four-somite embryos compared 
with six-somite embryos (data not 
shown). A somite-dependent 
sensitivity for the various 
administered solutions, as 
observed for ANP closure, was 
not found.  
 The mean gain in number of 
somites after six hr of incubation with significant differences is shown in Figure 6 and 
was not decreased for embryos treated with the 10 mM solutions compared to those 
treated with saline, but was significantly reduced for embryos treated with the 30 mM 
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Figure 3.  
Changes in width of the ANP during 6 hr of incubation for (A)
homocysteine (hcy), (B) cysteine and (C) leucine. Indicated are
the mean differences in width of the ANP per hour of incubation
with t=0 hours as reference width. Significant differences are
indicated with an asterisk if different from saline.  
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solutions, except for 30 mM L-homocysteine which was borderline significant 
different.  
The intraembryonic amount of homocysteine in the pooled embryos after 6 hr of 
incubation appeared 0.53 nmol /mg protein and 0.74 nmol/mg protein when 
respectively 10 mM and 30 mM 
homocysteine was applied, but 
was not detectable in embryos 
treated with saline. With a total 
volume of approximately 10 µl for 
the nine pooled embryos the 
estimated homocysteine con-
centration was 12 µmol/l for the 
10mM homocysteine-treated 
embryos and 19 µmol/l for        
the 30 mM homocysteine-treated 
embryos.  
As Figures 3 and 4 already 
indicated, the effect of a single 
dose of homocysteine resulted in 
a temporary widening of the ANP and in a closure delay of the RNP. At six hr of 
incubation the ANP was closing in all embryos on average. Several embryos were 
cultured for another 10 hr and invariably the ANP and RNP came to complete 
closure. 
 
 
DISCUSSION 
Administration of homocysteine to chick embryos in ovo did not increase the 
frequency of NTD. This is in contrast to the experiments of Rosenquist et al. ('96) where 
27% NTD were found. Several explanations for this discrepancy are considered. First, 
a variation in the chicken strain used is likely present. The embryos used in our model 
appeared to have a lower developmental rate than those used by Rosenquist et    
al. 164 Second, an influence of nutritional factors can not be ruled out. Differences in 
diet supplied to the chickens may change the composition of the egg yolk, 
supplying the embryos with a different set of factors involved in the metabolism of 
homocysteine. Besides these variations some other disadvantages of this model were 
observed. The amount of applied homocysteine reaching the embryos likely varied 
considerably, because the position of the embryos was not always straight 
underneath the injection hole. This can explain the finding of both completely 
normally developed as well as degenerated embryos after incubation with identical 
homocysteine concentrations. Another disadvantage was that the actual 
-150
-100
-50
0
50
100
150
0 1 2 3 4 5 6
Incubation time (hours)
D
iff
er
en
ce
 in
 A
N
P 
w
id
th
 (
µm
)
4 somites (n=7)
5 somites (n=4)
6 somites (n=3)
Figure 4. 
Changes in width of the ANP during 6 hr of incubation,
subdivided for number of somites at the start of the experiments
for 30 mM L-homocysteine. Indicated are the mean differences
in width of the ANP per hour of incubation with t=0 hours as
reference width. No significant differences were found,
however, numbers of embryos may have been to small to
detect any significant differences.  
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developmental stage of the embryos at time of administration of homocysteine was 
unknown; only an estimate could be made. As the developmental time window in 
which the homocysteine is affecting neural tube closure may be narrow, the age of 
the embryos at administration of homocysteine is an important issue. 
Recently, another study on chick embryos in ovo showed an increased frequency of 
spina bifida after L-homocysteine thiolactone administration 165. Although the 
administered homocysteine concentration of 2.5 M was much higher than the 0.1 M 
used in our in ovo experiments a low number of gross abnormalities was observed. 
The number of spinal NTDs of approximately 10% in the control group indicates that 
the white leghorn strain used in their study may be more susceptible for spinal NTD 
than the white leghorn strain used in our study.  
By using the culture model we were able to control the amount of homocysteine to 
be administered as well as the developmental stage of the embryos. Moreover, we 
were able to monitor the influence of the homocysteine concentrations on the 
developing embryo. Administration of homocysteine to chick embryos of four to six 
somites resulted in a transient, dose-dependent widening of the ANP and a delayed 
closure of the RNP. 
Comparison of the development of the embryos in the culture model with the in ovo 
situation 12 demonstrated highly similar timing and presence of developmental 
processes. The mean reduction in width of the ANP of 160 µm observed in embryos 
treated with saline in vitro corresponded to a similar reduction during development 
of four somite embryos to seven somite embryos in ovo. The mean necessary time 
observed for complete RNP closure of 2.7 hr in an in vitro saline-treated embryo of six 
somites implies that the embryo was seven to eight somites at time of completion of 
RNP closure. This is similar to the number of somites of seven to eight reported for 
completion of RNP closure in ovo 12. The development of three to four somites during 
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confidence intervals.
No significant
differences were
found. 
  90 
C
ha
pt
er
 8
C
ha
pt
er
 8
6 hr of incubation was comparable to the in ovo situation as well. The differences in 
grow rate, as reflected by the somite gain, observed for the saline treated embryos 
can be explained by the season-sensitivity of chick embryos. 
By using this culture model we found that homocysteine has an dose-dependent 
effect on the closure of the ANP and RNP in a narrow time window between four to 
six somites. Concerning ANP closure, the sensitivity of the embryos for homocysteine 
appeared to depend on their developmental age, the highest sensitivity being at 
four somites. An explanation for the decreased sensitivity at later stages may be that 
the process of closure of the neural folds had passed the stages of elevation of the 
neural walls. 
These findings 
indicate that 
not all phases 
of neural tube 
closure are 
susceptible for 
high homo-
cysteine levels 
and that the 
effect of ho-
mocysteine in 
ANP closure 
may even oc-
cur in a narrow 
time window. 
A delay in development, determined by the gain in somites, occurred when 30 mM 
homocysteine was applied but was not seen in embryos administered                       
10 mM L-homocysteine, whereas a transient widening of the ANP and closure delay 
of the RNP occurred at both homocysteine concentrations. This finding, including the 
reduced somite gain observed for 30 mM cysteine as well as for 30 mM leucine 
indicates that the 30 mM homocysteine concentration is too high to attain normal 
development of the embryos, apart from the widening of the ANP and the closure 
delay of the RNP. The normal gain in somites in embryos treated with 10 mM 
homocysteine suggest that the effects on ANP and RNP closure are specific and not 
general toxic effects.  
Homocysteine concentrations in embryos treated with homocysteine were 
increased, demonstrating that the homocysteine was internalized. Nevertheless, the 
concentration of homocysteine as measured in the embryos was 1000 times lower 
than that administered. We therefore suggest that either the embryos absorbed only 
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Figure 6.  
Mean gain in number of somites after 6 hr of incubation with (A) homocysteine (hcy), (B) 
cysteine and (C) leucine. Indicated are mean somite gain with 95% confidence interval. 
P-values are calculated in comparison to saline treatment. 
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a small part of the homocysteine or that the embryos metabolized or exported the 
homocysteine fast. 
The recovery of both,10 mM homocysteine and 30 mM homocysteine-treated 
embryos indicates that one dose of homocysteine might not be enough to achieve 
the maximum effect on ANP closure. The identical ANP development curves for 30 
mM L-homocysteine and 30 mM L-homocysteine thiolactone (Fig. 3) indicate that 
oxidation of homocysteine in the incubation medium is not the explanation for the 
recovery. The recovery is further illustrated by the complete closure of the ANP after 
16 hr of incubation.  
Another point of discussion is the small widening of the ANP during the first hour of 
incubation with 30 mM cysteine. Cysteine, which molecular structure closely 
resembles that of homocysteine, may affect ANP widening in the same way as 
homocysteine but less profound. Both homocysteine and cysteine are able to split S-
S bridges, which may be involved in neural tube closure. Presumably, cysteine is less 
harmful because in vivo cysteine concentration in blood is about 20-fold higher than 
homocysteine concentrations. The higher osmolarity of the 30 mM solution 
compared with the 10 mM solution and saline can not explain this effect as 30 mM 
leucine treatment did not result in a widening of the ANP. Taken together, although 
ultimately no final closure failure  arose, this culture model appeared very suitable to 
study the influence of homocysteine on the neurulation mechanism in a small time 
window. 
A few other studies on the effect of homocysteine to in vitro animal models are 
published. In cultured rat embryos, up to 6 mM homocysteine administration did not 
increase the frequency of NTD (Van Aerts et al., ’94), but some of the malformations 
they found: irregular somites and blisters, correspond to the malformations found in 
our in ovo experiments. Recently, Hansen et al. 166 reported that NTD did neither 
occur in mice embryos cultured with 1.3 mM D,L-homocysteine in the culture 
medium, nor in embryos cultured with approximately 78 mM L-homocysteine 
thiolactone applied to the amniotic sac. The transient widening of the ANP shown in 
our study may also have been present in the above mentioned experiments in rats 
(Van Aerts et al., ’94) and mice (Hansen et al., '00) but no data on specific ANP 
closure were presented. Hansen et al. 166 showed that 24 hr after administration of 
the 78 mM L-homocysteine thiolactone solution the homocysteine concentration in 
the embryos were not increased significantly. Van Aerts et al. ('94) however, found 
significantly elevated homocysteine levels in embryos cultured with                        
3 mM L-homocysteine for 2 hr. We found elevated homocysteine levels after 6 hr of 
incubation with L-homocysteine. The outcome of these studies may be explained by 
a poor uptake, a rapid metabolisation or a rapid export of applied homocysteine.  
A possible mechanism for the effect of homocysteine in widening of the ANP may 
regard the disturbance of methylation. One of the proteins in which methylation is 
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considered important is actin. Methylation of the histidine residue of actin occurs at 
a specific and highly conserved location on the molecule, which may be important 
in microfilament function 167. In neuroepithelial cells of the neural groove apical 
constriction by actin microfilaments is proposed to be an important factor in the 
elevation and convergence of the neural folds, being important especially in the 
cephalic region 9;19;168. A role for methylation in microfilament contraction during 
neural tube closure was originally suggested by Coelho et al. ('90). They found 
incomplete closure of the neural tube in rat embryos cultured on a methionine-
deficient serum, which has been confirmed by Van Aerts et al. (’94). Moephuli et al. 
('97) found that localization of actin and αβ-tubulin in the basal cytoplasm did not 
occur in embryos cultured on a methionine-deficient serum. They also showed that 
these proteins are among the most excessively synthesized during neural tube 
closure. 
The aim of our study was to examine the effects of high homocysteine 
concentrations on neurulation. When comparing our in vitro experiments to the in 
vivo situation in human the following comment should be made. In mothers of NTD 
children homocysteine levels are slightly elevated to about 15 µmol/l, caused by an 
acquired or genetic factors in the homocysteine and folate metabolism. Contrarily, 
the embryos in our experiments were treated with one bolus of an unphysiologically 
high homocysteine concentration of 10-30 mM, although in the embryos only 
homocysteine levels of 12-19 µmol/l were found. In addition, administration of one 
bolus of homocysteine resulted in a recovery of the effects on neural tube closure. 
In conclusion, the present study shows that high homocysteine concentrations affect 
the process of neural tube closure at multiple sites  in chick embryos. Whether this is 
due to a changed methylation of DNA, RNA or proteins like actin, caused by a high 
AdoHcy level or whether it is due to teratogenicy of homocysteine itself is unclear. 
Further research is necessary to elucidate how a disturbed homocysteine and folate 
metabolism interferes in neurulation. 
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ABSTRACT 
Periconceptional folic acid supplementation can prevent neural tube defects (NTD). 
Folate is required for the remethylation of homocysteine and elevated homocysteine 
concentrations have been reported in mothers of children with NTD. In our previous 
study we showed that treatment of chick embryos in our in vitro model resulted in a 
widening of the anterior neuropore (ANP) and subsequent closure delay. In present 
study we examined whether this was due to homocysteine itself our through a 
homocysteine-induced inhibition of methylation via elevation of S-adenosyl-
homocysteine (AdoHcy). 
Therefore, inhibitors of S-adenosylhomocysteine hydrolase (SAHH), and of methionine 
adenosyltransferase (MAT) were applied to chick embryos in vitro and the closure of 
the ANP was subsequently followed and measured. In addition, we studied whether 
co-administration of the MAT inhibitor with methionine could compensate a delayed 
closure. 
Inhibition of SAHH and MAT resulted in widening and closure delay of the ANP 
comparable to that observed after homocysteine treatment. The changes in             
S-adenosymethionine (AdoMet) and AdoHcy concentrations and the 
AdoMet/AdoHcy ratio in the chick embryos confirmed the inhibition of SAHH or MAT. 
The AdoMet/AdoHcy ratio after inhibition of SAHH was similar to the ratio after 
homocysteine treatment.  
This study provides evidence that the homocysteine-induced closure delay of the 
neural tube is not caused by toxicity of homocysteine itself but by inhibition of 
methylation via elevation of AdoHcy levels. 
 
 
INTRODUCTION 
Neural tube defects (NTD) are severe malformation with a multifactorial origin. The 
occurrence and recurrence rate of NTD can be reduced with approximately 60 % 
when folic acid is supplemented periconceptionally 41;42. To elucidate the molecular 
mechanism behind this protective effect research has been focussed on the folate 
metabolism. This resulted in the identification of the first genetic risk factor for NTD, i.e. 
the methylenetetrahydrofolate reductase (MTHFR) 677 C>T polymorphism 28;29;58. This 
enzyme catalyses the conversion of 5,10-methylenetetrathydrofolate (THF) to            
5-methylTHF, which is required for the remethylation of homocysteine to methionine. 
A reduced availability of 5-methylTHF due to a low folate status or the presence of 
the 677 C>T polymorphism results in a reduced remethylation of homocysteine to 
methionine with a subsequent rise in homocysteine levels (Figure 1). Increased 
homocysteine levels have indeed been reported in mothers of children with NTD 
101;102. Folic acid supplementation can reduce elevated homocysteine levels. This has 
lead to the hypothesis that homocysteine per se may be toxic to the developing 
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embryo. Another hypothesis presumes inhibition of methylation, of which elevated 
homocysteine is a metabolic marker. After the remethylation of homocysteine 
methionine is formed, which is subsequently converted to s-adenosylmethionine 
(AdoMet). The latter conversion is catalyzed by the enzyme methionine 
adenosyltransferase (MAT). AdoMet is the ultimate methyl donor for methylation of 
DNA, RNA and proteins. 
After donation of a methyl-
group S-adenosylhomo-
cysteine (AdoHcy) is 
formed which is 
subsequently hydrolyzed to 
homocysteine by the 
enzyme AdoHcy hydrolase 
(SAHH). The latter is an 
equilibrium that favors 
AdoHcy formation. An 
increase in homocysteine 
levels will therefore result in 
an increase in AdoHcy 
concentration, which is an 
allosteric inhibitor of methyltransferases. (Figure 1).  
The role of increased homocysteine levels in the etiology of NTD has been studied in 
several animal models. In vitro culture of mice and rat embryos with homocysteine 
did not result in an increased NTD frequency 162;166;169. Administration of homocysteine 
to chick embryos in ovo resulted in an increased number of a variety of NTD in the 
study of Rosenquist et al. 164 and an increased percentage of caudal NTD in the 
study of Epeldegui et al. 165. However, in our previously published study 170 we did not 
observe an increased NTD frequency when repeating the study of Rosenquist et al. 
164. A disadvantage of these studies is that they were all performed in ovo, which 
does not allow to follow the effect of homocysteine on neural tube closure in detail. 
To enable monitoring of these effects within a specific and narrow time window, we 
developed an in vitro chick embryo model. Administration of homocysteine to such 
chick embryos induced a transient dose-depending widening of the anterior 
neuropore (ANP), thus a temporary closure delay of the ANP, but in a small 
developmental time window of 4-6 somites only. Such a closure delay may 
eventually result in neural tube defects when it does not catch up with the 
development of the embryo 171. We suggested that the temporary closure delay is 
due to inhibition of methylation of DNA, RNA or important proteins involved in neural 
tube closure.  
Homocysteine
Methionine AdoMet
AdoHcy
SAHH
5-methylTHF
MS
B12
THF
Methylated product
Methyl acceptor-
MAT
5,10-methyleneTHF
MTHFR
Cycloleucine
-
-
Adox
C3Ado
Figure 1. 
Homocysteine metabolism with inhibitors of methylation (dotted line) 
MTHFR: Methylenetetrahydrofolate reductase, MS: Methionine synthase, 
SAHH: S-adenosylhomocysteine hydrolase, MAT: Methionine 
adenosyltransferase, THF: Tetrahydrofolate, AdoMet: S-
adenosylmethionine, AdoHcy: S-adenosylhomocysteine, Adox: periodate 
oxidized adenosine, c3Ado: 3-Deazaadenosine   
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In the present study, we investigated whether homocysteine itself causes a closure 
delay of the neural tube, or whether this is due to inhibition of methylation. Therefore, 
inhibitors of S-adenosylhomocysteine hydrolase (SAHH), which should result in 
increased AdoHcy levels, or an inhibitor of methionine adenosyltransferase (MAT), 
which should result in reduced S-adenosylmethionine (AdoMet) levels, were applied 
to our in vitro model. Finally, we studied whether co-administration of the MAT 
inhibitor with methionine could compensate for a delayed closure. 
 
 
METHODS 
Eggs were incubated in a roller incubator at 37 °C. The construction of the in vitro 
chick embryo culture model used is as previously described 170. Briefly, embryos were 
cut out of the yolk and placed on a substrate of agar and egg white in a Petri dish 
and hold at 37°C.  Only embryos of 4 and 5 somites were included in the present 
study, since our previous study showed that the ANP and RNP of these 
developmental stages were most sensitive to homocysteine treatment. After an 
adaptation period of approximately 30 minutes, 80 µL of one of the following 
solutions was applied: 20 or 50 µM periodate oxidized adenosine (Adox), 0.05, 0.5 or 1 
mM 3-Deazaadenosine (c3Ado), both inhibitors of SAHH, or 80 µL of 40, 60, 80 or 120 
mM cycloleucine, which is an inhibitor of MAT. All solutions were dissolved in saline 
(Locke’s solution: 154 mM NaCl, 6 mM KCl, 2 mM CaCl2, 10 mM D-glucose), which 
was also used as control. To examine whether methionine administration could 
abolish the effects of cycloleucine administration, embryos were pre-treated with 40 
µL 0.5 mM methionine 30 minutes in advance of administration of 60 µM cycloleucine 
or saline. All chemicals were obtained from Sigma. 
After administration of the solution embryos were incubated at 37°C for four hours. 
Digital images were made immediately before administration of a solution as well as 
every hour after the administration up to four hours using a video camera (JVC KY-F 
55B) mounted onto a stereo microscope (Leica MZ FLIII). 
The rate of development of the ANP was determined after measuring the width of 
the ANP on each digital image. The development of the embryos was determined 
by counting the number of somites at zero and four hours.  
 
AdoMet and AdoHcy determination 
After four hours of incubation, embryos were rinsed two times with saline to remove 
the adhering solution and subsequently stored at -80°C for determination of AdoMet 
and AdoHcy levels. For the group with MAT inhibitors, pools of six embryos were used, 
and pools of three embryos for that of SAHH inhibitors, because of anticipated higher 
AdoHcy concentrations. AdoMet and AdoHcy levels were determined by liquid 
chromatography tandem mass spectrometer (LC-MS-MS) (Quattro LC Micromass) as 
  
 
                                                                                                                                        97 
M
ethylation and neurulation
M
ethylation and neurulation
follows: frozen embryos were sonicated in 800 µL 0.9% NaCl on ice from which 100 µl 
was used to determine the protein content 163, 550 µL of the remaining solution was 
combined with 110 µL intern 
standard containing the stable 
isotopes AdoMet-d3 (S-methyl-d3) 
(CDN isotopes) and AdoHcy-d5 
obtained from Struys et al 172. This 
solution was applied to a solid-
phase extraction (SPE) bond-elute 
phenylboronic acid column 
(Varian), which was conditioned 
with 5 mL 0.1 N formic acid and 5 
mL 20mM ammoniumacetate of 
pH 7.4. AdoMet and AdoHcy 
were eluted from the column with 
1 ml 0.1 N formic acid and 
consecutively injected into the 
LC-MS-MS. Liquid chromato-
graphy was performed on a 
Symmetry shield column (2.1 mm 
by 100 mm; 3.5 µm, Watters) using 
a gradient of 100 % H2O and 0.02 
% butyric acid to 100 % MeOH 
and 0.02 % butyric acid, in 10 
minutes. The MRM transitions used 
are; AdoMetd3 402>249.8, 
AdoMet 399>249.8, AdoHcyd5 
390>135.7 and AdoHcy 385>135.7. 
The inter-run variations coefficient 
was 3.07 for AdoMet and 3.67 for 
AdoHcy. AdoMet and AdoHcy 
were calculated per gram 
protein.  
 
Statistical analyses 
Differences in mean width of the 
ANP, number of somites before the start of the experiment and gain in number of 
somites were analyzed using ANOVA followed by Bonferronni corrected test for 
multiple comparisons. All calculations were performed using SPSS version 10.0. 
Figure 2.  
Changes in width of the ANP in chick embryos during four hours
of incubation with inhibitors of SAHH. A. Periodate oxidized
adenosine (Adox), B. 3-Deazaadenosine (c3Ado) and an
inhibitor of MAT. C. Cycloleucine. Indicated are the mean
differences in width of the ANP at each hour of incubation with
t=0 hours as reference width. Asterisk: significantly different from
the control, P < 0.05.  
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Analyses were performed two-tailed, and P<0.05 was considered statistically 
significant.  
 
 
RESULTS 
In control embryos, the anterior neuropore (ANP) in chick embryos begins as a 
narrow slit at the stage of zero somites, broadens subsequently till the stage of four 
somites, then its neural folds begin to converge, thus narrowing the ANP, and it finally 
closes at the stage of ten somites 12;16. Treatment of chick embryos of 4 and 5 somites 
with the control solution resulted in a normal closure, i.e. a reduction in width of the 
ANP up to 150 µm was observed during four hours of incubation (Figure 2). As 
described previously 170, treatment with 10 mM L-homocysteine increased the width 
of the ANP for two hours (Figure 2) and for 4 hours after treatment with 30 mM L-
homocysteine.  
Treatment with Adox, a SAHH inhibitor, resulted in an increase in width during three 
hours at both administered con-
centrations (Figure 2A). Treatment 
with c3Ado, also a SAHH inhibitor, 
resulted in a distinct increase in 
width of the ANP in the first hour 
followed by a fast recovery 
(Figure 2B). This effect was 
observed for all concentrations 
administered and appeared 
dose-dependent. Inhibition of 
MAT with cycloleucine lead to an 
increase in width of the ANP 
during three hours (Figure 2C). The 
most distinct widening was 
observed after 80 and 120 mM 
cycloleucine administration.  
For all administered inhibitors of methylation an age-dependent sensitivity was 
observed: widening of the ANP was more enhanced in embryos with 4 somites than 
in those with 5 somites (data not shown).  
To elucidate whether pre-treatment of the embryos with methionine would abolish 
the inhibitory effects of cycloleucine on the ANP closure, embryos were pre-treated 
with 0.5 mM methionine in advance of 60 mM cycloleucine administration. This 
resulted in a reduced widening of the ANP compared to embryos without such 
treatment (Figure 3).   
Figure 3.  
Changes in width of the ANP in chick embryos of four somites 
during four hours of incubation with methionine and 
cycloleucine (MAT inhibitor). Indicated are the mean differences 
in width of the ANP per hour of incubation with t=0 hours as 
reference width. No significant differences between 
cycloleucine and methionine plus cycloleucine were found.  
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As indicator for the development of the embryo, the gain in number of somites 
during incubation was selected. We observed that control chick embryos developed 
2.6 somites on average, which is similar to the described development in ovo in 
which 1 somite develops in 100 minutes 12. A significant decrease in somite gain to 1.9 
was observed for the 1mM c3Ado-treated and to 2.3 for the 120 mM cycloleucine-
treated embryos. 
To measure the effect of inhibition, AdoMet and AdoHcy levels and the 
AdoMet/AdoHcy ratio were determined in embryos following the in vitro incubation 
(Figure 4). Con-
trol embryos 
had AdoMet 
concentrations 
of 1.12 mmol/g 
protein and 
AdoHcy con-
centrations of 
0.06 mmol/g 
protein leading 
to an AdoMet 
/AdoHcy ratio 
of 21. Homo-
cysteine treat-
ment resulted in 
a distinct in-
crease in Ado-
Hcy levels with-
out affecting 
AdoMet levels, 
leading to a decreased AdoMet/AdoHcy ratio. Both Adox and c3Ado treatment 
resulted in large increase of AdoHcy and a small increase of AdoMet concentrations 
and decreased AdoMet/AdoHcy ratios; the effects were the most profound for Adox 
treatment and were dose-dependent for AdoHcy concentrations. After cycloleucine 
administration a decrease in AdoMet levels and a small increase in AdoHcy levels 
was observed with a consecutive decrease in AdoMet/AdoHcy ratio. Pre-treatment 
with 0.5 mM methionine lead to a slightly higher AdoMet concentration and 
AdoMet/AdoHcy ratio compared to treatment with 60 mM cycloleucine alone. 
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DISCUSSION 
This study provides evidence that the homocysteine-induced closure delay of the 
neural tube is not caused by toxicity of homocysteine itself but by inhibition of 
methylation via elevation of AdoHcy levels. 
Disturbance of methylation in chick embryos via inhibition of MAT or SAHH lead to a 
temporary widening of the ANP similar to that observed after homocysteine 
treatment. This widening results in a closure delay of the neural tube.  
Inhibition of SAHH in embryos by Adox administration leads to an increase in 
widening of the ANP for three hours. Adox is a non-competitive and fast inhibitor of 
SAHH 173, as demonstrated by the 20-40 times increase in AdoHcy levels and the 10 
times decrease in AdoMet/AdoHcy ratio, and will therefore inhibit methylation. This 
may explain that the increase in widening lasted at least three hours. The Adox 
concentrations required to induce ANP widening in the present experiments are 
comparable to those required to induce inhibition of methylation in cell           
cultures 174;175. 
In comparison to Adox, c3Ado treatment, which is a SAHH inhibitor as well, resulted in 
a more enhanced widening, but only for one hour. After four hours, the neural tube 
was closing in the same rate as in control embryos. This is also reflected by a less 
profound effect on AdoMet levels, AdoHcy levels and AdoMet/AdoHcy ratio, as 
determined after four hours of incubation. Contrary to Adox, c3Ado also serves as a 
substrate for SAHH, leading to the formation of S-3-deazaadenosylhomocysteine, 
which may explain this less strong inhibition of SAHH. Our data are in line with those of 
other studies reporting that Adox induces a larger AdoHcy elevation than         
c3Ado 176;177. Nevertheless, a reduced protein methylation was observed after 
treatment of cultured cells with 10 µM c3Adox 178. Besides inhibition of SAHH, other 
effects of c3Ado, like perturbation of microfilament systems and inhibition of cell 
adhesion molecule expression 179;180 have been reported, which could have played 
a role in the ANP widening, as is discussed below. 
Inhibition of MAT by cycloleucine, which is a competitive inhibitor, resulted in a 
widening of the ANP resembling that after Adox treatment. Maximal inhibition of MAT 
seems to be achieved at 80 mM cycloleucine. In cell cultures, hypomethylation of 
DNA has been reported at 10 mM cycloleucine 181;182. Thus, the concentrations of 
cycloleucine used in our experiments may be relatively high. To exclude an 
osmolarity effect, inducing ANP widening, we pre-treated the embryos with 
methionine, which is expected to increase AdoMet levels. The widening of the ANP 
observed in 60 mM cycloleucine-treated embryos was attenuated when embryos 
were pre-treated with 0.5 mM methionine, pointing to exclusion of osmolarity as a 
cause for ANP widening. The AdoMet levels, AdoHcy levels and AdoMet/AdoHcy 
ratio of these methionine/cycloleucine treated embryos were comparable with 
those treated with 40 µM cycloleucine, in which a similar effect on the ANP was 
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observed, pointing towards a protective effect of methionine. This indicates that the 
widening of the ANP observed after cycloleucine treatment is caused by inhibition of 
methylation. 
The delay in development, indicated by a decreased somite gain for the 1mM 
c3Ado and the 120 mM cycloleucine concentration demonstrates that these 
concentrations are too high to attain normal development of the embryos. However, 
the AdoMet and AdoHcy do not indicate that this delay in development is caused 
by inhibition of methylation. Therefore, we presume a more general toxic effect of 
these compounds at such concentrations. 
The ANP curves for Adox and cycloleucine are comparable with that of 
homocysteine. In addition, Adox treatment results in a comparable AdoMet/AdoHcy 
ratio as after homocysteine treatment. These findings provide evidence that the 
homocysteine-induced ANP widening is due to inhibition of methylation via an 
increase in AdoHcy concentration and a decrease in AdoMet/AdoHcy ratio.  
The importance of methylation in developing embryos is demonstrated by the high 
AdoMet/AdoHcy ratio of 21 as observed in control embryos, whereas in adult 
species ratios between two and eight are found 94;183.  
The consequences of a disturbed homocysteine metabolism and methylation are 
demonstrated in CBS and MTHFR knockout mice. Both knockouts result in elevated 
homocysteine concentrations; parallel to this, these mice exhibit increased AdoHcy 
and decreased AdoMet concentrations and thus a decreased AdoMet/AdoHcy 
ratio, and DNA hypomethylation.  
Studies in cell cultures demonstrated that c3Ado had no effect, and Adox at the 
most a slight effect on DNA-methylation 177;184. On the contrary, a clear reduction in 
protein methylation was reported after Adox treatment to cell cultures 174;175;178. 
Moephuli et al. 185 examined the role of protein methylation in neural tube closure 
using an in vitro rat embryo model. These embryos develop NTD when cultured in a 
methionine-deficient medium. When labeled methionine was applied most methyl 
groups were passed to the proteins tubulin and actin. This suggests that the 
methylation of actin and tubulin is required for proper neural tube closure. Actin is 
ubiquitously present in the neural plate and tube and is suggested to reshape neural 
plate cells from columnar to wedge shape through apical constriction of actin 
microfilaments, leading to inward rolling of the neural plate 2. A decreased 
methylation of actin may result in a perturbed contraction of microfilaments and a 
consecutive halt or reverse movement of the inward rolling neural folds. Application 
of cytochalasin-D, which inhibits polymerisation of F-actin, results in reversion of the 
closing neural folds, especially in the region of the ANP 7-10, resembling the effects of 
homocysteine and methylation inhibitors administration in our study 170. Several 
studies reported increased homocysteine levels in mothers of a NTD child. This has 
lead to the following two hypotheses: homocysteine itself is toxic for the embryo, or 
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homocysteine is a marker for a reduced methylation. The results of this study support 
the last hypotheses. We therefore propose that periconceptional folic acid 
supplementation to women planning a pregnancy improves remethylation of 
homocysteine, leading to an adequate methylation of DNA and proteins essential 
for proper closure of the neural tube. 
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DISCUSSION 
PART I HUMAN 
Since the establishment that periconceptional folic acid supplementation reduces 
the occurrence and recurrence risk of NTD, research has focussed on the molecular 
mechanism behind this protective effect. Because elevated homocysteine levels 
were observed in mothers of children with NTD, attention is paid to the role of folate 
as co-substrate for the remethylation of homocysteine. Another factor that provided 
additional evidence for this pathway was the discovery of the MTHFR 677 C>T 
polymorphism as the first genetic risk factor for NTD.  
The remethylation of homocysteine is catalysed by the enzyme MS, which requires 5-
methyltetrahydrofolate as co-substrate and vitamin B12 as co-factor. Vitamin B12 
levels have been examined in mothers of NTD children. Decreased vitamin B12 levels 
in amniotic fluid of women carrying a NTD child have been reported but data on 
plasma vitamin B12 concentrations and NTD are sparse and non-conclusive. Most of 
these studies investigated plasma total vitamin B12 levels as parameter for vitamin 
B12 status. However, only 20 % of vitamin B12 is bound to TC (holo-TC), which 
transports the vitamin B12 to the cells. These holo-TC levels are therefore considered 
to be more accurate estimates of vitamin B12 status than plasma total vitamin B12.  
In our NTD study population, plasma TC as well as total vitamin B12 concentrations 
were determined (Chapter 3). An increased risk for NTD for a low TC-saturation and a 
trend towards low holo-TC concentrations was observed, while no such association 
was observed for low total vitamin B12 levels. No other studies have been performed 
on the relation between holo-TC levels and NTD, so far. The low TC saturation could 
only partly be explained by the Pro259Arg, which is one of the 5 polymorphisms 
found in the TC gene (chapter 4). We observed that this polymorphism reduces the 
binding of vitamin B12 to the TC gene as well as the TC protein amount, while the 
latter was not reduced in mothers of NTD children. The effects of this SNP on TC-
saturation and TC amount have been confirmed in a different study population 186. 
Other factors influencing the stability or function of TC, like variants in the non-coding 
region of the TC gene that may influence splicing, may be responsible for the 
reduced vitamin B12 binding to TC in these mothers. Another possible cause is the 
impaired function of proteins involved in the binding of vitamin B12 to TC. 
To further explore the possibly reduced cellular vitamin B12 status, MMA levels were 
determined. A decreased cellular vitamin B12 concentration results in a reduced 
activity of the vitamin B12-dependent enzyme methylmalonyl-CoA mutase leading 
to increased MMA concentrations. The observed higher NTD risk at elevated MMA 
levels, pointed towards an impaired cellular vitamin B12 status (Chapter 5). MMA 
levels in relation to NTD have been investigated before, but no association was 
observed in non-pregnant mothers of NTD children 136. The discrepancy between 
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these findings and our results may be explained by a different study population and 
the use of different methods for MMA determinations.  
The observed increased risk of indices for a low vitamin B12 status were not caused 
by a low folate status. We therefore concluded that the vitamin B12 status is reduced 
in mothers of NTD children in this study population and is related to an increased risk. 
Impaired disposition of vitamin B12 can result from variations in genes encoding 
receptors, transport proteins or enzymes involved in the vitamin B12 metabolism, 
leading to dysfunctional proteins.  
This is the first study that investigated plasma total vitamin B12, holo-TC, TC-saturation 
and MMA levels in relation to NTD. A reduced vitamin B12 status may be overcome 
by vitamin B12 supplementation. The question raised is whether vitamin B12, in 
addition to folic acid, should be supplemented to women planning a pregnancy. To 
elucidate whether supplementation with vitamin B12 confers an additional risk 
reduction beyond that obtained with folic acid, a randomised placebo controlled 
trial is required, comparing folic acid versus folic acid plus vitamin B12 
supplementation in women planning a pregnancy. 
Apart from vitamin B12, vitamin B6 (PLP) plays a role in the folate-dependent 
homocysteine metabolism as co-factor of CBS, γ-cystathionase and SHMT. We 
therefore investigated the PLP levels in relation to NTD and found that PLP 
concentrations tended to be lower in mothers of children with NTD than in controls 
(chapter 6). No association between PLP and homocysteine levels was observed. 
The lack of post-methionine load homocysteine levels in this study population 
precludes an indication concerning the possible association between PLP 
concentrations and CBS function. One study previously examined PLP levels and NTD 
but found no association 101.  
An important point is that a possible role of the PLP-dependent enzyme CBS in the 
developing embryo can be excluded because this enzyme is expressed in liver and 
kidney only, and thus not present in the embryo during the development and closure 
of the neural tube. This indicates that an increase in homocysteine levels of the 
mother may be the only way, in which the transsulfuration pathway can play a role 
in the aetiology of NTD. However, the lower PLP concentrations in mothers with NTD 
children indicate that a role of PLP levels in the aetiology of NTD cannot be 
excluded, especially because PLP has been studied in small NTD study populations 
only. Moreover, combinations of a low PLP status together with a low vitamin B12 or 
folate status or with genetic variations in vitamin PLP-dependent enzymes may 
additional influence homocysteine levels and possibly NTD.  
The 31 bp variable number of tandem repeats (VNTR) in the CBS gene, which was 
associated with increased post-load homocysteine values 152, was investigated in our 
NTD study population because increased post-load homocysteine levels were 
reported to be associated with NTD (Chapter 7). No association with NTD was 
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observed but we did observe an association of homocysteine with the three most 
common genotypes, i.e. the 17/18, 18-18 and 18-19 genotype, which was 
independent from vitamin B6 levels. We observed gene-gene interactions between 
this VNTR and the MTHFR 677 C>T polymorphism, i.e. persons with the 677 TT / 18-18 
VNTR genotype had an extra elevation of tHcy levels, while individuals with the 677 
TT/17-17 VNTR had no increased tHcy levels when compared with other 677 
genotypes. Interaction between genetic variations affecting parameters like 
homocysteine may play a role the aetiology of NTD.  
So far, none of the genetic variations described in the CBS gene have shown to be a 
distinct risk factor for NTD 72 73. Although dysfunctional CBS is associated with 
elevated homocysteine levels, no profound proof for a relationship between CBS 
dysfunction and NTD has been reported so far, again questioning the importance of 
the transsulfuration pathway in the aetiology of NTD.   
It was reported that the H475Y polymorphism in the GCPII gene led to a reduced 
function of the enzyme and subsequent decreased plasma folate levels 105. We 
observed that this H475Y polymorphism was not associated with NTD (chapter 2), 
and in contrast to the previous publication we found that this polymorphism effected 
plasma folate levels positively, probably by increasing the enzyme activity. Other 
studies found similar results or found no association with plasma folate levels 107. This 
polymorphism may be important in compensating a reduced enzyme activity 
caused by variations in genes encoding other enzymes in the folate pathway.   
Many genetic variations in genes encoding enzymes or proteins involved in the 
folate-dependent homocysteine pathway have been studied in relation to NTD. So 
far, only the MTHFR 677 C>T polymorphism has been shown to be a distinct risk factor 
for NTD. To elucidate whether other genetic variations are risk factors for NTD larger 
study populations are required. This especially accounts for genetic variations with a 
low frequency like some of the described TC SNPs (chapter 4) and some of the 31 bp 
VNTR genotypes in the CBS gene (Chapter 7). To obtain a large study population on 
NTD, a European study should be conducted in which study populations of different 
countries can be combined. 
 
PART II CHICK EMBRYO 
The finding of elevated homocysteine levels in mothers of children with NTD and the 
data that demonstrate that elevated homocysteine levels can be reduced with folic 
acid supplementation led to the hypothesis that elevated homocysteine levels may 
be teratogenic for the developing embryo. One of the possible explanations is that 
homocysteine per se may be teratogenic and induces NTD. Another explanation is 
that elevated homocysteine results in inhibition of methylation. Homocysteine is in 
equilibrium with S-adenosylhomocysteine (AdoHcy), which favours AdoHcy 
formation. An increased homocysteine concentration will thus lead to increased 
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AdoHcy levels, which inhibit methyl group donations by S-adenosylmethionine 
(AdoMet). As a consequence hypomethylation of DNA, RNA and proteins may 
occur. In case of a low folate and low vitamin B12 status an additional reduction in 
methylation occurs via a reduced conversion of homocysteine to methionine, and 
subsequent decreased formation of AdoMet. Decreased AdoMet levels will reduce 
the donation of methyl groups to methyltransferases and result in a reduced 
methylation of DNA, RNA or proteins involved in neural tube closure. In this case, an 
elevated homocysteine concentration is only a marker of a reduced remethylation 
of homocysteine to methionine. 
To study the role of homocysteine in the development of the neural tube, studies 
have been performed, in which homocysteine was administered to the developing 
embryo. Administration of homocysteine to chick embryos in ovo resulted in an 
increased frequency of NTD 164. We repeated this experiment but could not confirm 
these findings (Chapter 8). Possible explanations for this discrepancy are differences 
in chicken strain, diet or age of the embryos in ovo. The latter could only be 
estimated on the basis of the incubation time. To overcome the disadvantages we 
developed an in vitro chick embryo model enabling to monitor the effects of 
homocysteine on neural tube closure. One of the advantages of this in vitro model is 
the possibility to determine exactly the stage of development of the embryo 
enabling the selection of embryos of a specific age for treatment with 
homocysteine. Moreover, the homocysteine can be administered directly onto the 
embryo, where after the development and closure of the neural tube can be 
monitored throughout. Homocysteine administration to chick embryos in this model 
led to a transient dose-dependent widening of the anterior neuropore (ANP) within a 
restricted developmental age of the embryo (Chapter 8). This ANP widening led to a 
closure delay of the neural tube, which has been considered as cause for 
incomplete closure of the neural tube 171.  
To elucidate whether this effect of homocysteine on neurulation was due to inhibition 
of methylation, we inhibited AdoHcy hydrolase (SAHH) with periodate oxidised 
adenosine (Adox) or 3-deazaadenosine. As a result, AdoHcy levels increase and are 
supposed to consecutively inhibit methylation (Chapter 9). To investigate whether a 
reduced AdoMet formation leads to ANP widening as well, we inhibited methionine 
adenosyltransferase (MAT) with cycloleucine. A transient dose-depending widening 
of the ANP comparable with homocysteine treatment was observed after inhibition 
of SAHH and MAT. However, the cycloleucine concentrations required to induce the 
effects by inhibition of MAT were relatively high and a toxic effect of these 
cmpounds, in addition to inhibition of methylation, cannot be excluded. Inhibition of 
MAT and SAHH was confirmed by a reduction of AdoMet and a elevation of AdoHcy 
levels, respectively. Comparison of AdoMet, AdoHcy, AdoMet/AdoHcy ratio and the 
effect on ANP closure between homocysteine-treated and methylation inhibitor-
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treated embryos revealed that inhibition of SAHH with Adox closely resembles the 
effects of homocysteine treatment on the embryo.  
These findings provide evidence for a homocysteine-induced effect on neurulation 
through inhibition of methylation via increased AdoHcy levels. Because a reduced 
methylation via decreased AdoMet formation resulted in ANP widening as well, a 
low folate or vitamin B12 status inhibiting methylation via a reduction in AdoMet as 
well as via an increase in AdoHcy concentrations, may affect neurulation as well.  
The studies described in chapters 8 and 9 are the first ones in which the effect of 
homocysteine as well as the effect of inhibition of SAHH and MAT on neural tube 
closure were monitored. Several studies have been performed in which embryos 
were treated with homocysteine. Only in those using chick embryos increased NTD 
frequencies were observed. This raises the question whether our results can be 
extrapolated to the human situation. The human embryo is exposed to a constantly 
present low dose of homocysteine, while the chick embryo is treated with one bolus 
of a relatively high homocysteine concentration. A model in which the chick embryo 
is exposed to a constant flow of a lower concentration of homocysteine would 
mimic the human situation better. To imitate the effects of a low folate and vitamin 
B12 status on the homocysteine metabolism, inhibition of MS would be preferred 
above inhibition of MAT. Because MS inhibition will lead to reduced AdoMet as well 
as increased AdoHcy concentrations, while MAT inhibition leads to a reduced  
AdoMet formation only. However, MS inhibition would indirectly reduce methylation 
via a reduced methionine formation, while MAT inhibition directly reduces 
methylation via a reduced AdoMet formation. To investigate the effect of 
hypomethylation on the closure of the neural tube, MAT inhibition is preferred above 
MS inhibition.. 
In summary, chapters 8 and 9 provide evidence for an effect of homocysteine on 
neurulation via an AdoHcy-induced inhibition of methylation of DNA, RNA or proteins 
involved in neurulation.  
 
FUTURE PERSPECTIVES 
PART I HUMAN 
Our results described in chapters 8 and 9 point towards a role for homocysteine-
induced elevation of AdoHcy levels in the aetiology of NTD. Levels of AdoHcy and 
AdoMet regulate the methylation of DNA, RNA and proteins. Determination of 
AdoMet and AdoHcy concentrations in children with NTD and controls may 
elucidate a possible relation with NTD. Genes encoding enzymes that regulate the 
AdoMet and AdoHcy concentrations, like MAT and SAHH, are good candidate 
genes to screen for genetic variations that are possibly associated with NTD. 
Moreover, the extent of DNA-methylation may be a risk factor for NTD.  
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The MTHFR 677 C>T polymorphism, which is associated with an increased NTD risk, 
can only partly explain the elevated homocysteine levels reported in mothers of 
children with NTD. Other variations in genes that influence homocysteine levels may 
therefore be present. Adequate levels of 5-MethylTHFand vitamin B12 are required 
for an appropriate remethylation of homocysteine, preventing a reduction of 
AdoMet and an accumulation of AdoHcy levels, ultimately preventing 
hypomethylation. Genes encoding enzymes, receptors or transport proteins that 
regulate the supply of 5-methylTHF or vitamin B12 like thymidylate synthetase, the 
reduced folate carrier, dihydrofolate reductase and methionine synthase reductase 
are good candidate genes for genetic variations that may be associated with NTD.  
Chapter 7 demonstrates that combinations of genetic variations in different genes 
are important in regulating metabolic parameters. In the future, attention should 
therefore be paid to combinations of genetic variations encoding different proteins 
and their effect on metabolic indices and risk for NTD. Such studies will require 
relatively large case/control populations. 
Chapters 3 and 5 demonstrated a reduced vitamin B12 status in mothers of NTD 
children. To elucidate whether this reduced vitamin B12 status results in a reduced 
remethylation of homocysteine, MS enzyme activity should be determined in these 
individuals. 
 
PART II CHICK EMBRYO 
In chapter 8 we demonstrated that homocysteine induces a delay in closure of the 
neural tube. In chapter 9 we showed that this may well be caused by inhibition of 
methylation via increased AdoHcy levels. In addition, we showed that inhibition of 
MAT also lead to a closure delay of the ANP. Interestingly, in case of a low folate and 
vitamin B12 status, a reduced AdoMet formation as well as an increased AdoHcy 
formation is present. To mimic this situation folate or vitamin B12 supply should be 
decreased. As this is hard to perform in our in vitro chick embryo model, the best way 
to mimic this situation is inhibition of MS, which would enable the exploration of the 
role of homocysteine remethylation in the closure of the neural tube.  
 A disturbed methylation influences protein function directly by protein-methylation 
or indirectly by DNA methylation, with repercussion on gene expression. To elucidate 
whether methylation of DNA is involved global DNA-methylation can be determined 
and compared between homocysteine-treated and control embryos. 
To identify proteins that play a role in the widening of the neural tube observed in the 
embryos after administration of homocysteine and methylation inhibitors, protein 
expression patterns of the embryos can be compared. Differnces between 
unmethylated and methylated proteins should identify the role of methylation of 
proteins in neural tube closure. F-actin is a good candidate protein because it needs 
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to be methylated for proper functioning and plays a pivotal role in the microfilament 
contraction essential in neural tube formation.  
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SUMMARY 
Periconceptional folic acid supplementation reduces the risk for neural tube defect 
(NTD) with approximately 60 %. Folate is involved in the remethylation of 
homocysteine and increased plasma homocysteine (tHcy) levels have been 
reported in mothers of children with NTD. This thesis deals with the molecular basis of 
folic acid-preventable NTD in relation to the homocysteine metabolism and is 
divided in two parts. In PART I (Chapters 2-7) metabolic or genetic risk factors for NTD 
in the homocysteine metabolism are investigated in a human study population 
consisting of children with NTD, their parents and a control group. PART II (Chapters 8 
and 9) describes the influence of a disturbed homocysteine metabolism on the 
closure of the neural tube in an in vitro chick embryo model. 
Chapter 1 gives a short introduction of the process of neural tube closure in human 
and chick embryos and a detailed description of the folate-dependent 
homocysteine metabolism is given. 
 
PART I HUMAN  
In the human diet, the natural form of folate exists predominantly as polyglutamates. 
Prior to absorption, these polyglutamates must be deconjugated to 
monoglutamates by the enzyme folylpoly-γ-glutamate carboxypeptidase, located in 
the jejunum. The gene encoding this enzyme, i.e. the GCPII gene, contains a H475Y 
polymorphism, which was described to be associated with a decreased plasma 
folate concentration. To examine a possible role of this variant in NTD, we screened 
this genetic variation in a study population of patients, their parents and controls 
(Chapter 2). We observed no association between this genetic variation and risk for 
NTD, but, contrary to the first published data, we found increased folate 
concentrations in individuals heterozygous for this polymorphism, indicating rather an 
increased enzyme activity.   
Apart from the co-substrate folate, vitamin B12 is required as co-factor of methionine 
synthase for the remethylation of homocysteine. In plasma, approximately 20 % of 
vitamin B12 is bound to transcobalamin (TC ). Only this part of the vitamin B12 is 
transported to the cells. We examined transcobalamin levels in relation to NTD and 
observed a five times increased risk of low TC-saturation (percentage vitamin B12 
bound to TC) and a trend towards a three times increased risk of low holo-TC 
(vitamin B12 bound to TC) for NTD (Chapter 3). To explore whether this low TC-
saturation was due to genetic variations in the TC gene, we performed sequence 
analyses of the coding region of the TC gene in the respective individuals      
(Chapter 4). From the five single nucleotide polymorphisms (SNPs) found, the 
Pro259Arg variant resulted in a decreased TC-saturation but could only explain for a 
small part the low TC-saturation observed, and it was not associated with an 
increased NTD risk. A reduced transport of vitamin B12 to cells will lead to a reduced 
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cellular vitamin B12 status, which results in increased plasma homocysteine and 
increased methylmalonic acid (MMA) concentrations. Because the latter is mainly 
depending on vitamin B12 concentrations, we investigated MMA levels in the above 
described study population (Chapter 5) and observed a two to seven times 
increased risk for NTD when MMA levels were above the 70th to 90th percentile of the 
control distribution. Taken together The findings from chapters 3-5 demonstrate a 
reduced cellular vitamin B12 status, in part due to a low TC-saturation, in mothers of 
children with NTD. The question raised is whether vitamin B12 supplementation in 
addition to folic will lead to a further reduction in NTD risk.  
Another vitamin that plays a role as cofactor of enzymes in the folate-dependent 
homocysteine metabolism is vitamin B6 (pyridoxal 5’-phosphate (PLP)).  We 
investigated the possible association of whole blood PLP concentrations with NTD 
and with homocysteine concentrations (Chapter 6). No significant association was 
observed with NTD risk or homocysteine concentrations, although low PLP 
concentrations were more frequently present in mothers of children with NTD, with 
odds ratios between two and five for the lowest three quintiles . Cystathionine β-
synthase (CBS) is a PLP-depending enzyme that catalyses the transsulfuration of 
homocysteine to cystathionine. A 31 bp variable number of tandem repeats (VNTR) 
in this CBS gene was reported to be associated with post-methionine load 
homocysteine levels. Because elevated homocysteine levels after a methionine load 
has also been described as a risk factor for NTD, we explored the frequency of this 
VNTR in the NTD study population and observed no relationship with NTD (Chapter 7). 
However, a association between the three most common genotypes, i.e. the 17-18, 
18-18 and 18-19 VNTR genotype, and homocysteine concentrations was f ound. We 
also observed gene-gene interactions between these genotypes and the MTHFR 677 
C>T polymorphism. Individuals with the CBS18-18/MTHFRTT genotype had increased 
tHcy concentrations, while persons with the CBS17-17/MTHFRTT genotype did not 
have increased tHcy concentrations when compared with other 677 genotypes. This 
chapter indicates the influence of combinations of variations in different genes on 
metabolic parameters and may thereby also influence the risk for NTD.  
 
PART II CHICK EMBRYO  
As described above increased plasma tHcy concentrations have been reported in 
mothers of children with NTD. This lead to the suggestion that tHcy itself may be toxic 
for the embryo. The other hypothesis supposes a homocysteine-mediated inhibition 
of methylation of DNA, RNA and proteins involved in neural tube closure. An increase 
in homocysteine may result in an increase in S-adenosylhomocysteine (AdoHcy) 
concentration with subsequent inhibition of methylation by S-adenosylmethionine 
(AdoMet).  
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Increased NTD frequencies have been observed after homocysteine administration 
to chick embryos in ovo. We repeated this experiment but could not confirm these 
findings (Chapter 8). Disadvantages of the used in ovo model were the inability to 
control the developmental age of the embryo at time of homocysteine 
administration and to control the application site. We therefore developed an in vitro 
chick embryo model, in which we could monitor the closure of the neural tube after 
application of homocysteine (Chapter 8). Treatment of chick embryos in this in vitro 
model with homocysteine resulted in a closure delay of the cranial neural tube. We 
subsequently examined whether this closure delay could be due to inhibition of 
methylation. Therefore, embryos were treated with inhibitors of enzymes that result in 
an AdoHcy elevation or an AdoMet reduction, which both should lead to inhibition 
of methylation (Chapter 9). The treatment with inhibitors of methylation resulted in a 
closure delay of the cranial neural tube comparable with that after homocysteine 
treatment. This indicates that the homocysteine-induced closure delay of the neural 
tube is likely caused through inhibition of methylation of various targets like DNA, RNA 
or proteins. Which genes, RNA or proteins are hypomethylated is our next challenge. 
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SAMENVATTING 
Foliumzuur inname voor en tijdens de zwangerschap verlaagd de kans op het krijgen 
van een kind met neurale buis defecten (NBD) met ongeveer 60%. In de cel speelt 
folaat, de natuurlijke vorm van foliumzuur, een rol bij de omzetting van homocysteine 
naar methionine. Verhoogde plasma homocysteine concentraties zijn gevonden in 
moeders van kinderen met  NBD. Dit proefschrift beschrijft zowel genetische, 
metabole als functionele studies naar de relatie tussen het homocysteine 
metabolisme en NBD. DEEL I (hoofdstukken 2-7) beschrijft studies naar genetische en 
metabole risicofactoren voor NBD die gerelateerd zijn aan het homocysteine 
metabolisme welke uitgevoerd zijn in een humane studiepopulatie bestaande uit 
kinderen met NBD, hun ouders en een controle groep. DEEL II (hoofdstukken 8-9)  
beschrijft studies naar het functionele effect van een verstoord homocysteine 
metabolisme op het sluiten van de neurale buis in kippenembryo’s. 
Hoofdstuk 1 geeft een korte introductie over het sluitingsproces van de neurale buis 
in de mens en in de kip. Daarnaast bevat dit hoofdstuk een gedetailleerde 
uitwerking van het folaat-afhankelijk homocysteine metabolisme. 
 
DEEL I HUMAAN 
Folaat in de voeding bestaat voornamelijk in de vorm van polyglutamaten. Voor 
absorptie worden deze polyglutamaten gehydrolyseerd naar monoglutmaten door 
het enzym folylpoly-γ-glutamate carboxypeptidase, dat gesitueerd is in het jejunum. 
Het GCPII gen dat codeert voor dit enzym bevat een H475Y polymorphisme. Van dit 
polymorphisme is beschreven dat het geassocieerd is met een verlaagde folaat 
concentratie in plasma. Om een mogelijk rol van deze genetische variant in NBD te 
onderzoeken hebben we patiënten, hun ouders en een controle groep (hoofdstuk 2) 
gescreend op dit polymorphisme. De H475Y variant was niet geassocieerd met NBD, 
maar in tegenstelling tot de eerste publicatie vonden we verhoogde folaat 
concentraties in individuen die heterozygoot voor dit polymorphisme zijn, wat wijst 
op een toegenomen enzym activiteit.  
Naast folaat is ook vitamine B12 betrokken bij de omzetting van homocysteine naar 
methionine. Ongeveer 20% van de vitamine B12 in plasma is gebonden aan 
transcobalamin (TC). Het resterende deel is gebonden aan haptocorrin (HC). Alleen 
het vitamine B12 dat gebonden is aan TC wordt getransporteerd naar de cellen. De 
functie van HC is onduidelijk. We hebben de relatie tussen TC waarden en NBD 
onderzocht en vonden een vijf keer verhoogd risico op het hebben van een kind 
met NBD wanneer de TC-verzadiging ( het percentage vitamine B12 dat gebonden 
is aan TC) laag was en een trend naar een 3 keer verhoogt risico op NBD wanneer 
de holo-TC (B12 gebonden aan TC) laag was (hoofdstuk 3). Om uit te zoeken of de 
lage TC-verzadiging veroorzaakt werd door een genetische variant in het TC gen, 
welke de binding van vitamine B12 zou kunnen beïnvloeden, hebben we het 
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individuen (hoofdstuk 4). Van de vijf gevonden singel nucleotide polymorphisms 
(SNPs) was één geassocieerd met een verlaagde TC-verzadiging. Deze variant kon 
slechts voor een klein deel de lage TC-verzadiging waargenomen in moeders van 
NBD kinderen verklaren en was niet geassocieerd was met een verhoogd risico op 
NBD. Een verminderde vitamine B12 transport naar de cellen zal uiteindelijk leiden tot 
een verlaagde cellulaire vitamine B12 status, welke vervolgens resulteert in een 
verhoogde plasma homocysteine en methylmalonic acid (MMA) concentratie. Om 
de cellulaire vitamine B12 status in de NBD studiepopulatie te bepalen zijn MMA 
concentraties in plasma gemeten (hoofdstuk 5). Een twee tot zeven keer verhoogd 
risico op NBD werd gevonden indien de MMA concentraties boven het 70ste tot 90ste 
percentiel van de controle verdeling waren. Samengevat laten de bevindingen in 
hoofdstuk 3-5 een gereduceerde vitamine B12 status zien in moeders van een kind 
met NBD dat gedeeltelijk veroorzaakt wordt door een lage TC-verzadiging. Dit leidt 
tot de vraag of periconceptionele inname van vitamine B12 naast foliumzuur zal 
leiden tot een extra reductie in de kans op NBD.  
Een ander vitamine dat een rol speelt als co-factor bij enzymen in het folaat-
afhankelijk homocysteine metabolisme is vitamine B6 (pyridoxal 5’-fosfaat (PLP)). We 
hebben onderzocht of er een relatie bestond tussen PLP concentraties in bloed en 
NBD (hoofdstuk 6). Alhoewel we geen significante associatie tussen PLP concen-
traties en het risico op NBD of tussen PLP en homocysteine concentraties vonden, 
bleken moeders van NBD kinderen vaker een lage PLP waarde te hebben dan 
controle vrouwen met odd ratio’s tussen de 2 en 5 voor PLP concentraties in de 
laagste drie quintielen.  
Cystathionine β-synthase (CBS) is een PLP-afhankelijk enzym dat de transulfurering 
van homocysteine naar cystationine katalyseert. In het CBS gen dat codeert voor dit 
enzym is een 31 basen paren variable number of tamdem repeats (VNTR) 
beschreven dat geassocieerd was met post-methionine load homocysteine 
concentraties. Omdat verhoogde post-methionine load homocysteine 
concentraties ook gerapporteerd zijn als risico factor voor NBD, hebben de 
frequentie van deze VNTR onderzocht in de NBD studie populatie, maar een 
associatie met het risico op NBD werd niet gevonden (hoofdstuk 7). We vonden wel 
een associatie tussen de drie meest voorkomende VNTR genotypen, n.l. de 17-18, 18-
18 en de 18-19 VNTR en plasma homocysteine waarden. Tevens namen we gen-gen 
interacties waar tussen deze 31 bp VNTR en de MTHFR 677 C>T polymorphisme. 
Personen met het CBS18-18/MTHFR-TT genotype hadden verhoogde homocysteine 
concentratie terwijl individuen met het CBS17-18/MTHFR-TT genotype geen 
verhoogde homocysteine concentraties hadden. Dit hoofdstuk geeft het belang 
aan van combinaties van variaties in verschillende genen op metabole parameters 
welke weer hun weerslag kunnen hebben op de kans op NBD. 
  132 
Sa
m
en
va
tti
ng
Sa
m
en
va
tti
ng
DEEL II KIPPENEMBRYO 
Zoals hierboven beschreven staat zijn verhoogde plasma homocysteine waarden 
gerapporteerd in moeders van kinderen met NBD. Dit heeft geleid tot de suggestie 
dat deze verhoogde homocysteine concentratie van de moeder zelf toxisch zou 
kunnen zijn voor het embryo. Een andere hypothese veronderstelt een 
homocysteine-gemedieerde remming van de methylering van DNA, RNA en 
eiwitten. Een toename in homocysteine kan namelijk leiden tot een toename in S-
adenosylhomocysteine (AdoHcy) concentratie, welke vervolgens de methylering 
door S-adenosylmethionine (AdoMet) remt.  
Een toename in NBD frequentie is beschreven na toediening van homocysteine aan 
kippenembryo’s in ovo. Deze experimenten hebben we herhaald maar we konden 
deze resultaten niet bevestigen (hoofdstuk 8). Nadelen van het gebruikte in ovo 
model waren onder anderen dat het onmogelijk was om de leeftijd en positie van 
het embryo op het moment van homocysteine toediening te bepalen. Daarom 
hebben we een in vitro kippenembryo model ontwikkeld waarin we the sluiting van 
de neurale buis kunnen volgen na toediening van homocysteine (hoofdstuk 8). 
Behandeling van kippenembryo’s met homocysteine in dit in vitro model resulteerde 
in een vertraagde sluiting van het craniale deel van de neurale buis. Om te 
onderzoeken of deze vertraagde sluiting veroorzaakt werd door remming van de 
methylering hebben we de embryo’s behandeld met enzym remmers die leidden tot 
een AdoHcy verhoging of tot een AdoMet verlaging (hoofdstuk 9). Zowel een 
AdoHcy verhoging als een AdoMet verlaging kan namelijk resulteren in een remming 
van de methylering. Toediening van deze remmers leidde tot een vertraging van de 
sluiting van de craniale kant van de neurale buis, welke vergelijkbaar was met het 
effect na homocysteine behandeling.  Dit wijst erop dat de door homocysteine 
geïnduceerde vertraagde sluiting van de neurale buis waarschijnlijk veroorzaakt is 
door remming van de methylering van DNA, RNA of eiwitten. Hypomethylering van 
deze producten zou de sluiting van de neurale buis nadelig kunnen beïnvloeden. 
Uitzoeken welke genen, RNA of eiwitten gehypomethyleerd zijn is onze volgende 
uitdaging. 
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als labtafel- en kamergenoot wil ik je bedanken voor alle uren die we deelden. Ik 
ben blij dat je mijn paranimf wil zijn. Mijn andere paranimf is Sandra, ook jij bedankt 
voor de gezellige afgelopen vierenhalf jaar. Het laatste jaar deelden we de 
computerruimte en hebben we heel wat discussies over onderzoek  en andere 
interessante onderwerpen gevoerd. Nathalie van der Put, jij bedankt voor het 
schrijven van het projectvoorstel; het kippenembryo werk heb ik met veel plezier 
gedaan. Leo, bedankt voor de vele adviezen met betrekking tot het onderzoek. 
Beste, Addie, Alexandra, Anita, Brenda, Dinny, Erik, Gerly, Henk-Jan, Henriëtte, Ivon, 
Jacqueline, John, Maarten, Maria en Suzanne: bedankt voor het gezellige 
koffiedrinken, de gezamenlijke barbecues, het skiën, lasergamen enzovoort en ook 
bedankt voor de homocysteine, SAM en SAH bepalingen in de kippenembryo’s.  
Annemarie, bedankt voor het werk dat je als student hebt gedaan. Ook de 
collega’s van de DNA-groep, Carin, Connie, Eric, Iwan, Jan, Karin A, Marieke, Marije, 
Maroeska, Ralf, Rikke, Roel, Rolf en Sandy, bedankt voor de heerlijke klaaguurtjes 
over computers en verhuizen, maar vooral bedankt voor het ‘bieren’ in de stad. Ook 
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alle andere collega’s van het lab kindergeneeskunde en neurologie bedankt voor 
de interesse in mijn onderzoek.  
Naast mijn werk in Nijmegen heb ik ook een groot deel van mijn onderzoek 
uitgevoerd in Maastricht.  Beste Marie-Jose, bedankt voor  het kweken van de vele 
kippenembryo’s, hierdoor kon ik doorgaan met het onderzoek in Maastricht. Johan, 
bedankt dat je me wilde inwerken in het prepareren van kippenembryo’s en tevens 
bedankt voor het wijzen en mee rennen via de korte uitgang wanneer ik de trein 
weer eens dreigde te missen. Mijn onderzoek was een stuk lastiger geworden als ik 
niet in Maastricht had kunnen blijven slapen, Madeleine, bedankt dat je huis altijd 
open stond.  Ook Paul en Els bedankt voor de leuke gesprekken en het inleggen van 
de eieren. Hans bedankt voor het maken van de tekeningen van het kippen- en 
humane embryo en Rinus bedankt voor de hulp bij alles wat met computers te 
maken had. De rest van de afdeling wil ik bedanken voor de gezellige koffiepauzes 
met twee stukken vlaai (of was het vla?), ik zal het zeker missen. Marisol, its was nice 
working with a student from Ecuador, thanks for the work you did for my project. 
Behalve alle mensen die mij geholpen hebben met het onderzoek, wil ik ook 
degenen bedanken die me er soms juist van weerhouden hebben om te werken. 
Mijn vrienden; naast jullie interesse zorgden jullie opmerkingen er altijd weer voor dat 
ik me realiseerde dat er meer is dan onderzoek op deze wereld. Alhoewel de vragen 
over het slikken van foliumzuur wel erg vaak ter sprake kwamen het afgelopen jaar. 
Mijn schoonfamilie wil ik ook hartelijk bedanken voor de interesse in mijn onderzoek. 
Mijn ouders, pap en mam, bedankt dat jullie mij altijd de vrijheid hebben gegeven 
om te doen wat ik zelf wilde en me vervolgens te steunen in de keuzes die ik maakte. 
Ook Kornelis, Gean, Geranda, Mendy, Arnoud en Annette bedankt voor de interesse 
in mijn onderzoek. Als laatste wil ik natuurlijk de belangrijkste van allemaal bedanken, 
lieve Floris, je opbeurende taal wanneer het niet mee zat en je interesse in het, in 
jouw ogen “abracadabra”  hebben me erg geholpen de afgelopen jaren. Je 
gevleugelde uitspraak; “en anders gaan we toch gewoon gezellig samen een 
wereldreis maken” deden mij de toekomst weer zonnig inzien. Best gezellig, ’s 
avonds en in het weekend allebei achter de computer. Nu je zelf je MBA gehaald 
hebt, kunnen we ons af gaan vragen wat we nu eens zullen gaan doen.  
 
 
  
 
